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Summary
Transforming growth factor beta 1 (TGF-pi) is an important mediator of progressive 
renal tubiilointerstitial fibrosis, and therefore the TGF-pl signalling pathway plays 
an important role in progressive renal disease. Renal inflammation is also thought to 
be an important determinant of progression, involving infiltration of the 
tubulo-interstitum by microphages, and consequent release of cytokines including 
interleukin-1 beta (IL-ip). Bone Morphogenetic Protein-7 (BMP-7) is a powerful 
inhibitor of TGF-p dependent fibrosis in animal models of renal disease and has 
attracted substantial interest as a potential therapeutic target. The aim of my thesis is 
to examine the regulation of TGF-pl signalling pathway by IL-lp and BMP-7 in 
proximal tubular epithelial cells (PTC) and to investigate the mechanisms underlying 
them.
The data presented show that IL-lp has a biphasic effect on PTC TGF-pl signalling, 
with early NF-xB-mediated inhibition and delayed sensitization via an autocrine 
IL-6 loop, and possibly also via a switch from NF Kappa B p65/p50 heterodimer to 
p50/p50 homodimer formation. Secondly, the data indicate that BMP-7 prevents 
TGF-pl-mediated loss of the transcriptional repressor SnoN and hence specifically 
limits Smad3 DNA binding, altering the balance of transcriptional responses to 
TGF-P 1 in PTC.
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Chapter One: 
Introduction
10
1.1 End stage renal disease and Chronic Kidney Disease
End stage renal disease (ESRD), or stage V of chronic kidney disease (CKD) is 
defined as GFR (Glomerular Filtration Rate) less than 15 mL/min/1.73 m2, according 
to the classification system established by the National Kidney Foundation Kidney 
Disease Outcomes Quality Initiatives. This is taken to be the point at which an 
irreversible deterioration of renal function has occurred, and where renal 
replacement therapy is typically required. The majority of patients with ESRD 
present initially with CKD, whereas acute renal failure with no recovery is a 
relatively uncommon cause of ESRD. Beyond a certain degree of CKD, progression 
to ESRD is likely therefore predictable but not avoidable [1,2].
1.2 Tubulointerstitial fibrosis and ESRD
1.2.1 Tubulointerstitial components of normal kidney
Macroscopically, the kidney comprises two layers: an external layer, the cortex, 
displaying an intense and red coloration; and an inner pale layer, the medulla. The 
components of the kidney are nephrons, the collecting duct system, a unique 
vasculature, and the interstitium.
The nephrons are renal functional units, consisting of the glomerulus and renal 
tubules. Regarding physiological function of the nephron, the glomerulus is 
responsible for the production of an ultrafiltrate of plasma. The renal tubules play a 
vital role in regulation of fluid, electrolyte and acid-base homeostasis. The renal
11
interstitium is composed of cells, such as fibroblasts, perivascular cells, and other 
non-resident cells, and extracellular components including fibrillar structures, and 
ground substance such as proteoglycans, glycoproteins and interstitial fluid [3]. The 
extracellular components of the interstitium comprise a matrix, containing type I and 
III collagens in addition to fibronectin, non-collagenous glycoproteins and 
proteoglycans [4]. There are very few resident cells in the interstitium of normal 
kidney. Among them, interstitial fibroblasts constitute the major cell type and are 
assumed to be the major source of matrix production in the normal kidney [5].
Due to the close relationship between tubules and interstitium, they are often 
regarded as one term ‘tubulointerstitium’, or ‘tubulointerstitial fibrosis’. The 
tubulointerstitium comprises the tubules, vascular structures, and interstitium, 
together occupying more than 90% of the kidney volume [6].
1.2.2 Tubulointerstitial fibrosis
1.2.2.1 The importance of tubulointerstitial fibrosis in progressive renal disease
Progressive renal failure results from the loss of nephrons and is associated with 
glomerulosclerosis, tubulointerstitial fibrosis and vascular sclerosis pathologically. 
Risdon et al. and Schainuck et al showed that in patients with glomerulonephritis, 
the decline of renal function such as GFR correlated well with structural 
abnormalities of the tubules and interstitium, but less with histologic glomerular 
injury [7, 8]. Studies by Bohle et al also revealed that tubulointerstitial fibrosis 
grading was more closely correlated with functional impairment than glomerular 
injury in a wide range of renal diseases including chronic sclerosing interstitial
12
nephritis, mesangioproliferative glomerulonephritis (GN), membranoproliferative 
GN, diabetic glomerulosclerosis and glomerular amyloidosis using renal biopsies [9- 
12]. Furthermore, in animal models, work has demonstrated that interstitial leucocyte 
accumulation has an important role in improving renal function [13]. In addition, 
cellular immunity has been proposed as a principal effector of interstitial injury 
leading to renal failure [14].
1.2.2.2 The histological changes of interstitium in tubulointerstitial fibrosis
The normal biological function of the renal interstitium depends on an integrated 
network of cellular and extracellular matrix (ECM) interactions [15]. Any alteration 
in the elements and structure of the resident cells and ECM is likely to have 
important effects for the function of the kidney [16].
Under physiological conditions, only a few renal fibroblasts can be found in the 
interstitium. During renal fibrogenesis, fibroblast accumalation occurs in the 
tubulointerstitium. These pathologic, activated fibroblasts directly mediate fibrosis 
by leading to excessive deposition of ECM, and also by secretion of many pro- 
fibrotic factors such as transforming growth factor (TGF-p), platelet derived growth 
factor (PDGF) and fibroblast growth factor (FGF) [17].
There are several potential origins for the fibroblasts that drive tubulointerstitial 
fibrosis, including local proliferation of resident fibroblasts, migration from the 
perivascular region, and recruitment of bone marrow derived precursors ( reviewed 
by Hewitson) [18, 19]. Fibroblasts can also originate from acquisition of a fibroblast 
phenotype by other highly differentiated cells. This can apply to epithelial and
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endothelial cells, through the processes of epithelial-mesenchymal transition (EMT) 
[20, 21] and endothelial-mesenchymal transition (EndMT) [22] respectively. Data 
from animal models and clinical biopsy samples suggests an important role for 
proximal tubular cells, from which a significant proportion of tubulointerstial 
fibroblasts may develop via EMT [23-25]. The compelling study by Iwano et al has 
indicated in mice with genetically tagged proximal tubular cells and bone marrow 
chimeras during EMT in fibrosis, that 36% of renal fibroblasts originated from the 
epithelium whereas 15% came from the bone marrow [20].
1.2.2.3 The role of proximal tubular epithelial cell in tubulointerstitial fibrosis
Renal proximal tubular cells (PTC) represent the most abundant cell type in the 
cortex. In vivo the proximal tubule is formed as an intact single layer of polarized 
columnar epithelial cells integrating with tight junctions and adherens junctions. The 
apical side of PTC faces the tubular lumen with a well developed brush border, 
which results in an increase of the luminal surface area of the cell. The basal side of 
the PTC contacts the tubular basement membrane separating PTC from the 
interstitium. This polarised apical and basolateral surface membrane structure of 
PTC is important to maintain their unique function for electrolyte, acid-base or 
solute balance. Also, the PTC reabsorbs macromolecules such as polypeptides and 
proteins that have passed through the glomerular filter with a prominent lysosomal 
system. Furthermore, PTCs is required for tubular basement membrane (TBM) 
formation by the secretion of type IV collagen and laminin [3].
It has become apparent that tubular epithelial cells actively participate in the 
interstitial fibrosis in both immunologically and non-immunologically-mediated
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renal diseases [26-28]. PTC can act on T-cell activation and produce a variety of 
chemokines, cytokines and growth factors such as TGF-P 1, endothelin-l(ET-l), 
tumour necrosis factor a  (TNF-a), monocyte chemoattractant protein-1 (MCP-1), 
interleukin 8 (IL-8) and interleukin 6 (IL-6), thus contributing to interstitial 
inflammatory and reparative events [29-37]. Also, in response to the above secreted 
profibrotic cytokines, they can produce matrix proteins, leading to accumulation of 
ECM.
In addition to being a source of profibrotic cytokines, PTCs may directly mediate 
fibrosis by acquiring a myofibroblast phenotype during renal injury, a process called 
EMT. EMT has been indicated to be particularly significant in the pathogenesis of 
tubulointerstitial fibrosis that accompanies all progressive kidney disease [18]. 
During EMT, tubular epithelial cells acquire mesenchymal gene expression and a 
migratory phenotype, accumulate excess ECM and secret of pro-fibrotic factors. In 
renal tubular cells, fibroblast-specific protein 1 (FSP1, also called SI004A), a 
member of the SI00 family of calcium-binding proteins exclusively expressed in 
fibroblasts, has been detected in numerous independent studies, in the process of 
EMT in different animal models of chronic renal disease and also in human kidney 
biopsies [21, 38-41]. Blocking EMT such as by BMP-7 attenuates renal fibrosis [42, 
43]. Tubular EMT is proposed as a highly regulated process involving four crucial 
events. These include: (1) loss of epithelial cell adhesion, (2) de novo a-smooth 
muscle actin expression and remodelling, (3) disruption of tubular basement 
membrane, and (4) enhanced cell migration and invasion [43].
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A series of reports have shown TGF-pl is a vital pro-fibrotic factor in renal fibrosis, 
and is the principal stimulus of related processes including EMT [40]. Recent studies 
by Zeisberg et al show that inhibiting TGF-pl function can reverse EMT [44].
1.3 Transforming growth factor-pi (TGF-pi)
1.3.1 Superfamily and isoforms
TGF-P 1 belongs to a group of polypeptide growth/differentiation factors called the 
TGF-P superfamily, which comprises five distinct TGF-p isoforms, inhibins/activins, 
bone morphogenetic proteins (BMPs), and other structurally related polypeptide 
growth factors in vertebrates and invertebrates. These cytokines play very vital roles 
during organ development, as well as in physiological and pathophysiological 
processes, by regulating a broad range of cellular processes, such as cell growth, 
differentiation, migration, apoptosis, and extracellular matrix production in a cell and 
context specific manner [2, 45, 46]. They can be expressed by most cell types and 
are abundant both in circulating forms and bound to the extracellular matrix [47], 
exerting a wide range of effects in a context-dependent autocrine, paracrine, or 
endocrine fashion [2].
In mammals, the TGF-p branch exists in 3 highly homologous isoforms [48], TGF- 
P 1, 2 and 3 [49] arising from different genes and chromosomes, 19ql3, lq41, and 
14q24, respectively [50]. The three TGF-P isoforms in mammalian have a molecular 
weight of approximately 25,000 and share a high degree of sequence homology (70- 
80%) in the carboxy-terminal mature region across species [2]. The deletion of the
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three distinct TGF-(3s isoforms in mice provides evidence that these TGF-p isoforms 
play entirely different roles in embryonic growth and development. Knock-out of 
TGF-p 1 gene does not display any gross embryonic abnormality, but the newborn 
mice exhibit lethal multifocal inflammation, starting three weeks after birth [51]. 
Therefore, TGF-P 1 appears as an essential regulator of immune system. The TGF-p3 
null mice bom with cleft palate die within a few hours due to a concomitant lack of 
pulmonary development, indicating the responsibility of TGF-p3 for normal 
embryonic growth [52]. Also, TGF-p2 knockout mice represent perinatal mortality 
and a wide range of organ defects including the heart, lung,, kidney, eye, and inner 
ear [53, 54].
1.3.2 Structure and synthesis of TGF-pi
Of the TGF-ps isoforms, the effects of TGF-pl on tissue homeostasis and response 
to injury have been the most fully characterized [55]. In vitro the three isoforms have 
similar functions, but in vivo TGF-pl is most strongly implicated in renal fibrosis
[56].
The TGF-P 1 gene encodes a 390-amino acid precursor molecule that contains a 
signal peptide, the active TGF-P 1 molecule, and a latency-associated peptide (LAP)
[57]. After removal of the signal peptide, the TGF-p 1 gene product is proteolytically 
cleaved within the endoplasmic reticulum to form mature TGF-pl and the LAP [58]. 
Before secretion, TGF-P 1 noncovalently associates with the LAP to produce an 
inactive latent TGF-P 1 complex [59, 60]. TGF-pl is activated when released from
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LAP, therefore conditions of extremes pH, heat and radiation, proteases such as 
plasmin and cathepsin D, detergents, and thrombospondin all result in TGF-pl 
activation {2, 56, 61-63]. Once activated, TGF-P 1 is capable of binding its cell 
surface receptors, thereby initiating intracellular signalling pathway activation.
1.3.3 Biological functions of TGF-pl
Abundant studies have shown that all TGF-P isoforms including TGF-pi are potent 
endogenous mediators of tissue repair via stimulating chemotaxis, angiogenesis, and 
ECM deposition following wounding [2]. It is also known to suppress 
immunological performance by inhibiting B- and T-cell activities via other cytokines 
directly or indirectly. The disorder of TGF-P 1 expression or activity has been 
implicated in a wide ranges of disease including autoimmune disorders, fibrotic 
disease and chronic inflammation, neurodegenerative disease, and carcinogenesis [64, 
65].
Pathologic autoinduction of TGF-P 1 may be characteristically involved in the
progress of fibrosis in the kidney and other organs, such as lung, liver and related
systemic sclerosis [55, 56]. Also, TGF-pl is regulated by YB-1 and itself [66, 67].
TGF-pl exerts a biphasic role during inflammation. At the early stage it promotes
the inflammatory process. Serving as a powerful chemoattractant for leukocytes,
TGF-pl assembles monocytes with enhanced mRNA levels for various cytokines. At
the late stage, however, TGF-P 1 has immunosuppressive effects. It decreases T cell
mediated immune response [68], cytokines production by macrophages [69], and
the severity of inflammation [70]. In cancer, it has been considered that TGF-pl acts
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as both a tumour suppressor and tumour promoter [71]. Overall, these pleiotropic 
and sometimes apparently contradictory actions of TGF-pl are regulated in a cell- 
type and -context dependent fashion [72].
1.3.4 The role of TGF-pi in fibrotic renal disease
There are several lines of evidence supporting the role of TGF-pl as a key regulator 
of fibrosis in kidney disease. The first milestone observation of the correlation 
between TGF-pl and renal disease was reported by Border et al., who discovered a 
causal role of TGF-pl in ECM accumulation in an experimental rat model of acute 
mesangial proliferative glomerulonephritis [73]. In vivo and in vitro, many studies 
have shown that increased expression or increased activity of TGF-pl is seen in 
various chronic kidney diseases. In addition, elevated plasma and urinary TGF-pl 
protein was detected in patients with renal fibrotic diseases including chronic 
allograft nephropathy, focal segmental glomerulosclerosis, and diabetic nephropathy 
[74-76]. In cultured rat mesangial cells, renal fibroblasts, and tubular epithelial cells, 
all three TGF-p isoforms have fibrogenic effects, notably TGF-p2 and TGF-p3 
effects may be partially mediated by TGF-pl [77]. In cultured kidney tubular 
epithelial cells, TGF-pl can induce IL-8, MCP-1, and fibronectin production [78].
On the other hand, several therapeutic strategies have been applied to inhibit 
profibrotic TGF-pl activity in experimental models of renal fibrosis. Treatment with 
TGF-pl antibodies and with TGF-p 1 antisense oligodeoxynucleotides has been 
associated with reduced histological evidence of glomerular injury and reduced ECM 
deposition in various animal models of renal disease (reviewed by Gagliardini E )
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[79].
In normal cells, TGF-pl has various cellular functions such as blocking the cell 
cycle at the G1 stage to inhibit proliferation as a tumor suppressor, inducing 
differentiation, and boosting apoptosis. It is also an immune suppressor, and a 
promoter of extracellular-matrix components, which are essential for wound healing 
and tissue repair progress [80]. Overproduction or overactivity of TGF-P 1 can result 
in excessive ECM deposition leading to scar tissue and fibrosis [56]. But in cancer 
cells, TGF-p 1 causes immunosuppression and angiogenesis thus increasing the 
invasiveness of the tumor [65].
But, TGF-pl blockade has not yet translated into an effective and safe therapeutic 
approach in clinical patients [81]. This probably stems from the. multifunctional 
biological activities of TGF-pl, such as anti-proliferation, differentiation, anti- 
tumorigenesis, anti-migration and apoptosis. These additional actions of TGF-pl 
mean that complete blockade is hazardous, and that understanding the fundamental 
signalling events underlying TGF-pl-dependant process is important. It is also 
notable that, in the recovery phase of Acute Renal Failure (ARF), the expression of 
TGF-pl is enhanced [82]. This indicates that increased expression of TGF-pl alone 
is not the whole cause of progressive CKD, and suggests that the modulation of 
TGF-pl signalling may be a key step in progressive CKD.
1.4 TGF-P signalling pathway
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As with other signalling systems, key steps of TGF-P signalling include TGF-p 
ligand binding to the cell surface receptors, intracellular transduction of signal from 
the activated receptor to the nucleus, integration with other signalling pathways, and 
together with other co-factors, changes in target gene expression. Recent 
developments in these aspects of TGF-P signalling are now summarized below.
1.4.1 Smad signalling pathway
1.4.1.1 TGF-pi receptors
TGF-P signalling is initiated through the formation of a heteromeric transmembrane 
receptor complex consisting of activated ligand, two TGF-P type I and two type II 
receptors. Type I and II receptors are glycoproteins of approximately 55 kDa and 70 
kDa, respectively, with core polypeptides of 500 to 570 amino acids including the 
signal sequence [45]. After activated TGF-P binds to the type II receptor, the type II 
receptor recruits and phosphorylates the type I receptor within its GS domain 
because of a characteristic SGSGSG sequence it contains in its juxtamembrane 
region. Then the activated type I receptor phosphorylates cytoplasmic substrates (the 
receptor-regulated Smad proteins), which subsequently form R-Smad-Smad4 
complexes that translocate to the nucleus, thereby regulating transcription of target 
genes with the assistance of other transcriptional factors.
As well as type I and II receptors, the original search for cell surface TGF-P binding
proteins using ligand crosslinking methods also revealed type III receptors [83].Type
III receptors were discovered to correspond to two related proteins, betaglycan and
endoglin [84-86]. The evidence suggested that type III receptors do not have an
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intrinsic signalling function but only regulate TGF-p access to the receptors. Their 
functions are varied in line with TGF-p isoforms, and cellular phenotype. There is no 
concrete evidence for type III receptors for other TGF-P family members [45].
Betaglycan is a membrane-anchored proteoglycan with an 853-amino acid core 
protein [84, 85, 87]. Betaglycan binds all three TGF-p forms with high affinity and 
facilitates TGF-P access to the type II receptor forming a betaglycan/TGF-p/TpR-II 
complex in the process [84, 85, 88, 89].
Endoglin, known as CD 105, is a cell surface molecule mainly expressed in vascular 
endothelial cells, and at lower levels in vascular smooth muscle cells, leukemic cells 
of pre-B and myelomonocytic origin, fibroblasts, macrophages, and erythroid 
precursors [90, 91]. Endoglin binds TGF-P 1 and -P3 in the presence of TGF-P type I 
and II receptors, but unlike betaglycan, it does not bind TGF-P2 [91, 92]. 
Furthermore, endoglin can bind to type I or II receptors even in the absence of ligand
[93]. But endoglin alone may not bind TGF-p in endothelial and leukemic cells [92]. 
Some work show that endoglin counteracts TGF-p 1-induced extracellular matrix 
genes (i.e. collagen, fibronectin), PAI-1, and connective tissue growth factor via 
mediating inhibition of TGF-pl signalling [93-95].
1.4.1.2 Smads family and nuclear accumulation
Based on structural and functional features, Smads fall into three subfamilies: 
receptor-regulated Smads (R-Smads), a common pathway Smad (co-Smad), and 
inhibitory Smads (I-Smads). R-Smads include Smad2 and Smad3, which are
recognized by TGF-p and activin receptors, and Smads 1, 5, and 8, the substrates of
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BMP receptors. TGF-p-Smads are phosphorylated directly by TGF-p type I receptor. 
Smad4 is a common pathway Smad (also called cooperating Smad or co-Smad), 
which is not phosphorylated by the TGF-P type I receptor [45]. I-Smads include 
Smad6 and Smad7, which regulate TGF-p signalling in a negative feedback pathway.
TGF-p type I receptor phosphorylates the C-terminal sequence SSXS of R-Smads to 
free these two domains from a basal mutually inhibitory interaction, leading to R- 
Smad activation and combination with Smad4. Co-Smads and I-Smads lack the 
SSXS sequence and therefore can not be phosphorylated by the activated type I 
receptor.
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Smads contain an N-terminal mad homology 1 domain (MH1), and a C-terminal
MH2 domain. MH1 domain has DNA-binding activity, whereas MH2 triggers
Smads complex accumulation into the nucleus and regulates target genes
transcription by combing with co-activators or co-repressors. The MH1 domain, is
highly conserved among R-Smads and Co-Smads, regulating nuclear import and
transcription by binding to target DNA promoter elements and interacting with
nuclear transcriptional factors [94, 95]. The MH1 domain of the R-Smads and
Smad4 also contains a nuclear localization signal (NLS) and in the R-Smads the
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MH1 domain appears to inhibit the functional activity of the MH2 domain prior to 
receptor phosphorylation [96] .The MH2 domain is highly conserved among all 
Smads. The MH2 domain regulates Smad oligomerisation and recognition by type I 
receptors and interacts with cytoplasmic adaptors and several transcription factors
[94]. The linker region is highly variable in length and sequence. In R-Smads, the 
linker region contains Mitogen-activated protein kinase (MAPK) phosphorylation 
sites [45, 97]. MAPK activated phosphorylation of these sites inhibits nuclear 
translocation of Smads. Also, the linker region of I-Smads contains a proline- 
tyrosine (PY) motif, which specifically interacts with an E3 ubiquitin ligase 
implicated in the regulation of the TGF-p and BMP pathways [98-100]. The I-Smads 
are structurally related to the R-Smads and Smad4 in their MH2 domain, but have a 
more divergent N-terminus [94] (see Fig.l).
R-Smads and Smad4 are continuously shuttling between the cytoplasm and nucleus 
in the absence or presence of signal [101-103]. The Smad shuttling in the presence of 
TGF-P allows the Smads to continuously monitor membrane receptor activity. 
Particularly with respect to Smad2, additional proteins are required to facilitate the 
phosphorylation of R-Smads by the activated receptor complex. The MH2 domain of 
R-Smads interacts with a Smad-binding domain in Smad Anchor for Receptor 
Activation (SARA) [95], an accessory protein that forms a bridge between the type I 
receptor and R-Smads [97]. Upon phosphorylation R-Smads are released from 
SARA. In addition, evidence in both early vertebrate embryos and mammalian cells 
showed that the cellular microtubule network and the kinesin-1 motor are necessary 
for Smad2 phosphorylation, by assisting Smad2/receptor interaction [104]. 
Following receptor-mediated phosphorylation, R-Smads oligomerise with the co-
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Smad, Smad4, and accumulate in the nucleus. Although Smad4 is not required for 
nuclear accumulation of R-Smad complexes, it is necessary for the formation of 
transcriptional R-Smad-DNA-binding complexes. The precise stoichiometry of R- 
Smad/co-Smad interaction has been a subject of debate, however, Isothermal 
titration calorimetry and mutational studies have revealed the crystal structure of 
heterotrimers recruited by two phosphorylated R-Smad subunits and one Smad4 via 
the MH2 domains of phospho-Smad2-Smad4 and phospho-Smad3-Smad4 
complexes [105-107].
1.4.1.3 DNA-binding and transcriptional factor interaction
After R-Smad phosphorylation and association with Smad4, the complex 
translocates into the nucleus, participating in DNA binding via a p-hairpin structure 
protruding from the surface of the MH1 domain and recruitment of transcriptional 
cofactors to initiate the transcription of target genes, both positively and negatively.
Utilizing TGF-P-activated plasminogen activator inhibitor-1 (PAI-1) promoter, 
DNA-binding site selection experiments and mutation analysis identified the Smad3- 
Smad4 recognized DNA binding element. It contains a repeated AGAC sequence or 
its reverse complement GTCT in the opposite strand, [38, 108], and is known as a 
Smad-binding element (SBE). The most common splice form of Smad2 cannot bind 
DNA directly because of a small extra exon-3-encoded insert [46].
R-Smad-containing complexes have been shown to recruit the ATPase subunit of the 
SWI-SNF chromatin remodelling complex, Brgl [102, 109], Fasti, 3 and also 
histone modifying enzymes such as the histone acetyltransferases p300 and CREB
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(cAMP response element binding protein) binding protein (CBP) to participate in 
TGF-p-induced transcription responses [110, 111]. Smad-dependent chromatin 
remodeling and histone modifications are thought to facilitate the subsequent 
recruitment of the general transcription machinery to target gene promoters. Once 
within the nucleus, the R-Smads may associate with specific nuclear transcription 
coactivators such as activating protein-1 (Ap-1) family of transcription factors, 
P300/CBP [112-115], nuclear factor-kappaB (NF-kB) [116-118], runt-related 
transcription factor-2 (Runx2) [119, 120], signal protein-1 (Spl) [121] and 
transcriptional corepressors such as Sloan-Kettering Institute proto-oncogene (Ski), 
TG-interacting factor (TGIF) and Ski-related novel gene (SnoN, non Alu-containing) 
by MH2 domain [122-129].
1.4.2 Crosstalk with Non-Smad Signalling Pathways
It has been firmly established that Smad pathways are central mediators of TGF-p 
signalling. However, there are several non-Smad signalling pathways that are 
involved in the TGF-P 1 signal pathway including MAPK, phosphatidylinositol 3- 
kinase (PI3K), RhoA and Racl small GTPases. These non-Smad pathways are 
implicated as mediators of TGF-p-induced outcomes such as EMT, apoptosis, cell 
proliferation and differentiation [130-132]. There are three fashions of cross-talks 
contributing to responses to TGF-p: (1) non-Smad signalling pathways directly 
modify the Smads activity and thus regulate the TGF-P signalling pathway, such as 
MAP-kinase activated phosphorylation of Smads linker region; (2) Smads directly 
interact and modulate the other signalling mediators, thus transmitting Smads signals 
to other pathways. For instance, TGF-P 1 can activate ERK (extracellular signal-
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regulated kinase), c-Jun N-terminal kinase (JNK) and P38 MAPK kinase pathway; 
and (3) at the TGF-p receptors level, the non-Smad proteins directly can be activated 
and initiate parallel signalling collaborating with the Smad pathway[131]. An 
example for this is the link between TGF-P 1 receptors and RhoGTPase to regulate 
EMT. TGF-pl type II receptor phosphorylats type I receptor as well as type I 
receptor-tethered Par6, leading to the recruitment of Smad ubiquitination related 
factor 1 (Smurfl) and then final degradation of RhoA [133].
The MAPK is a major signalling system involved in TGF-pl classical signalling 
pathway [134]. Three major subgroups of the MAPK superfamily members have 
been identified: the extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2); 
JNK; and the p38 MAPK. Besides MAPK pathway, RhoGTPases, PI3K/Akt and 
protein kinase c (PKC) signalling pathway are also key participants in TGF-P 1-Smad 
signalling pathway [131].
These non-Smad pathways are initiated by activated TGF-pl receptors through 
either phosphorylation or direct interaction independently of Smads, then the 
activated non-Smad pathways interact with R-Smads such as phosphorylating linker 
region of R-Smads or recruiting other co-factors to take part in the Smads-regulated 
target genes ,such as matrix metalloproteinase-1 (MMP-1) and tissue inhibitors of 
MMP-1 (TIMP-1) [132].
1.5 Regulation o f TGF-pl signalling
1.5.1 Regulation of TGF-pi activation and interaction with TGF-p 
receptors
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The production of TGF-pl in a latent form is likely to be an important determinant 
for the strength of TGF-pl activity, ensuring that TGF-pl activity is only generated 
in a specified situation. Latent TGF-P 1 can be activated by denaturing and by heat, 
detergents, extremes of pH, and radiation [135,136].
Thrombospondin-1 (TSP-1) may also serve to activate TGF-pl in the kidney. TSP-1 
is expressed in platelets, platelet alpha-granules, vascular smooth muscle cells and 
mesangial cells during inflammation and wound healing. It is a trimer of disulfide- 
linked 180 kDa subunits, consisting of several domains that bind to matrix and cell 
surface proteins [137-140]. In human renal disease and experimental renal disease 
models, there is increased TSP-1 expression in human focal sclerosis, vasculitis, 
membranous glomerulonephritis (GN), and diabetic GN as well as in several animal 
models of glomerulonephritis (such as anti-Thyl model, aminonucleoside nephrosis, 
passive Heymann nephritis) [141, 142]. With specific strategies to block TSP1 
activity, such as synthetic peptides (GGWSHW or LSKL) or TSP-1 antisense 
oligonucleotide, the latent activation of TGF-pl to bioactive growth factor was 
inhibited, especially in glomerular mesangial cells exposed to high glucose in vitro 
or in vivo [139, 140, 143]. Hereby, TSP-1 might trigger latent TGF-pl activation via 
binding to the LAP, as a non-protease mediated release of active TGF-pl.
Plasmin and the lysomal serine protease cathepsin D, both of which are proteases, 
can activate latent TGF-P 1 in fibroblasts under cell-conditioned medium in vitro. 
This result suggested that activation of latent TGF-pl may occur by proteolytic 
nicking within the LAP, thereby resulting in the release of active, mature TGF-pl 
[63, 144]. In terms of another latent TGF-p binding protein (LTBP), evidence
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showed that TGF-pl activation can be achieved via proteolytic release of LTBP 
from ECM by cleavage at a specific protease-sensitive site in LTBP [145,146].
Activation of TGF-pl may also be mediated by integrins. Induction of integrin 
alphavbetab led to activation of TGF-pl, whereas inhibition of integrin with its 
specific antagonist EMD527040 blocked TGF-pl activation, suggesting integrin was 
required for this process [147, 148]. There are two possible models to explain how 
integrins is involved in the latent TGF-pl activation. Firstly, in a protease-dependent 
mechanism, integrins are proposed to simultaneously bind the latent TGF-pl 
complex together with proteinases and the adjacent proteinases improve enzymatic 
cleavage of the latent complex to release active TGF-pl. Secondly, Integrin binds 
LAP and changes the conformation of the latent TGF-pl complex by transmitting 
cell traction forces with the ECM support of mechanically resistant ECM in a non­
protease method [124,149].
As discussed before, betaglycan can facilitate TGF-P 1 binding to the type II receptor 
and promote TGF-P 1 responses. Wang et al also found in L6 myoblasts lacking the 
endogenous type III receptor, the recombinant receptor increases ligand-receptor 
bound and integrates with type II TGF-P receptors. This indicates that the type III 
receptor may regulate the ligand-binding ability or surface expression of the type II 
receptor [85, 150]. Additionally, CTGF (connective tissue growth factor ) can 
increase the crosslinking between TGF-P 1 and its three receptors via its carboxy- 
terminal cystine knot (CT) domain in vitro to facilitate TGF-p signalling pathway 
[151].
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1.5.2 Regulation of TGF-p receptor turnover and degradation
Cell surface receptor internalization is a primary step to initiate signal transduction. 
In higher eukaryotic cells, internalization of cell surface proteins occurs through both 
clathrin-dependent and -independent pathways [152], Studies have demonstrated that 
TGF-p receptor internalization is through the classic clathrin-dependent pathway as 
well as the raft-caveolin non-clathrin pathway [153]. The clathrin-dependent 
internalisation into the EEA1 (early endosome antigen-1) positive vesicles, promotes 
TGF-pl-activated Smads signalling [154]. In contrast, the Smad7-Smurf2 -  
dependent receptor degradation is dependent on the caveolar pathway [153]. Thus, 
segregation of TGF-p receptors into the two distinct endocytic membrane pools 
regulates receptor turnover and subsequently Smad activation. In addition, the E3 
ligase Smurfl is also targeted to the activated TGF-p type I receptor by Smad7 and 
promotes receptor degradation [99,155].
In our lab, previous work has shown that the interaction of hyaluronan (HA) with its 
receptor CD44 leads to the majority of TGF-P receptors trafficking to caveolin-1 
lipid raft-associated membrane pools in PTC. In the presence of HA, concomitant 
with TGF-p receptor partitioning into the lipid raft compartment, there was an 
increase in the association of the TGF-P receptor with Smad7, and a decrease in the 
association of phosphorylated Smad proteins. This implies that HA-mediated 
downregulation of TGF-P signalling is related to increased TGF-P receptor 
trafficking to lipid raft compartment away from the endosomal signalling 
compartment [156].
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1.5.3 1-Smads: Negative feedback regulators of TGF-P signalling
I-Smads negatively regulate the TGF-p signalling pathway in a feedback loop 
primarily. I-Smads (Smad6 and Smad7) bind directly to type I receptors and compete 
with R-Smads phosphorylation by the receptors and then interfere with their 
association with Smad4, resulting in inhibition of TGF-p signalling [72, 157-159]. I- 
Smads also bind to the Smurf family of E3 ligase as adaptors to recruit Smurfs to the 
receptor complex and thereby mediate receptor degradation and downregulation of 
TGF-P signalling [99,100]. I-Smads inhibit transcriptional factors recruitment by the 
R-Smads [160] or disrupt the formation of the TGF-p-induced functional Smad- 
DNA complex in nucleus [161].
1.5.4 Regulations of Smads
1.5.4.1 Ubiquitin proteasome system related Smads degradation
The ubiquitin-proteasome pathway (UPP), a main path to degrade protein, regulates 
the stability of proteins. It consists of ubiquitin, ubiquitin ligases and 26S 
proteasomes. Degradation of target protein by UPP system involves two steps: target 
proteins are poly-ubiquitinated by ubiquitin ligases (ubiquitination), and 26S 
proteasomes subsequently recognize and degrade poly-ubiquitinated target proteins 
[162, 163]. Ubiquitin ligases which link ubiquitin to target proteins include three 
distinct classes of enzymes: El ubiquitin-activating enzyme, E2 ubiquitin- 
conjugating enzymes and E3 ubiquitin ligases. El and E2 enzymes are not highly 
substrate specific, whereas E3 ubiquitin ligases play key roles in the recognition of
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target proteins and subsequent degradation by 26S proteasomes specifically [164]. 
The E3s can be divided into two main functional classes, the Really Interesting New 
Gene (RING) domain E3s that function primarily as adapter proteins and the 
Homologous to the E6-AP Carboxyl Terminus (HECT) domain E3s that catalyse the 
transfer of the ubiquitin from the E2 to the substrate [165].
The degradation of R-Smads, including Smad2 and Smad3 by ubiquitin-proteasome 
pathways in a ligand-dependent manner results in TGF-P signalling termination 
[166]. Smad3 activated by TGF-p is degraded by ROC1-SCF complexes in the 
nucleus [167].
Smurfl (Smad ubiquitination related factor) and Smurf2 are HECT type E3 ligases. 
In in vitro studies, it was shown that Smurfl/2 can interact with R-Smads including 
Smadl, -2, and -3, and degrade them [168, 169]. Similar to Smad2, once bound to 
and ubiquitinated by the E3 ligase complex, nuclear Smad3 is exported from the 
nucleus and proteasomally degraded in the cytoplasm. Moreover, recruitment of the 
transcriptional coactivator p300 to activated Smad3 facilitates the interaction with 
the E3 ligase complex, and triggers the process of Smad3 degradation [166]. In 
addition, Smurfs stimulate I-Smads to export from the nucleus to the cytoplasm after 
forming Smurfs-I-Smads complex. Then the I-Smads are recruited to TGF-P and 
BMP receptors as an adaptor, initiating the degradation of these receptors via UPP 
pathway [99, 100, 170]. Thus, Smurfs support inhibitory activities of I-Smads in 
TGF-p superfamily signalling pathways.
Arkadia was originally isolated through gene-trap insertion mutagenesis in mice [99].
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Arkadia contains a RING finger domain in its C-terminal region, suggesting activity 
as an E3 ubiquitin ligase. Arkadia is expressed ubiquitously in embryonic and adult 
tissues [171, 172]. In normal renal tissue, Arkadia protein was expressed weakly in 
medullary renal tubular, abundantly in cortical renal tubular, glomeruli and renal 
interstitium. Arkadia only interacts strongly with I-Smads, and associates with 
Smad3 weakly, but not with other Smads (Smadl, Smad2, Smad4, Smad5, Smad8) 
[173]. Immunostaining of Arkadia in unilateral ureteral obstruction (UUO) kidneys 
in mice showed it is gradually enhanced, but that of Smad7 is decreased [173]. In 
contrast, Koinuma D et al have shown that Arkadia expression is transiently 
repressed but Smad7 induced by TGF-p in HaCaT cells and that it enhances TGF-p 
signalling by interacting with Smad7 and then inducing degradation of Smad7 [172]. 
During renal tubular EMT in HKC cells, Arkadia expression was increased by TGF- 
P treatment, and Arkadia can positively contribute to EMT through degradation of 
Smad7 [174]. Overall, Arkadia regulates the transcriptional activity of TGF-p 
through degradation of Smad7. In contrast to Smurfs, Arkadia is not recruited to 
TGF-p receptors [173].
1.5.4.2 R-Smads dephosphorylation at C-terminals
Clearly, regulation of R-Smad degradation is an important potential mechanism of 
regulation of TGF-p signalling. However, more recent findings suggest that the 
majority of activated R-Smads are not degraded but recycled [101] and that 
dephosphorylation is a prerequisite for the recycling of R-Smads [102]. It was 
demonstrated that the TGF-p-regulated R-Smads, Smad2 and Smad3, constantly 
shuttle between the nucleus and the cytoplasm both in basal context [175] and during 
TGF-p signalling. Smad nucleocytoplasmic shuttling was suggested as a mechanism
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whereby the Smads monitored receptor activity [102]. Most importantly, cycles of 
Smad phosphorylation and dephosphorylation are required to maintain this 
nucleocytoplasmic Smad shuttling in the presence of a TGF-P signal. Thus 
phosphatases have been proposed to be key regulatory molecules in these important 
signal pathways. Xin-Hua Feng and colleagues [176] have identified PPM1A to 
dephosphorylate TGF-p-activated Smad2/3. Removal of C-terminal phosphates from 
R-Smads terminates TGF-P signalling without proteasome-mediated R-Smad 
degradation. This indicates another crucial regulation partner of R-Smads 
phosphorylation in TGF-p signalling pathway.
1.5.4.3 Acetylation of Smads
Acetylation is a lysine-specific modification that regulates most histones, but also 
non-histone proteins such as transcriptional regulators [177]. Smad7 was shown to 
be a substrate of acetylation by the histone acetyltransferase (HAT) activity of the 
co-activator p300, preventing Smad7 ubiquitination and degradation in the 
proteasome [178]. Also, decreased acetylation of Smad7 is correlated with 
upregulation of Smad7 ubiquitination and decrease of Smad7 stability [178]. In 
keeping with this, histone deacetylase (HDAC) can mediate Smad7 deacetylation 
thus leading to an acceleration in Smad7 degradation [179]. Therefore it appears that 
there is a balance between acetylation and HDAC-medicated deacetylation 
regulating Smad7 stability [178,180].
The TGF-p-R-Smads have also been shown to be acetylated by p300 and CBP. 
Acetylation of Smad2 and Smad3 enhances transcriptional activity, however unlike 
Smad7, these modifications do not affect the stability of the R-Smads [111, 180,
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181].
1.5.4.4 Sumoylation of Smad4
Small ubiquitin-like modifier (SUMO), an ubiquitin-related polypeptide, has also 
been shown to be important in altering target protein functions. Some studies 
demonstrated that Smad4 is modified by sumoylation localizing in its linker segment 
or MH1 domain [182, 183]. Sumoylation of Smad4 regulates its stability, represses 
Smad4 transcriptional activity, and increases its nuclear accumulation at basal level 
and in the presence of TGF-P [183, 184]. However, some tumour-associated 
mutations allow ubiquitination and/or decrease the stability of Smad4[185]. The 
Smad activation domain (SAD) in the linker region of Smad4 has been showed to 
play an essential role in Smad4 transcriptional activity [186]. In addition, SUMO 
modification of Smad4 may change the complex conformation, thus inhibiting the 
assembly of active transcriptional complexes or promoting the assembly of 
transcriptional repressor complexes [183].
1.5.5 Transcription modulation
In the nucleus, R-Smad-Co-Smad complexes are involved in transcriptional 
regulation of target genes, but Smads do not act as transcription factors alone. The 
complex of Smads with other appropriate transcription factors confers DNA binding 
specificity to the Smad-containing transcription complex [187]. The Smads 
transcriptional regulation on DNA-binding is mainly through the modulation of 
chromatin structure. There are two essential ways to modulate transcription via 
chromatin structure: either post-translationally modify histones or move the position
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of nucleosomes on DNA. The Smads have been shown to interact with a series of co­
activators and co-repressors to modify chromatin activities or a chromatin- 
remodelling complex.
1.5.5.1 HATs
Histone acetylation enables transcription factors and the transcription machinery to 
access DNA, and many transcription co-activators have histone-acetyltransferase 
activity. Co-activators, p300/CBP are identified as histone acetyltransferases that 
potentiate transcription by loosing the acetylation-dependent chromatin structure, and 
then enhancing the DNA-binding activity. There are several mechanisms to undergo 
the chromatin modulation structurally and functionally. They act as a bridging factor 
between transcription factors and the basal transcription machinery [188]. TGF-p 1- 
mediated phosphorylation of Smad3 promotes the conformational assembly between 
Smad3 and p300, leading to transcriptional regulation [109,189,190].
In addition p300/CBP alone, several other factors modulate TGF-p-dependent gene 
expression related to p300/CBP. One of the ZEB family, ZEB-1/deltaEFl binds to 
p300 and promotes the p300-Smad transcriptional complex formation [191, 192]. 
The nuclear factor MSG1 and the steroid receptor co-activator 1 (SRC1) both 
enhance TGF-p-regulated transcription in a p300/CBP dependent manner [193, 194]. 
Whereas transcriptional co-repressors such as Smad nuclear interacting protein 1 
(SNIP1) and TGIF suppress TGF-p-regulated gene expression through interfering 
with the p300/CBP-Smad complex partly [125,195]. In addition, Lithium and BCL6 
disrupts Smad3/4-p300/CBP complex and suppresses transcriptional Smad3/4- 
dependent genes transcription [196,197].
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1.5.5.2 HDACs
HDACs remove acetylation groups from histones to prevent the transcription 
complex from binding to the promoter DNA-binding sites, thus leading to 
transcription inhibition. HDACs are recruited directly by Smads or by associated co­
repressors [109].
Antagonizing Smad-mediated gene transcription by co-repressors, Ski, SnoN and 
TGIF, is also an important regulatory component [126]. In response to TGF-P, SnoN, 
and to a certain extent Ski, is rapidly degraded, therefore allowing the the activation 
of TGF-pl target genes. However, SnoN expression is also induced in response to 
TGF-p acting as a negative feedback loop to terminate target gene transcription [198, 
199]. Ski and SnoN repress TGF-p-induced transcription by disrupting the 
interaction of the Smads with co-activtor p300 and on the other hand actively recruit 
a co-repressor complex consisting of HDAC1 [122, 200]. Some co-repressors 
including Smad-interacting protein 1 (SIP1), TGIF and ecotropic virus integration 
site 1 protein homolog (Evi-1) can inhibit Smad-mediated transcription, possibly 
through the recruitment of HD AC activity [201-204]. Overall, the final 
transcriptional outcome by TGF-pl may depend on the balance between HATs and 
HDACs under specific cellular conditions.
1.5.5.3 Chromatin remodelling by the Smads
ATP-dependant chromatin remodelling complexes such as switching of mating 
type/sucrose nonfermenting (SWI/SNF), imitation switch (ISWI), nucleosomes 
remodelling and deacetylase (NuRD) are involved in the regulation of gene 
expression, both activating transcription by moving nucleosomes and repressing
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transcription by altering the chromatin structure of promoters. For example, in vitro 
experiments with assembled chromatin templates have shown that Brgl is essential 
for phosphorylated Smad2 complexes to activate transcription [109].
1.5.6 Regulation of Non-Smad pathway on TGF-p signalling
TGF-pl stimulates ERK, JNK, and p38 via TGF-P 1 receptors independently of 
Smads [205, 206]. p38, ERK, and JNK MAP kinase inhibition blocks the expression 
of TGF-p-induced CCN2/CTGF in lung or with gingival fibroblasts [207], 
suggesting the involvement of MAPK pathways in TGF-pl signalling cascade.
On the other hand, ERK phosphorylation in the linker region of Smad proteins 
associates with decrease of Smads nuclear translocation, suggesting that ERK may 
also act as a negative regulator of TGF-P 1 signalling pathway [45]. ERK, JNK, and 
p38 have all been implicated in the transcriptional regulation of Smad7, therefore 
indirectly regulating TGF-p signalling [222].
TGF-pl can up or down-regulate Rho-like GTPases including RhoA and P13K/Akt 
pathways to contribute to TGF-P 1-induced functions independent of R-Smads 
activation [208-212].
The linker-region of Smads, which contains several serine and threonine residues, 
allows for regulation of R-Smads by multiple signalling participants including 
MAPK. The linker region of Smadl contains four MAPK phosphorylation sites (Ser- 
187, Ser-195, Ser-206, and Ser-214), whereas Smad2/3 linker regions contain four
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SP/TP sites for proline-directed kinases. In response to mitogens, ERK MAPK 
mediates the phosphorylation of these sites in vivo [213]. Cyclin-dependant kinases 
(CDK) CDK-2 and -4 have also been reported to mediate the phosphorylation of 
some of the linker residues in Smad2/3 in addition to residues at the N-terminus of 
Smad2/3. p38 MAPK and JNK also phosphorylate the linker region of Smad2/3 and 
regulate their transcriptional activity. MAPK mediated attenuation of Smad2 activity 
has been attributed to Smad2 linker phosphorylation [213]. The phosphorylation of 
MAP-kinase sites in the Smads linker region can inhibit the accumulation of Smads 
in the nucleus [214]. As for the importance of Smad2 and Smad3 in fibrosis, some 
work has implied that Smad3 probably is the more vital actor [215].
In summary, non-Smad signalling in response to TGF-pl plays an important role in 
determining the response to TGF-pl, but in some cases this is via modulation of 
Smad responses. Most of the evidence is consistent with Smad signalling being the 
key determinant of TGF-pl responses.
Even though massive amounts of work have been done to reveal the mechanisms of 
TGF-pl signalling regulation, a lot of the detail of how cellular response to TGF-pl 
is altered by other signalling pathways remains unclear. The aim of my work was to 
explore regulation of TGF-pl signalling in PTC in renal fibrosis. Two stimuli were 
chosen, namely IL-lp and BMP-7.
1.6 Interleukin-1 beta (IL-lp)
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Inflammation is a key contributor to kidney diseases. Acute inflammation is 
associated with repair following acute injury [216], but more prolonged 
inflammation is linked to fibrosis, in which inflammation, tissue remodeling and 
repair processes occur simultaneously [217, 218]. Most chronic fibrotic disorders 
have a long-term stimulation that sustains the production of growth factors, 
proteolytic enzymes, and fibrogenic cytokines, causing the excessive deposition of 
extra cellular connective tissue elements that progressively destroy and remodel the 
normal tissue architecture [218]. TGF-P 1 is a key profibrotic cytokine but also plays 
an important role in repair following acute injury. Pro-inflammatory cytokines are 
important negative regulators of TGF-P signalling in acute inflammation [219]. 
However, recent work suggests that chronic inflammation may promote fibrosis by 
enhancing epithelial cell signalling responses to TGF-pl [220, 221]. TGF-pl, with 
its broad and crucial functions in the immune system, inevitably also alters signalling 
responses to ILs, TNFa, and Interferon gamma (IFN-y) [222]. Taken together, there 
is a complex interplay between TGF-p and pro-inflammatory cytokine signalling, 
with the final transcriptional and other cellular responses determined by the 
integration of these hypothetically distinct signalling pathways in a manner that is 
dependent on on stimulus, cellular context, and time.
Interleukin-1 beta (IL-lp) is a key regulator of inflammatory responses, and many 
other physiological/pathological functions. IL-lp induces local Smad3-dependent 
tissue fibrosis when over-expressed in the murine lung [223] or peritoneum[224], 
and chronic IL-lp administration induces EMT [225], a key step in fibrogenesis 
[226]. Conversely, IL-lp inhibits renal mesangial cell TGF-pl generation [227], 
impairs TGF-pl response in chondrocytes via decreased type II receptor expression
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[228, 229], and delays TGF-pl-induced fibroblast to myofibroblast differentiation 
[230]. Furthermore, Interleukin Receptor Antagonist deficient mice, in whom IL-lp 
signalling is enhanced, exhibit suppressed TGF-pl signalling [231].
Therefore, IL-lp was studied as a prototypic proinflammatory stimulus, because the 
above apparently contradictory outcomes in respect of both stimulatory and 
inhibitory effects of IL-lp in different contexts. Furthermore, our lab has previously 
delineated altered PTC HA synthesis in response to IL-lp, and altered TGF-pl 
signalling via HA, a possible mechanism link shared by IL-lp and the second 
stimulus chosen for study, BMP-7.
1.7 Bone Morphogenetic protein 7 (BMP-7)
1.7.1 General introduction of BMP-7
BMPs are a group of proteins that were originally identified based on their unique 
ability to stimulate cartilage and bone formation in vivo [232]. More than 20 BMP- 
like proteins have been cloned in vertebrates. Except for BMP-1, all share sequence 
homology with transforming growth factor-beta superfamily members [233]. BMPs 
also function in a number of non-osteogenic development processes. Bone 
morphogenic protein-7 (BMP-7), also referred to as osteogenic protein-1 (OP-1) or 
DVR-7, is a 35-Kd homodimeric protein and was originally identified as a potent 
osteogenic factor purified from bone [234]; BMP-7 is a member of the TGF-p 
superfamily that is required during embryogenesis for normal skeletal, kidney, and 
eye development [235]. BMP-7 deficient mice die shortly after birth because of poor
41
kidney development [236, 237]. In the adult murine organism, BMP-7 is expressed 
in many tissues but kidney is the organ with the highest level of expression [238]. 
BMP-7 is detected in circulating blood and in vivo studies demonstrated BMP-7 acts 
as an endocrine modes at distant targets to promote liver regeneration [239]. 
Moreover, BMP-7, similar to other peptides within the TGF-p superfamily, binds to 
extracellular matrix proteins by paracrine mode [240].
1.7.2 BMP-7 and receptor distribution in developing and normal 
adult kidney
In adult mouse kidney, BMP-7 is abundantly expressed in the medullary region and 
ureter, and to a lesser extent in the cortical region. BMP-7 is expressed in podocytes, 
collecting ducts, thick ascending limb, distal convoluted tubule, but not in proximal 
tubules, thin descending limb, loop of Henle, or in the peritubular vasculature [241]. 
In adult rat kidney, BMP-7 is expressed immunohistologically lightly in some 
cortical proximal tubular cross-sections, but strongly in distal convoluted tubules and 
collecting ducts. There is evidence to show BMP-7 expression in glomerular 
podocytes in vivo specifically and exclusively in rats and in mice. But BMP-7 
expression from normal human kidney is rather scarce [242-244]. In situ 
hybridization and immunostaining have shown localization of mRNA transcripts and 
the protein for BMP type II receptor in convoluted tubule epithelium and the 
glomeruli in the cortex, and the collecting ducts in the medulla region in rat kidney, 
suggesting that the cellular targets for BMP-7 in the kidney are in similar areas of the 
cortex and medulla [245]. In vitro, BMP receptors are abundant in human proximal 
tubule HK-2 cells but also are present in mesangial cells [241]. In human primary
proximal tubular epithelial cells (PTEC), all known BMP type I and II receptors 
excluding the type I receptor, BMPR-IB were defined by RT-PCR [246].
1.7.3 Evidence of BMP-7 protective effects on renal acute and 
chronic renal injury
BMP-7 mRNA expression is decreased in the outer medulla and glomeruli in the 
acute ischemic rat kidneys after 16 h of reperfusion [244]. Expression of BMP-7 is 
reduced in obstructed kidney UUO animal model, pyelonephritis, chronic allograft 
nephropathy [247-250]. Decrease of BMP-7 expression was also detected in mouse 
podocytes under high glucose culture in vitro, and in renal biopsies of patients with 
diabetic nephropathy [240, 251]. In diabetic rats, the expression of BMP-7 in renal 
tubules is decreased gradually, along with BMP-7 receptors. In contrast, more and 
more TGF-pl is detected with the development of diabetes. Gremlin is an antagonist 
of BMP-7. Gremlin mRNA levels were significantly increased [252], suggesting 
overall that there is a balance between BMP7 and TGF-p, as has been suggested by 
some investigators.
Increasing evidence showed BMP-7 plays a key role in kidney development and 
postnatal function [253]. In addition, loss of BMP-7 signalling pathway activity, 
such as less phosphorylation of Smadl/5 protein, was also observed in experimental 
nephrotoxic serum nephritis and diabetic nephropathy [44,254].
Several in vivo studies using animal models of acute and chronic renal failure 
demonstrated that BMP-7 not only improves renal function and maintains, to a
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variable degree, renal epithelial cell morphology [244], but also prevents 
complications of chronic kidney diseases, like renal osteodystrophy and vascular 
calcification [255,256].
BMP-7 induces differentiation of metanephric mesenchymal cells into epithelial 
cells [244]. Blocking BMP-7 activity increased expression of fibronectin 
significantly. Also, exogenous BMP-7 blunted the epithelial cell apoptosis as well as 
increased interstitial volume based on excessive collagen IV matrix production and 
tubular atrophy, which is beneficial for the maintenance of tubular epithelial integrity 
[247, 257, 258]. In addition, transgenically expressed BMP-7 or exogenously 
rhBMP-7 adminstration reduces the diabetic podocyte injury and postpones initiation 
and progression of experimental diabetic nephropathy [240]. BMP-7 inhibits tubular 
epithelial cell damage in UUO model and maintains renal function by preventing 
tubular atrophy and attenuating tubulointerstitial inflammation and fibrosis activation 
[247,258,259].
BMP-7 diminished the activation of tubulointerstitial inflammational 
monocyte/macrophage interstitial infiltration [247] and CTGF [260]. In our lab, 
previous work has shown that BMP-7 inhibits monocyte-stimulated TGF-pl 
generation in human renal proximal tubular epithelial cells (HK-2) [261]. Gould et al 
have found that BMP-7 significantly reduces the expression of pro-inflammatory 
cytokines including IL-6 and IL-lp, the chemokines IL-8 and MCP-1, the vasoactive 
peptide endothelin-2 (ET-2) in primary human proximal tubule cells [246].
Michael Zeisberg et al showed that administration of BMP-7 leads to reversal of
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TGF-pl-induced EMT by reduction of E-cadherin in vivo and in vitro, in association 
with reversal of chronic renal injury in chronic renal injury mouse model [262]. 
Furthermore, BMP-7 might induce mesenchymal to epithelial transition (MET) 
involving adult renal fibroblasts in the injured kidney, generating functional 
epithelial cells [263]. On human peritoneal mesothelial cells (HPMcs), decreased 
expression of BMP-7 was observed in high glucose induced EMT and treatment with 
BMP-7 blocked this transition. In vivo, further evidence showed BMP-7 ameliorated 
peritoneal fibrosis in an animal model of peritoneal dialysis [264]. Controversially, 
Paul L. Dudas et al found BMP-7 was unable to inhibit EMT in either primary or 
immortalized human proximal tubule cells, however a protective effect observed at 
an elevated BMP-7 concentration in mouse renal tubular epithelial cells [265].
1.8 HA-CD44: A possible common mechanism for TGF-p 
signalling regulation?
HA is a ubiquitous connective tissue polysaccharide as a high molecular mass 
component of ECM in vivo. HA is a nonsulphated, linear glycosaminoglycan (GAG) 
consisting of the repeating disaccharide units, d-glucuronic acid and N-acetyl- 
dglucosamine. It exists as a polymer of approximately 104-107 kDa molecular 
weight [266]. The synthesis of HA is regulated by three mammalian HA synthase 
isozymes: HAS1, HAS2 and HAS3 [267, 268]. HA degradation is carried out by a 
family of six endo-N-acetylhexosaminidases, the hyaluronidases (Hyal) identified in 
human [269].
In addition to provide cellular support, it is now known that under normal
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circumstances, hyaluronan regulates cell-cell adhesion, migration, proliferation, 
differentiation, and the movement of interstitial fluid and macromolecules [266]. HA 
is only expressed in the interstitium of the normal renal papilla, and its alteration has 
been invovled in renal water handling regulation by affecting physiochemical 
characteristics of the papillary interstitial matrix and the interstitial hydrostatic 
pressure[270].
CD44 is a principal signal-transducing cell-surface glycoprotein receptor of HA that 
influences cell proliferation, survival and motility relevant to cancer. It contains an 
ectodomain, a transmembrane domain and a cytoplasmic domain [271, 272]. CD44 
also mediates the cellular uptake and degradation of hyaluronan, which affects 
growth regulation and tissue integrity in tumor growth and progression [273-276] . 
CD44 is expressed by tubular epithelial cells in areas of tubular injury, but hardly 
detected in normal kidneys [277, 278]. In ischemic DM kidneys, HA and CD44 
staining started to increase in the cortex and outer medulla [279]. The CD44 
expression is correlated closely with the degree of glomerular and interstitial damage 
histopathologically. There is also a positive correlation between proteinuria and the 
expression of CD44 in the tubulointerstitial compartment [280]. The work in our lab 
has shown in PTC, standard CD44 and CD44 variants were detected [281].
HA is expressed in the interstitium following renal injury caused by diverse diseases, 
such as interstitial nephritis, ischemia/refusion injury and IgA nephrology, lupus 
nephritis, various animal models [282-287] . In progressive renal disease associated 
with IgA nephropathy, the correlation between the excess deposition of interstitial
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HA and renal function has been investigated [284], but the role in the pathogenesis 
of these diseases is not clear.
Previous work in our lab has investigated the relationship between HA-CD44 and 
TGF-P 1. Addition of HA antagonized TGF-P 1-mediated functional increase in type 
III and type IV collagen and anti-migration in a CD44-dependent manner in HK-2 
cells. Furthermore in TGF-pl signalling pathway, Ito et al have shown that HA 
decreased TGF-pl activation of a luciferase-Smad responsive construct, and 
translocation of Smad4 into the cell nucleus [156], and HA increased trafficking of 
TGF-pl receptors to lipid raft-associated pools, which facilitates increased receptor 
turnover and attenuation of TGF-pl-dependent alteration in proximal tubular cell 
function. This suggests that HA attenuates TGF-pi-mediated function in PTC at 
least partially via altering TGF-pl receptor compartmentalization [288].
The above data shows that binding of HA to CD44 can inhibit TGF-p signalling in 
PTC. However, there is also good evidence for enhancement of TGF-P signalling 
activity by HA/CD44 interactions in some contexts. In a malignant breast cell line, 
HA binding to CD44v3 induces Smad signalling via direct Smad phosphorylation, 
dependent on an interaction between variable stalk region of CD44 coded for by the 
v3 exon [289]. Interestingly, mice lacking CD44, show decreased proliferation and 
increased apoptosis of tubular epithelial cells following acute unilateral uretic 
obstruction, but subsequently also show a reduced fibrotic response. These effects 
are associated with reduced TGF-pl signalling, characterized by the phosphorylation 
and nuclear translocation of Smad-2 and Smad-3, and suggest that CD44 exerts renal 
protective effects on tubuli but contributes to renal fibrogenesis related to
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enhancement of TGF-pl signalling pathway in obstructive nephropathy [290].
There are also data showing that both IL-lp and BMP-7 interact with HA/CD44. In 
PTC, previous work in our lab has shown IL-lp stimulated HA synthesis and 
promoted HA binding to CD44. Moreover, Smadl, a key mediator of BMP-7 
signalling, is known to interact with the cytoplasmic domain of CD44. Further, 
interrupting extracellular hyaluronan-cell interactions with hyaluronidase inhibited 
BMP-7-mediated Smadl phosphorylation, nuclear translocation of Smadl or Smad4, 
and SBE4-luciferase reporter activation [291]. Collectively, the above data led us to 
wonder if HA/CD44 might be a “master” regulator of TGF-pl signalling in PTC, 
potentially responsible for alterations in PTC TGF-P responsiveness secondary both 
to pro-inflammatory stimuli such as IL-ip, and to reparative cytokines such as BMP- 
7.
1.9 Aim o f this thesis
The aim of this thesis was to characterize changes in TGF-pl signalling caused by 
IL-lp and BMP7 in proximal tubular epithelial cells, and to investigate the 
mechanisms underlying them.
In summary, my objectives were:
1 To determine the effects of IL-lp and BMP-7 in response to TGF-pl in PTC
2 To characterise the mechanisms of effects on TGF-pl signalling by IL-lp and 
BMP-7 in PTC
3 To assess the role of HA-CD44 in the TGF-P 1-induced signalling regulation by IL- 
lp  and BMP-7
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Chapter Two: 
Methods
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2.1 Cell Culture
2.1.1 Selection of HK-2 cell line
Human Kidney-2 (HK-2) is a clonal cell line derived from transformation of human 
proximal tubular epithelial cells with Human papilloma Virus 16 E6/E7 genes [292]. 
They retain the functional characteristics of fully differentiated PTCs, showing 
sodium dependent and phlorizin sensitive sugar transport and adenylate cyclase 
responsiveness to parathyroid hormone but are not responsive to anti-diuretic 
hormone. They are positive for proximal tubular markers including alkaline 
phosphatase, gamma glutamyltranspeptidase, leucine aminopeptidase, acid 
phosphatase, cytokeratin, alpha 3 beta 1 integrin, fibronectin. They are negative for 
distal tubular cell markers, including factor VUI-related antigen, 6.19 antigen and 
CALLA endopeptidase.
There are some concerns with extrapolating the results obtained with transformed 
cells to those predicted with primary cell cultures, and it is worth noting that over­
expression of the E7 gene (used in transformation of HK-2 cells) in an already 
malignantly transformed cell line caused a downregulation of Smad signalling [293]. 
However, extensive comparison of HK-2 cells and primary proximal tubular 
epithelial cells by our laboratory has not yielded any difference in phenotype as 
assessed by light microscopic appearance, expression and distribution of epithelial 
cell markers such as E-cadherin, Smad expression and activity, and alteration in
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proliferation, migration and cytoskeletal reorganisation in response to TGF-P 1 [281, 
294-298]. >
2.1.2 Culture of HK-2 cells
A single frozen aliquot of HK-2 cells were purchased (American Type Culture 
Collection, Manassas, VA, USA). Stock cells were frozen in liquid nitrogen after 
three passages. Cells for freezing were removed from their flask with trypsin and 
pelleted by centrifugation for cell passage, before resuspension in complete HK-2 
cell culture medium supplemented with 10% v/v DMSO and 20% v/v bovine calf 
serum.
HK-2 cells were cultured in 1:1 mixture of DMEM/Ham’s F12 (Gibco, Sigma, UK) 
supplemented with 10% fetal calf serum (FCS) (Biological Industries Ltd, 
Cumbernauld, UK), 20 mM HEPES buffer (Gibco BRL, Paisley, UK), 0.4 pg/ml 
hydrocortisone, 5 fig/ml insulin, 5 pg/ml transferrin and 5 ng/ml sodium selenite 
(Sigma Chemical Company Ltd, Poole, UK). Cells were grown in a humidified 
incubator (Cell house 170, Heto Holten, Derby, UK) at 37°C in an atmosphere of 5% 
C02. Fresh growth medium was replaced every 2-3 days until cells reached 
confluence.
To achieve cell cycle synchronisation, cells were serum-deprived for 2 days prior to 
further manipulation, except as indicated in transfection experiments. All 
experiments were performed under serum free conditions to avoid the confounding 
influence of serum on cell function.
2.1.3 Subculture of HK-2 cells
After achieving confluency, cell monolayers were treated with Trypsin/EDTA 
(0.05w/v / 0.02%v/v, Gibco/BRL, UK) diluted 1:1 in PBS for no more than 10 
minutes in the incubator. Cell detachment was monitored by light microscopy and 
accelerated by agitation of the flask. After detachment, an equal volume of FCS was 
added to terminate the activity of Trypsin and the solution was collected for 
centrifugation at 2000rpm for 6 minutes at 4°C. The cell pellet was then 
resuspended in culture medium containing 10% FCS, and seeded on to culture flasks 
for experimental manipulation. All experiments were performed using cells below 
passage 30. Except the cells used for transfection and reporter gene assay, cells were 
growth arrest in serum-free and insulin-free medium for 48 hours before use in 
experiments unless otherwise noted. All experiments were performed in serum-free 
and insulin-free conditions.
2.2 Transfection
2.2.1 Transient transfection 
Plasmids preparation
A range of plasmids were acquired for experiments listed below. Plasmids from other 
investigators were received dried into a filter paper. The spot containing the plasmid 
was rehydrated in 20ul 50mM Tris.-HCl pH 8.0. Approximately lng of the plasmid 
to be amplified was introduced into competent E.coli using heat shock at 42°C for 45 
seconds before culture in Luria-Bertani (LB) medium supplemented with lOOug/ml 
ampicilin for 1 hour. Bacteria were smeared on the LB medium/ampicilin for culture
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overnight. Only the bacteria transformed by the plasmids, which contained the 
ampicillin resistant gene, were able to grow on the plates.
The following day a single colony of transformed ampicillin resistant e.coli was 
inoculated and grown in LB medium containing ampicillin (LB/amp+medium) at 
37°C overnight. Plasmid DNA was extracted and purificated using Maxi Kit 
(QIAGEN). The remaining culture was stored in LB medium containing 20% 
glycerol (v/v) at -70°C until further plasmid production.
The pGL3-basic (SBE) 4-Lux, CAGA (4) Smad3 responsive reporter construct was a 
gift from Aristidis Moustakas [299]. It is Smad 3/4-specific. The ARE and MF1 
Smad2 responsive reporter constructs were a gift from Lalage Wakefield [300]. It is 
Smad 2/4-specific. p65, p50 overexpression vectors are pcDNA3-based expression 
vectors [301].
Reporter gene transfection
Transient transfection was achieved using the mixed lipofection agent Fugene 6 
(Roche, UK). Briefly, cells were seeded onto 6 -well plates and grown in serum- 
containing medium until 50-80% confluent. The culture medium was then replaced 
by serum-free medium prior to transfection. To introduce plasmids into cells, each 
plasmid was mixed with Fugene 6 in a ratio of 1:3 (pg : pi) and serum-free medium 
to make a final volume 100 pi, followed by incubation at room temperature for 15 
minutes before adding to each well. Following addition of plasmid-Fugene 6 mixture, 
cells were incubated overnight prior to further manipulation according to 
experimental design. At the end of the experiments, the medium was removed and
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the remaining cells were washed with PBS and subsequently subjected to cell lysis 
for measurement of luciferase activity.
Measurement of luciferase activity
To assess the luciferase activity of the reporter, 0.9 pg of each plasmid including the 
reporter gene and 0.1 pg of the Renilla, were co-transfected in 6-well plates using a 
transient transfection as described above. The purpose of co-transfection with the 
Renilla was to normalise data to take account of transfection efficiency.
Following the transient transfection and at the end of the experiments, the medium 
was removed and cells washed with ice-cold PBS. The cells in each well of 6-well 
plates were lysed by adding 400 pi of lx  Passive Lysis Buffer (Promega), followed 
by incubation at -20°C overnight. The following day, the cell lysate were thawed at 
room temperature for at least 30 minutes to ensure complete lysis of the cells. After 
pipetting the mixtures, 30pl of cell lysate in each sample was gently mixed with 
lOOpl of Luciferase Assay Reagent II (Promega) to generate a stabilized luminescent 
signal. Because the total amount of light measured during a given time interval is 
proportional to the amount of luciferase reporter activity in the sample, firefly 
luciferase measured using a luminometer (MLX micro titer plate luminometer, 
Dynex Ltd) represents the reporter activity.
Firefly and Renilla luciferase have distinct evolutionary origins, so they have 
dissimilar enzyme structures and substrate requirements. Firefly luciferase catalyses 
a reaction using D-luciferin and ATP in the presence of oxygen and Mg2+, resulting 
in light emission, whereas Renilla luciferase utilizes oxygen and coelenterate
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luciferin to generate light emission. These differences make it possible to selectively 
discriminate between their respective bioluminescent reactions. Thus, the 
luminescence from the Firefly luciferase reaction may be quenched while 
simultaneously activating the luminescent reaction of Renilla luciferase.
To evaluate transfection efficacy, Renilla luciferase activity was measured in the 
same cell lysates using Dual-Luciferase Reporter Assay System (Promega Ltd.). 
After quantifying the Firefly luciferase luminescence using a luminometer (Fluostar 
Optima, BMG), lOOpl of Stop & Glo Reagent (Promega Ltd.) was added to the same 
sample. That means firefly luciferase reaction was quenched and then Renilla 
luciferase luminescence reaction was activated and measured using the same 
luminometer again.
Presentation of luciferase activity
The luciferase activity was calculated as the amount of Firefly luciferase 
luminescence divided by the amount of Renilla luciferase luminescence in each 
sample, and the data was presented as the relative change in luciferase activity 
compared to the control for each experiment.
2.2.2 Small interfering RNA (siRNA) transfection
RNA interference (RNAi), or gene silencing, is a technique for down-regulating the
expression of a specific gene in living cells by introducing a double-stranded RNA
(dsRNA) with homology to the gene of interest. In my work, siRNA transfection was
used to study the role of ski, SnoN in BMP-7 effect on TGF-P 1 mediated activation
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of Smad3, by introduction of a gene silencing using CD44, ski, SnoN, Id (inhibitor 
of DNA binding/differentiation) 1-3 siRNA to inhibit mRNA and protein expression.
siRNA/ transfection agent complexes preparation
All siRNA were purchased from Ambion. The sense and antisense siRNA strands 
are chemically synthesized, column purified, and annealed.
Delivery of siRNA into cultured cells
Delivery of small interfering RNA (siRNA) into HK-2 cells was optimised using the 
Silencer siRNA Transfection Kit II (Ambion) according to the manufacturer’s 
instruction. Briefly, 9xl04 cells per 12-well plate well were transfected in suspension 
with 30nM siRNAs and 5 pi siPORT Amine (Ambion) in a final volume of lOOOpl 
per well. Subsequently, the transfected HK-2 cells were incubated at 37°C prior to 
further manipulation according to experimental design. At the end of the 
experimental time point, the medium was removed and the remaining cells were 
treated to assess gene expression using QPCR (Quantitative polymerase chain 
reaction) or Westren Blot to detect protein expression or to compare luciferase 
activity using reporter gene transfection. Mock-transfected and scrambled siRNA 
transfected controls were included parallell in these experiments. To evaluate the 
target gene knockdown efficacy, mRNA levels were quantitated by RT-qPCR, 
protein levels were detected by Western blot (See Table 2.1).
2.3 Protein extraction and analysis
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2.3.1 Protein extraction
Protein extraction was performed as follows: cell monolayers were washed three 
times with ice cold PBS and were subsequently put in complete lysis buffer on ice 
for 10 minutes. Then the lysate was collected by scraping the cells into the tube.
Table 2.1 The knockdown efficiency of siRNAs
Knockdown efficiency Method
CD44 92% QPCR(48h)
Idl 60% QPCR(48h)
Id2 88% QPCR(48h)
Id3 68% QPCR(48h)
SnoN 71% QPCR(48h)
Ski 67% Immunoblot(72h)
Whole cell protein extraction
To obtain the whole cell lysates, RIPA lysis buffer was used (lx  TBS, 1% Nonidet 
P-40, 0.5% sodium deoxycholate, 0.1% Sodium dodecyl sulphate-polyacrylamide 
(SDS), 0.04% sodium azide), with added 2mM PMSF, ImM sodium orthovanadate, 
protease inhibitor cocktail freshly each time. Samples were centrifuged at 13,000 
rpm at 4°C for 30 minutes and then the supernatant was transferred to a separate tube 
and kept at -70°C until use.
Nuclear extraction
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To obtain nuclear fractions, the confluent monolayers were washed three times with 
cold PBS, scraped and rinsed into 2ml cold PBS. After centrifugation at 3,000 rpm 
at room temperature for 10 minutes, cell pellets were extracted in buffer A (lOmM 
Hepes, pH7.9, 1.5mM MgC12, lOmM KC1, 50pM DTT, 100pM sodium 
orthovanadate, 0.2mM PMSF, 50mM NaF), and then put on ice for 10 minutes. 
Following centrifugation at 13,000rpm for 1 minutes at 4°C, the supernatant was 
collected as cytoplasmic protein, and the remaining pellets were extracted in buffer 
C (20mM Hepes pH 7.9, 25% v/v Glycerol, 420mM NaCl, 1.5mM MgC12, 0.2mM 
EDTA, 50pM DTT, IOOjiM sodium orthovanadate, 0.2mM PMSF, 50mM NaF), and 
put on ice for 20 minutes. Following centrifugation at 13,000rpm for 1 minute at 4°C, 
the supernatant containing nuclear proteins was collected and stored at -70°C until 
use.
2.3.2 Quantification of proteins
To ensure equal protein loading of each sample subjected to Western blot analysis, 
the amount of protein in cell lysate was measured by a dye-binding method (Bradford, 
Bio-Rad protein assay). Briefly, each sample was diluted with distilled water 
(typically 1/4 v/v) and 5ul added in triplicate to a flat-bottomed 96-well microtitre 
plate. Following gentle agitation, the sample was mixed with 250pl of 20% Bio-Rad 
dye binding reagent per well to give a colour reaction. Concentration of sample 
proteins could be calculated by comparing with known concentrations of bovine 
serum albumin (BSA, Sigma-Aldrich Ltd), which are available as standard proteins, 
ranging from 0-2000 pg/ml. Where necessary, the assay was repeated with altered 
dilution of samples to achieve readings in the linear range of the assay.
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2.3.3 Western blot
Western blot is a technique for separation, transfer, and detection of a particular 
protein using specific antibodies. Briefly, using gel electrophoresis denatured 
proteins are separated, and then transferred onto a nitrocellulose membrane by 
transblot. Subsequently, membranes are probed using specific antibodies to detect 
the proteins.
Protein separation ?.
Equal amounts of protein (30pg) were mixed with reducing SDS sample buffer (2% 
v/v SDS, 10% v/v glycerol, 60mM Tris and 0.05% v/v mercaptoethanol) boiled for 
5-7 minutes at 95°C. After cooling on ice for 1 minute, the samples and the 
molecular weight marker (SeeBlue Plus2 Pre-Stained Standard, Invitrogen) were 
loaded onto SDS-PAGE gels.
Subsequently, electrophoresis was carried out using discontinuous vertical minigel 
apparatus (Becton Dickinson) in running buffer (25mM Tris-HCl, pH 8.3, 192mM 
glycine, 1% SDS, Sigma) at 150V until the 3kDa standard had just run off the bottom 
of the gel. Following electrophoresis, the separated proteins in the gel were 
transblotted onto a nitrocellulose membrane (Amersham, Little Chalfont, UK) using 
a Biorad miniblot apparatus in transfer buffer containing 25mM Tris-HCl, pH8.3, 
192mM glycine, 20% (v/v) methanol for 90 minutes at 150 V.
Protein detection
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After transblotting, the membrane was incubated with Tris-buffered saline-Tween 
(TBS-Tween, 50mM Tris-HCl, 200mM NaCl, and 0.1% (v/v) Tween-20, pH 7.6) 
containing 5% non-fat powdered milk for 1 hour at room temperature to block non­
specific binding. After washing 3 times with TBS-Tween, the membrane was 
incubated with primary antibody in Tris-buffered saline-Tween containing 5% non­
fat powdered milk or BSA overnight at 4°C. The following day, the blots were 
washed 3 times with TBS-Tween, and subsequently incubated with an appropriate 
horseradish peroxidase (HRP) conjugated secondary antibody in Tris-buffered saline- 
Tween containing 5% non-fat powdered milk for 1 hour at room temperature (Goat 
anti-rabbit HRP conjugated IgG or goat anti-mouse HRP conjugated IgG, Santa 
Cruz, USA, 1:10000 diluted concentration). After three times further washes with 
TBS-Tween, proteins were detected using enhanced chemiluminescence (ECL plus 
Western Blotting Detecting Reagents, Amersham, UK) according to the 
manufacturer’s instruction.
Briefly, the blot was dabbed dry on filter paper and its protein side was placed face 
up on a sheet of SaranWrap. Followed by mixing detection solution A and B 
(Amersham) in a ratio of 40: 1, the mixed detection reagent is pipetted onto the 
membrane. After incubation for 5 minutes at room temperature, excess detection 
reagent was drained with filter paper, and the blot was put down on to a fresh piece 
of SaranWrap. The blot was gently wrapped up and smoothed out any air bubbles 
before its being placed protein side up in an x-ray film cassette. In a dark room, a 
sheet of Hyperfilm ECL (Amersham) was put on the top of the membrane and 
exposed for 15-60 seconds. Then the film was removed from the x-ray cassette and 
developed immediately.
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Stripping and reprobing
To detect the other proteins in the same blot membrane, the method of stripping and 
reprobing was used. Briefly, the membrane was submerged in stripping buffer 
(lOOmM 2-Mercaptoethanol, 2% SDS, 62.5mM Tris-HCl, pH 6.7), followed by 
incubation at 50°C for 30 minutes with occasional agitation. After washing the 
membrane 3-5 times using a large volume of TBS-Tween at room temperature, it was 
blocked in 5 % non-fat dried milk in TBS-Tween (0.1%) for 1 hour at room 
temperature. Finally, the immunodetection was repeated as described above. I have 
checked the adequate stripping by developing the stripped membrane directly. 
Basically, there was no band or very faint band detected. If the very faint band was 
detected , a parallel gel was run at the same time to detect the other target proteins 
with similar molecular weight.
2.3.4 Enzyme linked immunosorbent assay (ELISA)
Human cytokine measurements were made on cell culture supernatants using the 
commercially available ELISA kit for TGF-pl (DY240, R & D system) and IL-6  
(DY 206, R & D system).
TGF-pi ELISA
TGF-P 1 concentrations were determined using a commercially available ELISA 
development kit. The kit contains paired anti-TGF-P antibodies for capture and 
detection. The capture antibody is a mouse anti-human polyclonal antibody, and the 
detection antibody is a biotinylated chicken anti-human TGF-P 1 antibody. These
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show 0.3 to 0.96% cross reactivity with TGF-p2 and TGF-(33 (R & D system, 
summary of product characteristics). The within sample coefficient of variation was 
0.27 to 6% in the data presented. Briefly, high protein binding 96 well plates 
(Immulon 4, Dynex Technologies) were coated with TGF-p capture antibody 
(2ug/ml in PBS) overnight at room temperature. Wells were washed three times with 
wash buffer (0.2% v/v Tween-20 in PBS) using a plate washer (Denley Wellwash 4, 
Thermo Life Sciences, Basingstoke, UK) at this and each subsequent wash step. The 
plate was incubated for 1 hour at room temperature with block buffer (5% v/v 
Tween-20, 5% v/v sucrose in PBS) then washed before addition of TGF-p standards 
and acid cell culture supernatant samples. Recombinant human TGF-P was prepared 
in fresh tissue culture medium according to the kits instruction to provide a standard 
curve of 7 concentrations from 2000pg/ml to 31.25 pg/ml. Cell culture supernatant 
samples were acid activated according to the kit instructions: 20ul 1M HC1 was 
added to each lOOul sample, and the samples were incubated for 10 minutes at room 
temperature. The samples were neutralised with 20ul 1.2 M NaOH/0.5M HEPES. 
The pH of the samples following neutralisation was checked with pH indicator paper, 
and was in the desired range for the assay of 7.2-7.6. [302]
Following the addition of standards and samples, plates were covered and incubated 
for 2 hours at room temperature, then washed three times with wash buffer. 
Detection antibody was added at 300ng/ml in reagent diluents (1.4% w/v delipidized 
bovine serum albumin (Sigma) 0.05% v/v Tween-20 in PBS, 0.2um filter sterilised) 
and the plate incubated for 2 hours at room temperature, then washed. Streptavidin- 
Horseradish Peroxidase (0.5% v/v in reagent diluent) was added to the wells and the 
plate incubated in the dark for 20 minutes then washed. Substrate solution (1:1 H2O2
solution and Tetramethylbenzidine, R & D system) was added to the wells and the 
plate incubated for 20 minutes in the dark before the addition of stop solution (2M 
H2SO4 ). The plate was read immediately at 450nm. A standard curve was prepared 
and the amount of TGF-pl in each sample quantified using the Plate Reader’s 
software packages.
IL-6 ELISA
IL-6  concentrations were measured using a commercially available ELISA 
development kit. The kit contains anti- IL-6 antibodies for capture and detection. 
Firstly, the high protein binding 96 well plates (Immulon 4, Dynex Technologies) 
were coated with IL-6  mouse anti-human polyclonal capture antibody (2ug/ml in 
PBS) overnight at room temperature. Wells were aspirated and then washed three 
times with wash buffer (0.2% v/v Tween-20 in PBS) using a plate washer (Denley 
Wellwash 4, Thermo Life Sciences, Basingstoke, UK). The plate was blocked for 1 
hour at room temperature with block buffer (5% v/v Tween-20, 5% v/v sucrose in 
PBS) then washed three times with wash buffer before adding in IL-6  standards and 
cell culture supernatant samples. Recombinant human IL-6 was prepared in distilled 
water according to the kits instruction to produce a standard curve of 7 
concentrations from 2000pg/ml to 31.25 pg/ml.
Following the addition of standards and samples, plates were covered and incubated 
for 2 hours at room temperature, aspirated and then washed three times with wash 
buffer. Biotinylated goat anti-human IL-6 detection antibody was added at 200ng/ml 
in reagent diluent (1.4% w/v delipidised bovine serum albumin (Sigma) 0.05% v/v 
Tween-20 in PBS, 0.2um filter sterilised) and the plate incubated for 2 hours at room
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temperature, then washed. Streptavidin-Horseradish Peroxidase (0.5% v/v in reagent 
diluent) was added to the wells and the plate incubated in the dark for 20  minutes 
then washed. Substrate solution (1:1 H2O2 solution and Tetramethylbenzidine, R & 
D system) was added to the wells and the plate incubated for 20 minutes in the dark 
prior to the addition of stop solution (2M H2SO4 ) with gently mixing. The plate was 
read immediately at 450nm. A standard curve was prepared arid the amount of IL-6 
in each sample quantified using the Plate Reader’s software packages.
2.3.5 Fluorescence Activated Cell Sorting (FACS)
Preparation and staining of cells
Cells for FACS were grown to confluence in 6 -well-plate and growth arrested in 
serum-free medium for 48 hours before use in experiments. Adherent cells were 
removed from their tissue culture plate using Trypin: PBS in 1:4 to avoid the 
destruction of membrane protein and transferred to tubes. The solution was 
centrifuged at 2000 rpm for 6 minutes. The pellets were washed with PBS, 
centrifuged and resuspended in 1% BSA (50mg BSA) in FACS buffer (500ml PBS, 
lOmM EDTA, 15mM sodium azide, pH to 7.35) with an approximate volume. The 
suspension was transferred to the individual wells of round-bottom 96-well-plate 
(Falcon) with lOOul aliquots in each well. The primary antibodies, CD44 (Rat anti- 
CD44 human monoclonal antibody, Calbiochem, UK) and CD44 V3 (Mouse 
monoclonal anti-CD44V3 human antibody, R & D, UK) were added to the samples at 
the manufacturers recommended dilution and incubated at 4°C for 30 minutes 
covered with tinfoil. Then the whole plate was spinned and washed with FACS 
buffer three times. Then the second antibodies (Rabbit anti-rat immunoglobulins
64
FITC-conjugated antibody for CD44, Goat Anti-mouse Immunoglobulins PRE- 
conjugated antibody for CD44 V3, DAKO, Denmark, 1:50 diluted concentration) 
were added in at the manufacturers recommended dilution and incubated at 4°C for 
30 minutes in the dark. After spinning and washing the whole plate with FACS 
buffer three times, the samples were resuspended in FACS buffer prior to analysis.
Acquisition and analysis of cells
The fluorescent labelled cells were analysed in a Becton Dickinson FACScaliber 
(Becton Dickkinson, San Jose, CA, USA) using previously defined setting for 
forward scatter (FSC), side scatter (SSC), and channel fluorescence(FLl for CD44 
and FL2 for CD44 v3). A minimum of 10,000 cells was acquired for each sample. 
All experiments included negative controls of unlabelled cells. For the cells 
examined, it was possible to define a population of cells including > 50% of the 
cells counted in the mid-range of FSC and SSC values. These populations were used 
for analysis to exclude the cell debris and small cell clusters.
2.4 Immunocytochemistry
Immunocytochemistry is a method to detect localization of protein in cells using 
antibodies binding to target antigens in cells. In my work, expression of Smad3 in 
HK-2 cells was examined by immunocytochemistry. Briefly, HK-2 cells were grown 
in 8-well multi-chamber slides (In Vitrogen Ltd, Paisley, U.K.) until 80% confluent, 
and then incubated in serum free medium alone for a further 48 hours. Subsequently, 
cells were stimulated with different cytokines or chemical reagents under serum free 
conditions. At the end of each time point, cells were rinsed with PBS three times
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prior to fixation. Cells were fixed by adding 1:1 (v/v) methanol/acetone at room 
temperature for 10 minutes. Following fixation, cells were washed with PBS and 
blocked with 1% BSA in PBS at 4°C for 1 hour prior to a further washing step with 
0.1% BSA in PBS. Subsequently, cells were incubated with the Smad3 antibody (1: 
50 diluted concentration, anti-rabbit polyclonal antibody, Santa Cruz) for 2 hours at 
room temperature. After washing 3 times with 0.1% BSA in PBS, the specimen was 
further incubated with the fluorescein isothiocyanate (FITC) conjugated anti-rabbit 
IgG antibody (1:1000 diluted concentration, DAKO) at room temperature for 1 hour. 
After washing 3 times with 0.1% BSA in PBS, slides were mounted with 
Vectashield fluorescent mountant (Vecta Laboratories, Peterborough, UK), and 
examined on a Leica Dialux 20m fluorescent microcope (Leica Microsystem (UK) 
Ltd., Milton Keynes, UK).
2.5 RNA extraction and analysis
2.5.1 RNA extraction and quantification
When the experiments were ended, cell monolayers were rinsed by PBS once and 
total RNA was extracted from cells with 1ml of Tri Reagent (Sigma) per well of 6 
well plate. The lysates were incubated at room temperature for 10 minutes to disrupt 
nucleo-protein complexes and collected in eppendorfs. To separate RNA from the 
mixture of DNA and proteins, phase separation was achieved by adding chloroform 
(Sigma, USA) and centrifugation at 12,000rpm for 20 minutes at 4°C. The interphase 
and the lower chloroform phase were discarded, and the aqueous supernatant
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containing predominantly RNA was carefully collected into a sterile eppendorf. To 
further purify RNA extracts, RNA was precipitated from the aqueous phase by 
mixing with isopropanol (Sigma, USA) at -20°C overnight. Following 
centrifugation at 12,000rpm for 20 minutes at 4°C, the supernatant was carefully 
aspirated and discarded, and the RNA precipitate was air-dried. The precipitated 
RNA pellet was washed with 75% ethanol twice. After aspiration of the final ethanol 
wash, the pellet was air dried for 20 minutes in a fume hood before being dissolved 
in 10)4.1 sterile water. Finally the sample was stored at -70°C until further analysis.
The purity and concentration of the RNA was measured using a Beckman DU® 64 
single beam spectrophotometer (Beckman Instruments, High Wycombe, UK) as 
follows: One microlitre of the dissolved RNA was diluted in 54 pi of sterile water 
and the absorbance of the resulting solution at 260nm and 280nm was measured. 
The RNA content was calculated as the value of the absorbance at 260nm multiplied 
by 40 (one A260 unit equals 40pg RNA/ml). The purity of total RNA was evaluated 
as the ratio of A26o/A28o, which should be in the range of 1.6-1.8.
2.5.2 Reverse transcription
Reverse transcription (RT) is the process where a ribonucleic acid (RNA) molecule 
is reversed transcribed into its DNA complement or complementary DNA (cDNA). 
Reverse transcription of mRNA into cDNA was performed as follows. One pg of 
purified RNA dissolved in lOpl sterile water was mixed with M-MLV™ reverse 
transcriptase (Gibco/BRL Life Technologies Ltd, Paisley, UK) in the presence of the 
mixture of lpl of lOOpM random hexamers (Pharmacia Biosystems Ltd, Milton
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Keynes, UK), 5pl of 2.5mM dNTPs (Gibco/BRL Life Technologies Ltd, UK), 2pl 
of 10X PCR buffer (Applied Biosystems, Beaconsfield, UK), and 2pl of 0.1M 
dithiothretiol (DTT; Gibco/BRL Life Technologies Ltd, UK). The reaction mixture 
was kept for 5 minutes at 95 °C to denature RNA in a GeneAmp PCR system 9700 
thermocycler (PE Applied Biosystems, Beaconsfield, UK), followed by cooling on 
ice for 2 minutes. Following the addition of lp l M-MLV™ Superscript Reverse 
Transcriptase (200Units; Gibco/BRL Life Technologies Ltd, Paisley, UK) and lpl 
RNAase inhibitor (40Units; Gibco/BRL Life Technologies Ltd, Paisley, UK), the 
reaction mixture was incubated for 10 minutes at room temperature to allow 
annealing of random hexamers, 45 minutes at 42°C for synthesis of a single cDNA 
strand, and 5 minutes at 95 °C to separate the strands and to halt the reaction. The 
product of reverse transcription was stored at -20°C until PCR amplification.
2.5.3 Quantitative Polymerase chain reaction (Q-PCR)
Polymerase chain reaction
The polymerase chain reaction (PCR) allows a small amount of a DNA template to 
be amplified exponentially. The principle is that PCR uses a thermostable DNA 
polymerase and two short oligonucleotides as primers to create millions of identical 
copies of DNA. In my work, I mostly used the fluorescent DNA binding dye SYBR 
Green to detect PCR products.
The sequences of the primers are complementary to those of the DNA template. 
Firstly, the double stranded DNA (dsDNA) of the template is denatured and 
separated to two single stranded DNA by heating to 94~98°C (step 1). Secondly, the
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primers are then allowed to hybridize (anneal) to the component strands of the target 
DNA following the reduction of temperature to 37~65°C (step 2). Finally, in the 
presence of four dNTPs, each primer can be extended by a thermostable DNA 
polymerase at 72°C (step 3). These 3 steps, which together constitute one cycle of 
PCR, produce twice the number of original templates. Therefore, successive cycles 
of template denaturation, primer annealing, and primer extension will generate an 
exponentially increasing number of DNA fragments.
Detection of PCR products
Detection of PCR products can be achieved by using fluorescent DNA binding dyes 
like SYBR green, or oligonucleotide probes such as TaqMan. In my work, I mostly 
used the SYBR green except for measuring CD44, in which case Taqman primer was 
used (Hs00153304_ml, Applied Biosystems, USA).
The principle of TaqMan detection system is that the TaqMan probe is designed to 
anneal to the target sequence between the forward and reverse primers. The probe is 
labeled at the 5' end with a reporter fluorochrome and a quencher fluorochrome at 
the 3' end. As Taq polymerase extends the primer, the intrinsic 5' to 3' nuclease 
activity of Taq degrades the probe, releasing the reporter fluorochrome. Thus, the 
amount of fluorescence released during the amplification cycle is proportional to the 
amount of product generated in each cycle. SYBR green is a dye in the PCR reaction 
which binds to all double-stranded DNA. SYBR fluoresces when it binds double 
stranded DNA, the greater the fluorescence the greater the amount of DNA bound. 
PCR amplification was performed in a total volume of 20pl including 1 pi of reverse 
transcription product and 19pl of master mix (7.8pl H2O, 0.6pl 5’-primer (20pM), 
0.6pl 3’-primer (20pM), lOul SYBR green master mix) or TaqMan assay (8pl H2O,
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lpl TaqMan probe, lOul TaqMan master mix) by using a GeneAmp PCR system 
7900HT thermocycler (Applied Biosystems). The repetition is 40 cycles.
2.5.4 Primers for QPCR
All the primers for SYBR were designed by Primer 3. The primers sequences and 
product sizes are listed below (see table 2.2).
Table 2.2 The sequences of the PCR amplification primers
Gene
TGF-pl
CTGF
PAI-1
Idl
Id2
Id3
Arkadia
Gapdh
Primers
F ACCGGCCCTTCCTGCTCCTCA
R CGCCCGGGTTATGCTGGTTGT
F GGCCCAGACCCAACTATGAT
R AGGCGGCTCTGCTTCTCTA
F TCTCTGCCCTCACCAACATTC
R CGGTCATTCCCAGGTTCTCT
F GGCTGTTACTCACGCCTCAA
R CAACTGAAGGTCCCTGATGTAGTC
F CAGCCTGCATCACCAGAGAC
R CTTATTCAGCCACACAGTGCTTT
F CGTCATCGACTACATTCTCGACCT
R ACCTGCGTTCTGGAGGTGTC
F AGGGGCAATTTTGAGGAACT
R TTCTTCCCCATCTTGTTTGC
F GAGTCAACGGATTTGGTCGT
R TTGATTTTGGAGGGATCTCG
Product size
288
143
150
111
152
179
144
238
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2.5.5 Presentation of Q-PCR data
The threshold cycle (Ct) value is determined by identifying the cycle number at 
which the reporter fluorescence emission intensity rises above background noise. 
The Ct is at the exponential phase of the reaction and there are two methods to 
analyse Q-PCR data. One is absolute quantification, which determines the amount of 
the transcript of interest usually by relating the PCR signal to a standard curve. 
Another is relative quantification, which describes the change in expression of the 
target gene relative to some reference groups such as an untreated control.
In my study, I used the method of relative quantification and the formula 2-(deltadeltaCt) 
to present my data. Fold change expression of target gene mRNA after treatment 
was calculated by DeltaDeltaCt method. The DeltaCt is the difference between the 
amplification threshold for target genes and Gapdh (Endogenous control). P values 
were calculated by t-test using excel.
2.6 Investigation o f Protein: DNA interactions
2.6.1 Electrophoretic Mobility Shift Assay (EMSA)
The electrophoretic mobility shift assay (EMSA) determines the binding interaction 
between DNA or RNA and nucleic acid binding proteins.
2.6.1.1 Radiolabelling of double-stranded oligonucleotide probes
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Annealing oligonucleotide for use as an EMSA probe
Oligonucleotides containing the transcription factor binding site of interest or region 
of gene promoter to be studied were annealed and labelled with [32P]a-dTTP. 
Annealed oligonucleotides contained short 5’-overhang of 3 to 4 bases 
complementary to the label deoxynucleotide (A for [32P]a-dTTP). The 
oligonucleotides are resuspended at 1 pg/pl in double distilled water.
To anneal the primers, the following reaction mix was made in a 1.5ml Eppendorf 
(lpg/pl sense primer 10pl, lpg/pl antisense primer lOpl, 1M NaCl lOpl, dP^O 
70pl). Afterwards, the annealing mix was heated to 95°C for lOmins in a water bath. 
Then the water bath was switched off and allowed to cool to room temperature 
overnight. The annealed oligonucleotide probe (lOOng/pl) was stored at -20°C. 
Before use, it was to be diluted 1:10 in dt^O  to lOng/pl.
Labelling oligonucleotide probe
The labelling reaction mixture (25ng oligonucleotide probe 2.5pl, 2.5mM mix of 3 
unlabelled dNTPs including dATP, dCTP, dGTP l.Opl, 10X Klenow Buffer 5.0pl, 
1M NaCl 5.0pl, Double distilled water 32.5pl) was centrifuged for a few seconds at 
6000rpm. Then behind the Perspex shield, the radionucleotide [32P}a-dTTP 3.0pl 
and Klenow fragment (2U/pl) l.Opl were added in the labelling reaction mixture. 
Then the labelling reaction mixture was votexed and centrifuged for a few seconds at 
6000rpm. Prior to stopping the reaction by adding 0.5M EDTA (pH 8) 2.0pl and 
STE 50.0pl, the mixture was incubated at room temperature for 10-20 minutes. Then 
the labelled probes were purified using probe quant micro columns (Amersham). The 
column end was broken off and placed in a 1.5ml eppendorf without a lid and
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centrifuging 3000rpm in a microfuge for 1 minute. The column was dried and placed 
in a fresh 1.5 ml eppendorf, added in labelling reaction. After spinning at 3000rpm 
for 2minutes, the labelled probe was transferred into a fresh eppendorf and stored at 
-20°C.
2.6.1.2 Electrophoretic Mobility Shift Assay
Nuclear protein extraction was performed as previously described. Briefly, cells 
were harvested in ice-cold PBS (pH 7.4) and pelleted by centrifugation. Cells were 
resuspended in ice-cold bufferA (10 mm HEPES-KOH [pH 7.9], 1.5 mM MgC12,10 
mM KC1, 0.5 mM DTT, 0.2 mM PMSF) and incubated on ice for 10 minutes. The 
cell pellet was collected by centrifugation, resuspended in buffer B (20 mM HEPES- 
KOH [pH 7.9], 25% glycerol, 420 mM NaCl, 1.5 mM MgC12, 0.2 mM EDTA, 0.3 
mM DTT, 0.2 mM PMSF), and incubated on ice for 20 minutes followed by brief 
high-speed centrifugation (12000 g for 10 seconds at 4°C), and the resulting 
supernatants (nuclear extract) were collected. Protein concentrations were 
determined using the Bradford method.
Oligonucleotides containing consensus motifs for NF-kB (5’ -gaTCCATGGG 
GAATTCCCC-3 ’ and 3 ’ -AGGTACCCCTTAAGGGGag-5 ’) were annealed for use 
in EMSA. Smad Binding Element Oligonucleotides were bought from Santa Cruz 
(Sense: 5’- TCGAGAGCCAGACAAAAAGCCAGACAT TTAGCCAGACAC-3’; 
anti-Sense:3’-AGCTCTCGGTCTGTTTTTCGGTCTGT AAATCGGTCTGTG -5’) 
and annealed for use in EMSA. These double-stranded fragments were labelled with
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[alpha32P] dTTP (Amersham-Pharmacia Biotech, Amersham, United Kingdom) 
using the Klenow fragment of DNA polymerase I.
The composition of NF-kB protein/DNA complexes was determined by supershift 
assays using rabbit polyclonal antibodies specific for NF-icB-p50 and NF-icB-p65 
(Santa Cruz Biotech Inc., Santa Cruz, California, USA).The composition of Smad 
binding element protein/DNA complexes was determined by supershift assays using 
rabbit polyclonal antibodies specific for Smadl (New England Biolabs, USA), 
Smad2 (New England Biolabs, USA), Smad3 (Invitrogen, USA), Smad4 (Santa Cruz, 
California, USA), and Smad 5 (New England Biolabs, USA).
2.6.2 Chromatin Immunoprecipitation (ChIP)
Chromatin Immunoprecipitation (ChIP) assays is used to evaluate the association of 
proteins with specific DNA regions. The technique involves crosslinking of proteins 
with DNA, fragmentation and preparation of soluble chromatin followed by 
immunoprecipitation with an antibody recognizing the protein of interest. The 
segment of the genome associated with the protein is then identified by PCR 
amplification of the DNA in the immunoprecipitates. Here, I gratefully acknowledge 
the kindly help from Prof. Ray Water’s Lab.
HK-2 cells were cross-linked by rotating gently with final concentration of 1% 
formaldehyde at room temperature for 20 min. Cross-linking was quenched by 
immediately washing cells twice with ice-cold PBS. Cells were scrapped into 10ml 
cold PBS and Centrifuged for 5 minutes at 3,000rpm. Cell pellets were resuspended 
in lysis buffer (50mM HEPES-KOH pH7.5, 140mM NaCl, ImM EDTA pH 8, 1%
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Triton X-100, 0.1% Sodium Deoxycholate, 0.1% SDS, with protease inhibitors 
freshly) and incubated on ice for 10 min. Cell lysates were sonicated to yield DNA 
fragments ranging in size from 200 to 500 bp (Bioruptor, Diagenode SA) 
Approximately 25ug protein of the cross-linked, sheared chromatin solution was 
used for immunoprecipitation.
A small portion of each IP mixture was saved as input DNA (5%). Supernatants 
were diluted 10-fold in RIPA buffer (50 mM Tris-HCl pH8,150 mM NaCl,2 mM 
EDTA pH8,l% NP-40,0.5% Sodium Deoxycholate) and immunoprecipitation was 
performed by rotating for 4 h at 4°C with 5ug of rabbit anti-Smad3 (Invitrogen, 51- 
1500). For each sample, the same amount IgG was added into the chromatin solution 
as a control. 60ul of protein A-Sepharose containing 1.5ug of sheared salmon sperm 
DNA was added to samples by rotating overnight at 4°C. The beads were 
centrifuged 1 minute at 13,000 rpm, and supernatant removed before washing 3x 
with wash buffer I (0.1% SDS, 1% Triton X-100, 2mM EDTA pH8, 150mM NaCl, 
20mM Tris-HCl pH8) and l x with wash buffer II (0.1% SDS, 1% Triton X-100, 
2mM EDTA pH8, 500mM NaCl, 20mM Tris-HCl pH8). Then the DNA was eluted 
by adding Elution Buffer (1% SDS, lOOmM NaHC03) to the protein-A beads and 
rotating at room temperature for 1 hour. Following centrifugation, the supernatant 
was removed and incubated with 5ul protease K (20ug/ml) at 65°C overnight.
The DNA was extracted by phenol: chlorophorm and ethanol precipitated in the
presence of lOul glycogen (5mg/ml). Precipitated DNA was amplified by real-time
PCR using SYBR green master mixture. Primers were designed using Primer 3
Software for the second and third Smad Binding Elements in the PAI-1 promoter,
•
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previously shown to cooperatively regulate the transcriptional response to PAI-1 to 
TGF-P [303]. (2nd primers, -580CAGA, F: 5’-GGGAGTCAGCCGTGTATCAT-3\ 
R: 5’-ACCTCCATCAAAACGTGGAA-3’), (3rd primers, -280CAGA, F: 5’- 
AGTC AACCTGGC AGGAC ATC-3’, R: 5’-CACCTC CCTCTCTGGGACT-3,). 
Data is presented as Smad3-precipitated signal/pre-immune globulin-precipitated 
signal, normalized to control.
2.7 Antibodies used in the thesis: See table 2.3
2.8 Statistical analysis
The data are presented as mean ± SEM of experiments. For each individual 
experiment, the mean of duplicate determinations was calculated.
Comparison of groups of data was by t-test, using the ‘two sample assuming unequal 
variances” t-test. Two-sided tests with a hypothesised mean difference of zero and 
an alpha level of 0.05 were performed. Implicit in this analysis is the assumption that 
the data were normally distributed, although this was not formally tested.
Table 2:3 Antibodies used in the thesis:
Immunohistochemistry: Rabbit anti-Smad3 (sc-8332), Santa Cruz, USA, dilution 
1:50.
ChIP: Rabbit anti-Smad3 (51-1500), Invitrogen, USA, 5ug/sample 
For Western Blot, EMSA supershift, FACS, see below:
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Antibodies Supplier dilution or working concentration
Rabbit anti-phospho- 
Smad3/1 (9514s) 
Rabbit anti-Smad3 (51- 
1500)
Rabbit anti-phospho- 
Smad2 (3101s) 
Rabbit anti-Smadl 
(9512s)
Rabbit anti-Smad2 
(3122s)
Rabbit anti-Smad4 ( sc- 
7154)
Mouse anti-Smad5 
(9517s)
Rabbit anti-Smad7 
(ab5825)
Rabbit anti-Gapdh 
(ab9485)
Mouse anti-TGF beta 
receptor I (sc9048) 
Rabbit anti-lKB a (sc- 
371)
Rabbit anti-lKB-p(sc- 
945)
Rabbit anti-p-IicK (2687)
Rabbit anti-IicK (sc- 
7607)
Rabbit anti-p65 (sc-109)
Rabbit anti-p50 (sc- 
7178)
Rat-anti-CD44(217594)
Mouse-anti-CD44v3
(BBA11)
Mouse anti-Arkadia 
(H00054778-B01) 
Rabbit anti-ski (sc-9140) 
Rabbir anti-SnoN (sc- 
9141)
Cell Signalling 
Technology ,US A
Invitrogen,USA
Cell Signalling 
T echnology ,U S A 
Cell Signalling 
Technology,USA
Cell Signalling 
T echnology ,U S A
Santa Cruz,USA
Cell Signalling 
Technology ,US A
abCam, USA
abCam, USA
Santa Cruz,USA
Santa Cruz,USA
Santa Cruz,USA
Cell Signalling 
Technology,USA
Santa Cruz,USA 
Santa Cruz,USA
Santa Cruz,USA
Calbiochem,UK 
R&D, UK
Abnova, Tai Wan 
Santa Cruz,USA 
Santa Cruz,USA
Western EMSA 
Blot super shift
1:1000
1:1000
1:1000
1:1000
2ug/5ug
nuclear
protein
2ug/5ug
nuclear
protein
2ug/5ug
nuclear
protein
1:500
1:1000
1:500
1:500
1:500
1:500
1:500
2ug/5ug
nuclear
protein
2ug/5ug
nuclear
protein
1:500
1:500
1:500
FACS
1:1000
2ug/ml
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Chapter Three:
The effects of IL-ip and BMP-7 on 
TGF-pl signalling in human proximal 
tubular epithelial cells
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3.1 Introduction
Increased expression of TGF-p 1 is widely known as a key stimulus to the 
progression of renal fibrosis after renal injury. However, the mechanisms by which 
other environmental cues may alter response to TGF-P are not well studied. 
Prolonged inflammation and macrophage influx adversely affect prognosis in 
chronic kidney disease, whereas acute inflammation does not appear to have the 
same consequences. In the short term, pro-inflammatory cytokines such as IFN-y 
[219] and TNF-a [304] have previously been shown to be important negative 
regulators of TGF-p signalling and exhibit anti-fibrotic activity [305]. More recently, 
sensitization to TGF-p, and hence profibrotic effects, has been described for chronic 
proinflammatory stimulation [220, 221]. But the differential effects of acute and 
chronic inflammation on TGF-p signalling are not widely studied.
On the other hand, anti-TGF-pi-induced fibrotic role in kidney has been raised as an 
important target to delay or even reverse renal fibrosis. BMP-7 has emerged as a key 
anti-fibrotic cytokine extensively demonstrated in vivo and in vitro. But the 
mechanism of BMP-7 on TGF-p signalling remains unclear.
As detailed in the next chapter, circumstantial evidence suggests IL-lp and BMP-7 
might affect TGF-p signalling via effects on the HA/CD44 axis. The aim of the work 
detailed in this chapter was to determine the effects of IL-lp and BMP-7 on TGF-p 
signalling in proximal tubular epithelial cells.
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With these experiments, I used lng/ml TGF-p 1 stimulation based on previous 
extensive characterisation of TGF-p responses at this dose in our lab [306]. For IL- 
lp and BMP-7,1 started with doses ranging from lOpg/ml to lOng/ml for IL-lp and 
ranging from 5ng/ml to 2000ng/ml for BMP-7 with the reporter gene construct assay. 
I selected the time points from 15 minutes to 24 hours to evaluate TGF-p Smad2 and 
Smad3 signslling separately by Western Blot.
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3.2 Results
3.2.1 IL-lp inhibits early Smad3 signalling but enhances late Smad3 
signalling in response to TGF-pi
Initially, I evaluated the time-course effects of co-administration of IL-ip with TGF- 
pl on Smad3 signalling response. HK-2 cells were cultured from 15 minutes up to 
24 hours in the presence of 1 ng/ml TGF-p 1 ±1 ng/ml IL-ip before detection of 
phospho-Smad3 by immunoblotting. Co-administration of IL-ip and TGF-P 1 caused 
a minor reduction in Smad3 phosphorylation compared to TGF-p 1 alone in the first 
1 hour (Figure 3.1.A). Longer IL-lp and TGF-p 1 co-treatment from 3 hours to 24 
hours showed an obvious increased phospho-Smad3 compared to TGF-p 1 alone after 
12 hours (Figure 3.1 .B and C).
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Figure 3.1: Time course of IL -lp  effect on Smad3 phosphorylation 
IL-1 p and TGF-p 1 were added to confluent monolayers of growth arrested HK-2 cells under 
serum free conditions. Immunoblots of phospho-Smad3 in growth arrest HK-2 cells treated 
with 1 ng/ml TGF-p 1 ±  1 ng/ml IL -lp from 15 minutes up to 24 hours, before protein 
extraction and immunoblotting for phospho-Smad3. Blots were stripped and reprobed for total 
Smad3. (A) Early effect of IL-1 p on TGF-p Smad3 signalling. (B and C) Enhancement of 
TGF-p 1 Smad3 signalling by chronic IL-1 p stimulation. One representative experiment of 
three separate experiments is shown.
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3.2.2 IL-ip leads to early inhibition but late stimulation of Smad3 
signalling
In order to confirm the result above, I used the reporter gene assay to assess the IL- 
lp effect on TGF-p 1 Smad3 signalling. The cells were transiently transfected with 
the Smad3-responsive reporter construct CAGA(4) Luc (together with pRV renilla to 
control for transfection efficiency) before co-incubation with 1 ng/ml TGF-P 1 and 
dose-course of IL-lp up to 10 ng/ml for 6 h, compared to cells incubated with TGF- 
pi alone. Control cells were incubated in the cytokine-free medium. These data 
show that at early time points, IL-lp 1 ng/ml led to significant inhibition in response 
to TGF-p 1 (Figure 3.2.A). In subsequent experiments, in order to test the effect of 
chronic IL-lp stimulation on TGF-p 1 responsiveness, cells were treated with IL-lp 
for 24h before incubation with TGF-p 1 1 ng/ml for 6h. These data show that after 24- 
hour IL-lp treatment, however, a distinct increase on Smad3 signalling was seen 
(Figure 3.2.B).
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AFigure 3.2: Early and late effect o f IL-1 p on Smad3 signalling
HK-2 cells were transfected with the Smad3 reporter construct CAGA(4) together 
with pRL-CMV renilla before incubation with IL-lp and/or TGF-p 1 . Subsequently, 
firefly and renilla luciferase activities were assayed. Ratio of firefly to renilla 
luciferase is displayed and normalized to control, n -  3, mean +  SEM is plotted. (A) 
HK-2 cells were treated with 1 ng/ml TGF-p 1 ±  variable dose course of IL-lp for 
6 hours. * P < 0.002 for TGF-p 1 vs Control. * P < 0.01 for both vs TGF-pl. (B) 
Incubation with control medium or 1 ng/ml IL-lp for 24h,then incubated with 
control medium or lng/ml TGF-pl only for 6 hours. * P < 0.01 for TGF-p 1 vs 
Control.* P < 0.01 for both vs TGF-p 1. One representative experiment of three 
separate experiments is shown.
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3.2.3 IL-lp has consistent early inhibition but late stimulation on 
TGF-pl Smad2 signalling
Immunoblots suggested a similar inhibitory action on Smad2 phosphorylation when 
HK-2 cells were cultured for 1 h in the presence of 1 ng/ml TGF-pl ±1 ng/ml IL-lp 
(Figure 3.3.A). The cells also were transiently transfected with Smad2-responsive 
construct ARE-luc before co-incubation with 1 ng/ml TGF-pl and dose-course of 
IL-lp O.lng/ml to lOng/ml for 6 h, compared to cells incubated with TGF-pl alone. 
Control cells were incubated in the cytokine-free medium. It shows IL-lp inhibited 
the TGF-pl Smad2-dependent signal (Figure 3.3.B). In keeping with Smad3, the 
transfected HK-2 cells were treated with IL-lp for a longer time of 24 hours and it 
shows an increase on Smad2 signalling, compared to cells incubated with TGF-P 1 
alone (Figure 3.3.C).
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Figure 3.3: Effect of IL-1 (3 on Smad2 signalling
(A) Immunoblots of pSmad2 in growth arrested HK-2 cells treated with lng/ml 
TGF-p 1 ±  1 ng/ml IL-1 p for 60 minutes, using the same experimental approach 
as for (3.1) above. Blots were stripped and reprobed for Gapdh. One representative 
experiment of three separate experiments is shown.
HK-2 cells were transfected with the Smad2 reporter ARE/MF-1 using the same 
experimental approach as for (3.2) above. (B) HK-2 cells were treated with 1 
ng/ml TGF-p 1 ±  lng/ml IL -lp for 6 hours. * P  < 0.01 for TGF-pl vs Control.
# P  <  0.01 for Both vs TGF-pl. (C) Incubation with control medium or lng/ml IL- 
lp  for 24h,then incubated with control medium or lng/ml TGF-pl only for 6 hours. 
Firefly and renilla luciferase activities were assayed. Ratio of firefly to renilla 
luciferase is displayed and normalized to control. Results represent mean ±  SEM 
of 3 individual experiments.
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3.2.4 Time and dose course of Smad3 signalling regulation in
response to TGF-pi by BMP-7
To investigate the alterations in TGF-pl response caused by BMP-7, HK-2 cells 
were incubated with BMP-7 for various time points from 15 minutes to 24 hours at 
BMP-7 dose of 50ng/ml (Figure 3.4.A), before incubation with TGF-p 1 lng/ml for 1 
hour. In parallel experiments, HK-2 cells were incubated with BMP-7 for a dose 
range from 50ng/ml to 2000ng/ml, before incubation with TGF-pl lng/ml for 1 hour 
(Figure 3.4. B). Immunoblots suggested phospho-Smad3 was not altered by pre­
treatment with BMP-7 regardless of time and dose.
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Figure 3.4: Effect of BMP-7 on Smad3 phosphorylation
(A) HK-2 cells were treated with BMP-7 50ng/ml for times up to 24 hours 
before incubation with TGF-01 lng/ml for 1 hour. After immunoblotting for 
phospho-Smad3, blots were stripped and reprobed for total Smad3. One 
representative experiment of four separate experiments is shown. (B) HK-2 
cells were treated with BMP-7 50ng/ml to 2000ng/ml for times up to 24 hours 
before incubation withTGF-01 lng/ml for 1 hour. After immunoblotting for 
phospho-Smad3, blots were stripped and reprobed for total Smad3 or Gapdh. 
One representative experiment of three separate experiments is shown.
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3.2.5 Regulation of Smad3 signalling by BMP-7 response to TGF-pi
HK-2 cells were transfected with Smad3 responsive plasmid CAGA(4), then 
incubated with BMP-7 for various doses (Figure 3.5.A and C) or times (Figure
3.5.B), before incubation with TGF-pl lng/ml for 6 hours. There was little 
difference in response to BMP-7 at doses above 50ng/ml for 24 hours pre-treatment 
before incubation with TGF-pl lng/ml for another 6 hours. BMP-7 inhibited 
subsequent Smad3 signalling response to TGF-pl after 12 or more hours (Figure
3.5.B) at concentrations of 50ng/ml.
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Figure 3.5: Effect of BMP-7 on Smad3 signalling
(A,B,C)HK-2 cells were transfected with Smad3 reporter construct 
CAGA(4) ,then incubated with BMP-7 for various time points and 
doses ,before incubation with serum free medium or TGF-pl 1 ng/ml under 
serum free conditions, n = 3, mean ±  SEM is plotted. Subsequently, firefly 
and renilla luciferase activities were assayed. Ratio of firefly to renilla 
luciferase is displayed and normalized to control. * P < 0.01 compared to 
TGF-pl. One representative experiment of three separate experiments is 
shown.
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3.2.6 BMP-7 has no effect on Smad2 signalling response to TGF-pi
In order to further investigate the alterations in Smad2 response caused by BMP-7, 
immunoblots and transient transfection of reporter genes of Smad2-responsive 
construct ARE/MF-l-luc was undertaken. HK-2 cells were cultured with BMP-7 
50ng/ml for time points to 24h before addition of TGF-pl lng/ml for lh and 
subsequent immunoblotting. No change in phospho-Smad2 was seen (Figure 3.6.A). 
Similarly, cells were transiently transfected with Smad2 reporter plasmids before 
incubation with BMP-7 at doses up to 2000ng/ml for 12 hours, and subsequent 
addition of TGF-pl lng/ml for 6h. No significant changes in reporter gene activity 
were seen (Figure 3.6 B and C).
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Figure 3.6: Effect of BMP-7 on Smad2 signalling
(A) HK-2 cells were treated with BMP-7 50ng/ml for times up to 24 hours before 
incubation with TGF-pl lng/ml for 1 hour. After immunoblotting for phospho- 
Smad2, blots were stripped and reprobed for Gapdh. One representative experiment 
of four separate experiments is shown. (B,C) HK-2 cells were transfected with 
Smad2 reporter construct ARE/MF-1, then incubated with BMP-7 for various doses 
before incubation with serum free medium or TGF-pl lng/ml under serum free 
conditions, n -  3, mean ±  SEM is plotted. Subsequently, firefly and renilla 
luciferase activities were assayed. Ratio of firefly to renilla luciferase is displayed 
and normalized to control. One representative experiment of three separate 
experiments is shown.
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3.2.7 Inhibition of TGF-pi-dependent profibrotic target genes by 
BMP-7 in PTC
The above data suggests that BMP-7 specifically inhibits Smad3 signalling without 
any apparent changes in Smad3 phosphorylation. In order to further verify the effect 
of BMP-7 in our in vitro system, I examined several Smad3-dependent downstream 
targets, including CTGF, PAI-1, and TGF-pl itself [307] which are related to TGF- 
pi-induced fibrosis. Initial experiments were performed to investigate inhibition of 
TGF-p-dependent transcriptional responses by BMP-7. HK-2 cells were incubated 
with TGF-pi lng/ml or control medium ± BMP-7 50ng/ml for 24h. Subsequent 
quantitative QPCR demonstrated increased expression of CTGF, PAI-1 and TGF-pl 
in response to TGF-pl. BMP-7 alone did not significantly alter expression of CTGF, 
PAI-1 or TGF-p, but BMP-7 significantly attenuated responses to TGF-P (Figure 3.7 
A-C). Additional experiments demonstrated inhibition of PAI-1 expression when 
BMP-7 was added to TGF-p treated cells at time points up to 8 days (Figure 3.7 D).
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Figure 3.7 Regulation of profibrotic TGF-pl transcriptional targets 
by BMP-7.
RT-qPCR analysis shows expression of profibrotic TGF beta-inducible genes 
in PTC after 24 hours ±  lng/ml TGF-p 1 incubation ±  BMP-7 50ng/ml. (A) 
TGF-pl. (B) Connective Tissue Growth Factor. (C) Plasminogen Activator 
Inhibitor-1. (D) Plasminogen Activator Inhibitor-1 expression after 8 days of 
culture +  TGF-p 1 lng/ml ±  BMP-7 50ng/ml. n=3, mean of duplicate 
determinations, mean +  SEM is plotted. * P < 0.01 TGF compared to control 
* P < 0.01 both compared to TGF-pl alone. Representative data from one of 
five experiments giving similar results.
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3.3 Discussion
TGF-P 1 is not only a key profibrotic cytokine leading to fibrosis in the kidney and 
other organs [56] but also plays an important role in repair following acute injury 
[216]. Acute inflammation is also associated with repair following injury, but more 
prolonged inflammation is associated with renal fibrosis [217, 218]. In this chapter, I 
have investigated the effects on TGF-p signalling of IL-lp and BMP-7 at various 
doses and times. I have found that short term IL-ip incubation inhibited TGF-pl 
responsiveness, whereas chronic IL-ip incubation facilitated TGF-pl responsiveness. 
In contrast, I found that BMP-7 served to limit Smad3 signalling response to TGF-pl, 
without apparent effect on Smad2 signalling. These observations have implications 
for our understanding of modulation of TGF-P 1 signalling by these important 
signalling pathways in the kidney.
Parti: IL-ip
Previously, Ulloa et al have shown pro-inflammatory cytokine interferon gamma 
negatively regulates phosphorylation of Smad3 and its downstream events, namely, 
the association of Smad3 with Smad4, the Smad3 accumulation in the nucleus, and 
the activation of TGF-p-responsive genes in acute inflammation [219]. A number of 
in vitro studies support the inhibition of TGF-p signalling by IL-ip [227, 230, 308]. 
In contrast, recent work suggests that chronic inflammation may promote fibrosis by 
enhancing signalling responses to TGF-pl. Specifically, in the liver, bacterial 
lipopolysaccharide-mediated toll like receptor 4 (TLR4) activation sensitizes hepatic 
stellate cells to TGF-P 1 signalling and leads to hepatic fibrogenesis [220]. Similar
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TGF-pl Smad3-associated effects are observed in PTC in which TLR2 is activated 
by leptospiral membrane proteins in vitro [221]. IL-lp also leads to lung fibrosis via 
the TGF-p Smad3 pathway [223]. In our lab, we have previously shown that another 
pro-inflammatory cytokine, IL-6, increases signalling response to TGF-pl [309]. 
These studies indicate that IL-ip has different effects on TGF-p signalling in a cell- 
specific and context-specific manner, and that the participation of inflammation to 
the acute organ injury and chronic organ fibrosis through TGF-p signalling 
regulation is complicated.
With my work in this chapter, these experiments demonstrate that short-term IL-lp 
exposure from 15 minutes to 3 hour inhibits PTC TGF-p Smad3 phosphorylation 
rapidly and transiently by co-incubation with TGF-P 1 by Western Blot. In keeping 
with this, data from the CAGA (4) Smad3 reporter gene assay shows that IL-lp 
inhibits Smad3 luciferase activity following 6 hours co-incubation with TGF-P 1. In 
experiments examining Smad2, Western Blot shows an inhibition of Smad2 
phosphorylation at 1 hour co-incubation, similar to Smad2 reporter gene assay at 6 
hours co-incubation subsequently with various doses of IL-lp. After 6 h or more of 
IL-lp prolonged treatment, there is a switch from early inhibition to later stimulation 
on TGF-p Smad3 signalling by both approaches as well as Smad2. Taken together, 
these data are suggestive that IL-ip has an early inhibitory effect on TGF-p 
signalling, but with chronic stimulation this is reversed. This may highlight an 
important difference in the interaction of pro-inflammatory and TGF-p signalling in 
short term versus chronic inflammation, in that IL-lp may inhibit TGF-pl dependant 
signalling in pathologies such as acute tubular necrosis, acute tubulointerstitial
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nephritis and acute rejection following renal transplantation. In contrast, chronic IL- 
lp stimulation enhances TGF-P 1 signalling, and may accelerate the progress of renal 
fibrosis in chronic kidney disease.
Part II: BMP-7
BMP-7 has emerged as a key anti-fibrotic cytokine in the kidney. BMP-7 expression 
and Smadl/5 phosphorylation are decreased in the acute ischemic kidneys and 
chronic kidney injury in vivo and in vitro. A lot of study suggests that exogenous 
BMP-7 can block ECM accumulation in chronic fibrosis as well as EMT. BMP-7 
diminished the activation of tubulointerstitial inflammational monocyte/macrophage 
interstitial infiltration [247] and pro-inflammatory cytokines expression such as IL-6, 
IL-lp and ET-1 in PTC [246]. As for TGF-pl, a key profibrotic cytokine for renal 
fibrosis, BMP-7 inhibits nuclear accumulation of main signalling Smad3 response to 
TGF-pl in mesangial cells. But little is known about the mechanism for TGF-P 1 
signalling regulation by BMP-7 in kidney diseases [260].
In terms of R-Smads, regulatory mechanisms and transcriptional responses may vary 
between Smad2 and Smad3 [310-312]. Some work has shown that the endogenous 
ratio of Smad2 and Smad3 influences the cytostatic function of Smad3 in vitro [311]. 
Also, several proteins interacting with R-Smads balances final Smad2/3 specific 
transcriptional initiation. The adaptor protein embryonic liver fodrin (ELF) interacts 
with receptor-associated Smad3/Smad4 complex, but not Smad2, after TGF-pl 
stimulation. This interaction facilitates nuclear translocation of Smad3/4 and 
subsequent TGF-pl transcriptional responses [313]. In contrast, TRAP-l-like protein
97
(TLP) differentially activates TGF-pl Smad2-dependent responses and blocking 
Smad3-dependent transcription accomplished by inhibiting Smad3/Smad4 complex 
formation [300]. A key observation is that the Smad3 null mouse is protected from 
TGF-p-dependent induction of c-Jun, collagen, and inflammatory cell infiltrates, as 
well as autoinduction of TGF-P, indicating Smad3 plays an important role in fibrosis 
[215]. My work in this chapter shows that BMP-7 inhibits TGF-P Smad3 signalling 
in PTC without apparent effect on Smad3 phosphorylation, or on Smad2 signalling.
It was important in view of this apparently subtle effect of BMP-7 in PTC to check 
that BMP-7 had measurable effects on TGF-p-dependent responses, therefore I did 
QPCR to confirm this. Some work has shown BMP-7 reverses TGF-P 1-induced 
EMT transition [44], extracellular matrix proteins, CTGF and PAI-1 [260, 314]. I 
also did QPCR to check the effect of BMP-7 on TGF-pl-induced profibrotic 
transcriptional target genes. All these data intimate that in PTC, BMP-7 specifically 
limits Smad3 signalling in PTC, without alteration in Smad2 signalling, leading to 
reduced activation of pro-fibrotic gene targets by TGF-pl, including PAI-1, CTGF 
and TGF-P 1 itself.
In conclusion, my results show that IL-lp causes an early inhibition but a later 
stimulation of Smad2/3 signalling. In contrast, BMP-7 inhibits Smad3-dependent but 
not Smad2-dependent transcription without altering Smad3 phosphorylation levels.
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Chapter Four:
The effects of HA-CD44 system on 
TGF-pi signalling in human proximal 
tubular epithelial cells
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4.1 Introduction
In chapter three, my results have shown the biphasic effects of IL-lp and inhibitory 
effects of BMP-7 on TGF-pl-induced Smad signalling. In our lab, the previous work 
indicated CD44 is co-localized with TGF-pl type I receptor in the cytoplasmic 
membrane of PTC, leading to altered TGF-p receptor distribution and association. 
We have previously shown that in PTC, TGF-P receptor distribution in the plasma 
membrane is regulated by stimuli including HA (via CD44) and IL-6, leading to 
changes in receptor degradation and signalling response to TGF-pl.
As the ligand of CD44, HA attenuates TGF-pl signalling in PTC [156]. Whereas in 
breast cancer cells, HA promoted TGF-pl signalling via interaction between CD44 
and type I receptor oppositely [289]. This contradiction indicated that the regulation 
of TGF-p/ TGF-p receptor and HA/CD44 contributes to the different biological 
functions in diverse cell contexts. In this chapter, the aims were to observe the 
possible roles of HA-CD44 system in the TGF-pl signalling regulation by IL-lp and 
BMP-7.
Part I:
Previous finding demonstrated the upregulation of HAS gene expression and 
subsequently HA synthesis in culture medium in PTC in response to prolonged IL- 
lp  treatment after 12 hours [294]. In breast cancer cells, HA promoted TGF-P 1 
signalling. Therefore 1 examined the potential role of HA-CD44 on the stimulatory 
effect of IL-lp on TGF-pl signalling. I also investigated the possibility that IL-lp
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might alter CD44 isoform expression in PTC, specifically whether it led to enhanced 
CD44v3 expression, as this has been linked to enhanced TGF-p signalling 
downstream of HA.
Part II: BMP-7
Previous work has found BMP-7 inhibits monocyte-stimulated TGF-P 1 generation 
in PTC via disruption of HA-CD44 interaction [315]. Therefore, at the start of my 
work, I hypothesized that changes in HA/CD44 might help define PTC responses to 
TGF-pl, and might underline observed alterations in Smad signalling consequent on 
IL-ip and BMP-7.
In conclusion, the aims in this chapter were to investigate the potential role of 
changes in HA/CD44 interaction in the effects of IL-lp and BMP-7 on TGF-pi 
signalling that I had already demonstrated.
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4.2 Results
4.2.1 IL-ip induces PTC CD44 expression, but this is not involved in 
the modulation of TGF-pi signalling by IL-ip
Previous work in our lab has shown that interaction of HA with CD44 decreases 
PTC sensitivity to TGF-pl by augmenting receptor degradation. In a breast cancer 
cell line, in contrast, following HA stimulation, CD44v3 binds to and activates the 
TGF-pl type I receptor and activates Smad signalling. Additionally, IL-lp induces 
PTC HA synthesis after 12h treatment. Therefore, I examined the potential role of 
HA/CD44 in augmentation of TGF-pl signalling by IL-lp.
Firstly, changes in PTC CD44 expression were examined by FACS after HK-2 cells 
were treated with lng/ml IL-lp from 15 minutes to 24 hours. IL-ip increased cell 
surface CD44 protein expression by 24h (Figure 4.1). Then I examined CD44 
protein expression at 24 hours with lng/ml and lOng/ml IL-lp treatment. However, 
there is no significant change between lng/ml and lOng/ml IL-lp stimulation 
(Figure 4.2A and B). Also, no difference in CD44 isoform v3 expression was seen 
(Figure 4.2C).
Next, I studied the effect of reduced CD44 expression on Smad signalling, and on 
the modulation of Smad signalling by IL-lp, using knockdown of CD44 with siRNA. 
Preliminary experiments showed greater than 90% knockdown of CD44 mRNA 
from 24-72 post-transfection (QPCR), and significant decrease in cell surface CD44 
expression detectable from 24-72h post-transfection by FACS. HK-2 cells were
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sequentially transfected with CD44 siRNA and the Smad3 reporter CAGA (4), as 
described in the materials and methods. In parallel control experiments, cells were 
transfected, with scrambled control siRNA. However, increased Smad signalling 
response was still seen in CD44 knockdown cells following IL-lp pre-treatment 
(Figure 4.3). (Scrambled siRNA group, IL-lp+ TGF-pl group, VS TGF-pl group, 
*p<0.01; CD44 siRNA group, IL-lp+ TGF-pl group VS TGF-P 1 group, #p<0.05). 
Smad3 phosphorylation was also examined by immunoblotting following CD44 
knockdown. Following CD44 siRNA transfection, cells were cultured in medium 
containing IL-ip lng/ml, or control medium, for 24h before change to TGF-pl 
lng/ml for 60 minutes. Cells were lysed, and phospho-Smad3 detected by 
immunoblotting. In parallel control experiments, cells were transfected with 
scrambled siRNA before culture as above. Enhanced Smad3 phosphorylation was 
still detectable in cells with CD44 knockdown following treatment with IL-ip 
(Figure 4.4).
To investigate the role of HA in the effects of IL-ip on Smad signalling, I used 
reporter gene analysis to examine Smad3 signalling response in IL-lp pre-treated 
cells in the presence of HA and hyaluronidase. Cells were transfected with CAGA (4) 
reporter gene, then treated with IL-lp for 24 hours. HA was added in the culture 
medium or removed by treatment with bovine testicular hyaluronidase for 15 
minutes. Both had no effect on sensitisation by IL-ip for Smad3 signalling (Figure 
4.5 and 4.6).
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Figure 4.1 Time course of CD44 expression by IL-1 |3.
IL-1 |3 was added to confluent monolayers of growth arrested HK-2 cells 
under serum free conditions. HK-2 cells were treated with IL-1 (3 lng/ml 
from 15 minutes to 24 hours. Cell surface expression of CD44 was analysed 
by FACS. Blue is control cells, green is IL-1 (3 treated cells. One 
representative experiment of three separate experiments is shown.
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Figure 4.2 Expression of CD44 and CD44v3 by IL-1 (3.
IL-1 p was added to confluent monolayers of growth arrested HK-2 cells under 
serum free conditions. HK-2 cells were treated with lng/ml (A and C) and 
lOng/ml (B) IL-1 p for 24 hours. Cell surface expression of CD44 (A and B) 
and CD44v3 (C) were analysed by FACS. Pink is secondary antibody only as a
negative control, blue are control cells without IL -lp treatment, green are 
IL-1 p treated cells. One representative experiment of three separate 
experiments is shown.
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Figure 4.3 Effect o f IL-1 P on Smad3 signalling by CD44 
knockdown.
HK-2 cells were transfected with CD44 siRNA for 24h, parallel with 
scrambled si RNA, then transfected Smad3 reporter construct CAGA(4)) 
together with pRL-CMV renilla. After incubation with control medium or 
IL-lp lng/ml for 24h, then incubated with control medium or lng/ml TGF- 
pi for 6 hours. Results represent mean ±  SEM of 3 individual experiments. 
*P < 0.01 compared to TGF- p i. #P < 0.05 compared to TGF- pi. One 
representative experiment of three separate experiments is shown.
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Figure 4.4 Effect o f IL-1 P on Smad3 signalling by CD44 
knockdown.
HK-2 cells were transfected with CD44 siRNA for 24h,' parallel with 
scrambled si RNA, then for another 24 hours under serum free. After 
incubation with control medium or IL-1 p lng/ml for 24h, then incubated 
with control medium or lng/ml TGF- pi for 1 hour. The whole lysats were 
immunoblotted by phospho-Smad3. Subsequently, blots were stripped and 
reprobed for total-Smad3 as a loading control. One representative gel of 
three experiments is shown.
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Figure 4.4 Effect o f IL-1 P on Smad3 signalling by CD44 
knockdown.
HK-2 cells were transfected with CD44 siRNA for 24h, parallel with 
scrambled si RNA, then for another 24 hours under serum free. After 
incubation with control medium or IL-1 p lng/ml for 24h, then incubated 
with control medium or lng/ml TGF- pi for 1 hour. The whole lysats were 
immunoblotted by phospho-Smad3. Subsequently, blots were stripped and 
reprobed for total-Smad3 as a loading control. One representative gel of 
three experiments is shown.
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Fig 4.5 Effect o f HA on IL-lp-induced Smad3 signalling 
augmentation.
HK-2 cells were transfected with Smad3 CAGA(4) and pRL-CMV renilla 
reporter constructs. After incubation with control medium or IL-1 p 1 ng/ml for 
24h, then incubated with control medium or lng/ml TGF- pi for 6 hours with or 
without HA all through the whole time. Data is presented as firfly/renilla 
luciferase activity, normalized to control. N=  3, mean ±  SEM is plotted of three 
separate experiments is shown.
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Fig 4.6 Effect o f HYAL on IL-ip-induced Smad3 signalling 
augmentation.
HK-2 cells were transfected with Smad3 CAGA(4) and pRL-CMV renilla 
reporter constructs. After incubation with control medium or IL-1 p lng/ml for 
24h,then incubated with control medium or lng/ml TGF- pi for 6 hours with or 
without HYAL to remove the coated-HA all through the whole time. Data is 
presented as firfly/renilla luciferase activity, normalized to control. N=  3, mean 
±  SEM is plotted of three separate experiments is shown.
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4.2.2 BMP-7 has no effect on PTC CD44 expression, and disruption 
of CD44-TGF-pl receptor type I receptor interaction is not involved 
in the reduction of TGF-pl signalling by BMP-7
Interaction of HA decreases PTC sensitivity to TGF-P 1 by augmenting receptor 
degradation via CD44. In my experiments, disruption of hyaluronan-CD44 
interactions had little effect on the TGF-p responses; however, re-establishing 
CD44-hyaluronan ligation promotes a robust cellular response to BMP-7 in articular 
chondrocytes [316]. Thus, I examined the hypothesis that interaction of HA/CD44 is 
involved in the inhibition of TGF-pl Smad3 signalling by BMP-7.
Similar to IL-ip, changes in PTC CD44 expression were examined by FACS before 
HK-2 cell was treated with 50ng/ml and 500ng/ml BMP-7 from 15 minutes to 24 
hours. BMP-7 had no detectable effect on regulation of cell surface CD44 protein 
expression (Figure 4.7 and 4.8). In subsequent experiments, HA-CD44 association 
was interrupted by employing CD44 siRNA to reduce CD44 expression. HK-2 cells 
were sequentially transfected with CD44 siRNA and the Smad3 reporter CAGA (4), 
along with a parallel transfection of CD44 siRNA and Smad3 reporter gene. The 
result showed that the inhibition of BMP-7 on Smad3 signalling still remains with 
disruption HA-CD44 interaction (Figure 4.9). (Scrambled siRNA group, BMP-7+ 
TGF-pl group VS TGF-P 1 group, *p<0.01; CD44 siRNA group, BMP-7+ TGF-P 1 
group VS TGF-P 1 group #p<0.01.) Smad3 phosphorylation was examined by 
immunoblotting following CD44 knockdown. Following CD44 siRNA transfection, 
cells were cultured in medium containing BMP-7 50ng/ml, or control medium, for
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24h before change to TGF-pl lng/ml for 60 minutes. In parallel control experiments, 
cells were transfected with scrambled siRNA before culture as above. Enhanced 
Smad3 phosphorylation was still detectable in cells with CD44 knockdown 
following treatment with BMP-7 (Figure 4.10).
To further evaluate the role of HA in the effects of BMP-7 on Smad 3 signalling, I 
used reporter gene analysis to examine Smad3 signalling response in BMP-7 pre­
treated cells in the presence of HA. Cells were transfected with CAGA (4) reporter 
gene, then treated with 50ng/ml BMP-7 for 24 hours before change to TGF-pl 
lng/ml for 60 minutes with or without HA in the culture medium. Similar to CD44, 
the effect of BMP-7 on TGF-pl Smad3 signalling is not changed by adding in HA 
(Figure 4.11).
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Figure 4.7 Time course of CD44 expression by BMP-7.
BMP-7 was added to confluent monolayers of growth arrested HK-2 cells 
under serum free conditions. HK-2 cells were treated with BMP-7 50ng/ml 
from 15 minutes to 24 hours. Cell surface expression of CD44 was analysed by 
FACS. Blue is control cells, green is BMP-7 treated cells. One representative 
experiment of three separate experiments is shown.
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Figure 4.8 Time course of CD44 expression by BMP-7.
BMP-7 was added to confluent monolayers of growth arrested HK-2 cells under 
serum free conditions. HK-2 cells were treated with BMP-7 500ng/ml from 15 
minutes to 24 hours. Cell surface expression of CD44 was analysed by FACS. 
Blue is control cells, green is BMP-7 treated cells. One representative experiment 
of three separate experiments is shown.
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Figure 4.9 Effect of BMP-7 on Smad3 signalling by CD44 knockdown.
HK-2 cells were transfected with CD44 siRNA for 24h, parallel with scrambled si 
RNA, then transfected Smad3 reporter construct CAGA(4)) together with pRL- 
CMV renilla. After incubation with control medium or BMP-7 50ng/ml for 24h, 
then incubated with control medium or lng/ml TGF- pi for 6 hours. Results 
represent mean +  SEM of 3 individual experiments. *P < 0.01 compared to TGF- 
P1.#P < 0.01 compared to TGF- pi. One representative experiment of three 
separate experiments is shown.
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Figure 4.10 Effect of BMP-7 on Smad3 phosphorylation by CD44 
knockdown.
HK-2 cells were transfected with CD44 siRNA , parallel with scrambled si 
RNA for 24 hours, then with fresh serum free medium for another 24 hours . 
After that, the cells were incubated with control serum free medium or BMP- 
7 50ng/ml for 24h, then incubated with control medium or lng/ml TGF-P 1 
for 1 hours. The whole lysates were immunoblotted by phospho-Smad3. 
Subsequently, blots were stripped and reprobed for total-Smad3. One 
representative gel of three experiments is shown.
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Fig 4.11 Effect of HA on BMP-7-induced Smad3 signalling reduction.
HK-2 cells were transfected with Smad3 CAGA(4) and pRL-CMV renilla 
reporter constructs. After incubation with control medium or BMP-7 50ng/ml for 
24h,then incubated with control medium or lng/ml TGF- pi for 6 hours with or 
without HA all through the whole time. *P < 0.01 compared to TGF- pi. #P <
0.05 compared to TGF- p plus HA. Results represent mean ±  SEM of 3 
individual experiments, normalized to control. One representative gel of three 
experiments is shown.
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4.3 Discussion
TGF-pi is a key stimulus leading to interstitial fibrosis and hence to progression of 
renal fibrosis after renal injury. It elicits deposition of ECM by decreasing the 
synthesis of proteases and by increasing the levels of protease inhibitors [317].
HA is a ubiquitous connective tissue polysaccharide which in vivo is present as a 
high molecular mass component of ECM in normal kidney [270]. In diverse renal 
diseases, it is expressed around PTC following renal injury. Previous data have 
demonstrated that HA activates the MAPK pathway through binding to its receptor 
CD44, enhancing PTC migration [318].
There are two forms of HA distribution on HK-2 cell surface. One is diffusely 
arranged HA over the cell surface. HA is also found in cable-like structures that span 
several cell lengths [294, 315]. IL-ip increases the general rate of HA synthesis in 
HK-2 cells, whereas BMP-7 induces formation of HA cable-like structures [315]. 
Previous studies have indicated that formation of these cables in response to BMP-7 
inhibits subsequent TGF-pl generation in PTC bound by monocytes [261].
In a malignant breast epithelial cell line, HA binding to CD44v3 induces Smad 
signalling via direct Smad phosphorylation, dependent on an interaction between the 
variable stalk regions of CD44 coded for by the V3 exon. In contrast, in PTC, the 
work in our lab has previously shown that CD44v3 expression is low [294], and that 
HA binding to CD44 downregulates signalling response to TGF-pl [156]. This led 
me to study possible changes in CD44v3 expression in PTC in response to IL-ip,
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and the potential role of CD44 in IL-ip mediated changes in TGF-pl signalling. In 
my results, IL-ip induced CD44 expression in PTC, but had little effect on CD44v3 
expression. Knockdown of CD44, IL-lp still augmented Smad signalling response 
following CD44 knockdown, suggesting that changes in CD44 expression are not 
responsible for the alterations in TGF-pi signalling in response to IL-lp.
In parallel experiments, HA was added in the culture medium or limited 
hyaluronidase digestion removed the cable-like HA structures. My data showed that 
both treatments did not alter modulation of TGF-pl signalling by IL-1 p.
Previous study showed that Smadl interacts with the cytoplasmic domain of the 
hyaluronan receptor CD44 in chondrocytes, suggesting a functional link between the 
BMP-7 signal cascade and CD44 [291]. Moreover, their further study found HA 
promoted the chondrocytes response to BMP-7 by enhanced Smadl phosphorylation 
and nuclear translocation, but not TGF-pi [316]. This led me to study the potential 
mediation of HA-CD44 on BMP-7 reduction upon TGF-pl-induced Smad3 
signalling.
Firstly, CD44 expression was examined and showed there was no change on CD44 
expression from 15 minutes to 24 hours at 50ng/ml and 500ng/ml BMP-7 by FACS. 
Following CD44 knockdown to disrupt the CD44-TGF-P1 receptor I interaction, 
BMP-7 still diminished Smad3 signalling response, suggesting that CD44 is not 
required for the alterations in TGF-pi signalling in response to BMP-7. Nystatin can 
disrupt cholestrerol, then preventing HA-mediated shift of TGF-p receptor into the 
raft fraction to inhibit signalling initiation [288]. Since the previous data implied
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BMP-7 induces HA cable-like structures formation, I have used nystatin to examine 
if HA-medicated TGF-p receptor shift blocking is involved in BMP-7 effect, but the 
results are not consistent. Together with exogenous HA in the culture medium, 
BMP-7 reduction on TGF-pl Smad3 signalling still remained. Above all, these 
findings indicate that HA-CD44-TGF-P type I receptor interaction is not implicated 
in TGF-pl signalling regulation by IL-lp and BMP-7.
Taken together, in this chapter I have observed the HA/CD44 system effect on the 
TGF-p 1 signalling regulation by IL-ip and BMP-7 in PTC. It showed HA/CD44 is 
not involved in Smad signalling regulation by either stimulus. Next, I further 
investigated the mechanisms underlying the results I obtained in chapter three.
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Chapter Five:
The mechanisms of IL-1 p early
inhibition and late stimulation on
TGF-pi signalling
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5.7 Introduction
In the chapter three, my findings indicate that IL-lp has two distinct effects on TGF- 
pi signalling: early inhibition and later a switch to enhancement of TGF-P 1 
signalling in PTC. In this chapter, I set out to examine potential mechanisms by 
which IL-ip might induce these different long-term and short-term effects, and 
hence might play a significant role in determining proximal tubular cell fate 
following renal injury.
IL-lp nuclear factor-KB (NF-kB) signalling pathway
On activation of the cell surface type I IL-lp receptor (IL-ip R) by IL-lp, a cascade 
of signalling events is initiated, leading to nuclear factor-kB (NF-kB) activation, 
which in turn eventually activates transcription of proinflammatory genes and 
regulates multiple aspects of cell survival, proliferation, and differentiation [319]. 
The NF-kB proteins family includes NF-kB 1 (p50 and its precursor p i05), NF-kB2 
(p52 and its precursor p i00), RelA (also called p65), c-Rel, and RelB, all of which 
are characterized by an N-terminal Rel homology domain (RHD) responsible for 
homo- and heterodimerization as well as for sequence-specific DNA binding [320].
p65, c-Rel, and RelB also contain a C-terminal transcription activation domain 
(TAD), whereas the p52 and p50 rely on interactions with other factors to positively 
regulate transcription [321]. RelB preferentially heterodimerizes with p52 precursor, 
p i00 [322] as well as p52 [323, 324], but p65 and c-Rel subunits predominantly 
heterodimerize with p50 [325]. The well studied major pathway by most stimuli is
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the canonical NF-kB signalling pathway, which mainly depends on p65:p50 and c- 
Rel: p50 heterodimers [320].
Regulation of NF-kB signalling pathway
IkB proteins are the most important NF-KB-interacting proteins inhibiting NF-kB 
[321, 325]. IkBs including hcBa, IkBp, and IkBe, which are classical IkBs, as well as 
a few “novel” hcB-like proteins, which include B cell CLL/lymphoma 3 (BCL3), 
IkB£, and IkBNS, retain NF-kB dimers inactive in the cytoplasm of nonstimulated 
cells. Extracellular stimuli can trigger the phosphorylation, ubiquitylation and, 
subsequently degradation of IkB thereby releasing the NF-kB complexes. The IkB 
degradation allows activated NF-kB proteins to enter the nucleus and act as 
transcription factors to regulate a wide range of target genes expression [326-329].
The degradation of IkB is an essential step for releasing NF-kB and exerting its 
subsequent activation [321, 325]. A crucial regulatory step in this process is the IKK 
(IkB kinase) complex, consisting of several proteins — the main ones being IKKa, 
IKKp and the regulatory subunit NF-kB essential modulator (NEMO; also known as 
IKKy). IKK -induced phosphorylation of IkB occurs at specific amino-terminal 
serine residues (such as Ser32 and Ser36 for IkBoi). After that, the phosphorylated 
IkBoi is ubiquitylated at Lys21 and Lys22 by P-TRCP (P-transducin repeat- 
containing protein), which targets it for degradation by the 26S proteasome[330].
NF-kB is an important downstream effector for IL-ip and has been linked to 
inhibition of TGF-P signalling [230, 305]. The major form of NF-kB exists as a
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heterodimer around p50 and p65 initiated by different pro-inflammatory cytokines, 
including interleukins and tumour necrosis factor-a (TNF-a) [331, 332]. NF-kB has 
previously been shown to inhibit TGF-pl-induced gene expression via sequestration 
of the transcriptional coactivator p300 by p65 NF-kB [333]. Further, NF-kB subunit 
of RelA (also named p65) is necessary for the inhibition of TGF-P 1-induced Smads 
phosphorylation, nuclear translocation, and DNA binding by TNF-a [305].
IKK phosphorylation leading to degradation of IkB is the main regulation axis, 
which is an essential process for freeing NF-kB and initiating its subsequent 
activation [321, 325]. It has been well known that h<Ba regulates transient NF-kB 
activation whereas IkBP maintains persistent NF-kB activation [334]. Thus, as well 
as measuring NF-kB activation directly, in this chapter I observed the iKBa, IkBP 
expression as well as IKK phosphorylation following short and long-term exposure 
to IL-lp. In terms of further mechanisms by which p65 antagonizes TGF-pl-induced 
Smads signalling by TNF-a, previous work has implicated up-regulation of Smad7 
synthesis and therefore more stable association between ligand-activated TGF-pl 
receptors and Smad7 [305]. In human chondrocytes, IL-ip prevents TGF-p 1 
response by downregulating TGF-pl R II and up-regulating Smad7 via NF-xB/p65 
pathway [228, 229]. Therefore, I have also studied Smad7 and TGF-pl R I 
expression responses to IL-ip in PTC.
In chapter three, independent of the early inhibition of TGF-P 1 signalling by IL-ip, I
have shown that in PTC, long term IL-lp stimulation leads to augmentation of TGF-
pl-induced Smad2 and Smad3 signal, and detectable Smad3 phosphorylation in the
absence of exogenous TGF-pl. My results show the augmentation of IL-lp on TGF-
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pi signalling is dependent on TGF receptor/ligand interaction without altering TGF- 
pi synthesis or Smad3 dephosphorylation. These outcomes suggest IL-lp enhances 
TGF-P 1-induced Smad signalling at or before the level of TGF-P 1 receptor-ligand 
interaction. Previous work has indicated IL-6 leads to enhancement of TGF-pl 
signalling via a shift of type I receptors from lipid rafts to non-raft associated plasma 
membrane [309]. Thus, I assessed IL-6 generation by IL-ip treatment in PTC.
In conclusion, aims in this chapter were:
1 To characterize the mechanism of early inhibition effect of IL-lp on TGF-pl 
signalling
2 To identify the mechanism of late stimulation effect of IL-lp on TGF-pl 
signalling
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5.2 Results
5.2.1 Early inhibition of NF-kB activity reverses the inhibitory effect 
on TGF-pi Smad3 signalling by IL-lp
HK-2 cells were stimulated for time points to 24h with IL-lp lng/ml before cell lysis 
and cellular protein extraction. Then I detected Smad7 and TGF-P 1 R I expression 
by immunoblotting. In HK-2 cells, the data indicates that neither TGF-p 1 nor IL-lp 
stimulation up to 24 hours regulates Smad7 and TGF-P 1 R I expression (Figure 5.1 
and 5.2).
Since NF-kB is an important downstream effector for IL-lp and has been shown to 
inhibit TGF-pl signalling, the effect of NF-kB inhibition on modulation of Smad 
signalling by IL-lp was investigated using the peptide inhibitor SN50, previously 
shown to be effective at preventing NF-kB signalling in HK-2 cells [335]. Blockade 
of NF-kB with SN50 prevented the inhibitory effect of IL-ip on TGF-P 1 Smad3 
signalling, assayed by immunoblotting (Figure 5.3 A). In related experiments, HK-2 
cells transfected with CAGA(4) and renilla vectors were treated with TGF-p 1+ IL- 
ip ±SN50 for 6 h. Inhibition of reporter gene activity by IL-lp was blocked by 
SN50 (Figure 5.3 B).
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Figure 5.1: Time course o f  Smad7 expression by IL -ip  ±  
TGF-P 1
IL-1 p and TGF-P 1 were added to confluent monolayer of growth 
arrested HK-2 cells under serum free conditions. HK-2 cells were co­
treated with lng/ml TGF-pl ±  lng/ml IL-lp for time points from 15 
minutes to 24 hours, before protein extraction and immunoblotting for 
Smad7. Blots were stripped and reprobed for Gapdh. One representative 
experiment of three experiments is shown.
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Figure 5.2: Time course of TGF-p type receptor I expression 
by IL-lp ±  TGF-pl
IL-1 p and TGF-P 1 were added to confluent monolayer of growth 
arrested HK-2 cells under serum free conditions. HK-2 cells were co­
treated with lng/ml TGF-pl ±  lng/ml IL-1 p for time points from 15 
minutes to 24 hours, before protein extraction and immunoblotting for 
TGF-p receptor I. Blots were stripped and reprobed for Gapdh. One 
representative experiment of three experiments is shown.
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Fig 5.3: Inhibition of TGF-P 1 signalling by IL-lp occurs via NF-kB.
(A) HK-2 cells were incubated with TGF-pl , TGF-P 1 and SN50, TGF-pl and 
IL-ip or TGF-pl, IL-lp and SN50 for 1 hour before lysis and analysis by 
immunoblotting for phospho-Smad3. Subsequently, blots were stripped and 
reprobed for total Smad3. One representative experiment of three experiments 
giving similar results is shown. (B) HK-2 cells were transfected with CAGA(4) 
and pRL-CMV renilla before incubation for 6 hour with the control 
medium,lng/ml TGF-pl ±  IL-1 p lng/ml or TGF-p 1+IL-l P +SN50. Ratio of 
firefly to renilla luciferase activity is shown, normalized to control cells. N  = 3, 
mean ±  SEM is plotted. One representative experiment of three separate 
experiments is shown.
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5.2.2 Over-expression of NF-kB subunits inhibits TGF-pi Smad 
signalling
Subsequently, the role of NF-kB in inhibition of Smad signalling was investigated 
using co-transfection of p65 and p50 over-expression vectors with the Smad3 
reporter construct CAGA (4). Over-expression of p65 and p50 or p65 alone inhibited 
subsequent reporter gene response to TGF-pl. In contrast, the over-expression of the 
p50 subunit alone had no effect on Smad3 signalling (Figure 5.4).
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Fig. 5.4: Role of NF- k B in the TGF-P 1 signalling inhibition by IL- 
ip .
HK-2 cells were transfected with an empty vector alone, empty vector and 
p65 over-expression vector, empty vector and p50 over-expression vector or p65 
and p50 over-expression vectors, together with CAGA(4) and pRL-CMV renilla 
for 24 hour before incubation with TGF-P 1 for 6 hour. Control cells were 
incubated in the TGF-pl-free medium. Equal amounts o f DNA were transfected 
into all wells. N  = 3, mean ±  SEM is plotted. The empty vector plus TGF-p 1 
versus p65 plus TGF-pl * P  < 0.001, versus p65 and p50 plus TGF-pl * P  < 
0.001, versus p50 plusTGF-pi P = not significant. Ratio of firefly to renilla 
luciferase activity is shown, normalized to control cells. One representative 
experiment o f three separate experiments is shown.
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5.2.3 IL-ip stimulates NF-kB activity from early p65/p50 complex to 
later p50/p50 complex
The time course of N F-kB activation in IL-1 (3-stimulated PTC was assessed by the 
electrophoretic mobility shift assay. Increased probe retardation was seen within 15 
min and persisted for up to 24 h (Figure 5.5). NF-kB probe retardation can be 
secondary to signalling p65/p50 heterodimers or to inhibitory p50/p50 homodimers 
[336]. Supershift experiments were performed with antibodies to p65 and p50, using 
PTC nuclear extracts from the cells treated for 1 h and 24 h with IL-1 (3 (Figure 5.6). 
Both p65 and p50 were detectable at 1 h, while only p50 was detected at 24 h. The 
classical regulation of NF- kB activation pathway involves IkK phosphorylation, 
which leads to degradation of IkB alpha/lKB beta, and release of active NF-kB 
subunits. Immunoblotting of the cell extracts following IL-lp stimulation showed 
rapid but transient IkK phosphorylation (Figure 5.7), followed IkB alpha and IkB 
beta rapid degradation. However, both IkB alpha and IkB beta have been 
reaccumulated by 24 h (Figure 5.7).
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Fig 5.5: Time course of NF-kB activation by IL-1 (3 in proximal 
tubular cells.
NF-kB electrophoretic mobility shift assay. PTC were stimulated with 1 
ng/ml IL-1 p for time points to 24 hour before nuclear protein extraction, and 
electrophoretic mobility shift assay with consensus NF-kB probe. Retarded 
probe and free probe are indicated . One representative gel of three 
experiments is shown.
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Fig5.6: Time course of NF-kB activation by IL-1 (3 in 
proximal tubular cells.
Supershift assay. NF-kB EMSA with addition of p60, p50 and an 
irrelevant antibody to nuclear protein from cells stimulated with IL-1 (3 
for 1 hour and 24 hours. Retarded probe and supershifted bands are 
indicated. One representative gel of three experiments is shown.
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Fig 5.7: NF-kB activation by IL-lp in proximal tubular cells.
IkK and IkB activation. HK-2 cells were stimulated with lng/ml IL-1 p 
for time points to 24 hours before immunoblotting of whole cell lysates 
for phospho-IKK. Blots were subsequently stripped and reprobed for 
total IKK. In separate experiments, immunoblotting for IkB-alpha and - 
beta was performed. One representative experiment of three separate 
experiments is shown.
3 0 ’ 6 0 ’ 24h
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5.2.4 The sensitizing effect of prolonged IL-lp on TGF-pi signalling 
required TGF-P receptor-ligand interaction and was independent 
on TGF-pi generation
The above SuperShift experiments showed there was a switch from an early NF-kB 
p65/p50 complex to a later NF-kB p50/p50 complex. Possible mechanisms for the 
observed increases in Smad2 and Smad3 signalling following chronic IL-lp 
exposure include increased TGF-pl generation or activation, changes in TGF-P 1 
receptor sensitivity or changes in Smad degradation or dephosphorylation. NF-kB 
responsive elements are present in the TGF-p promoter, and IL-lp increases TGF-p 
generation in human alveolar epithelial cells [337]. Therefore, I quantified the 
release of TGF-P 1 into the cell culture supernatant by PTC in response to IL-lp. 
HK-2 cells were cultured in with IL-lp (dose range 0-1 ng/ml) for 24 h before the 
assay of TGF-pl generation by ELISA. No increase in TGF-pl release was seen in 
response to IL-1 p (Figure 5.8 A).
In terms of whether TGF-pl receptor-ligand interaction is required for the 
sensitizing effect of IL-lp 6n TGF-pl signalling, the experiments were performed in 
the presence of TGF-pl receptor blocking antibody by Smad3 reporter gene assay. 
Addition of a blocking antibody to the TGF-pl type II receptor inhibited IL-1 p- 
mediated changes in Smad signalling in a dose dependent fashion (Figure 5.8 B), 
suggesting that the effect of IL-1 P on Smad signalling was due to increased response 
to TGF-pl, rather than the activation of Smad signalling independent of TGF-P 1 
receptors.
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Fig. 5.8: Mechanism o f sensitization to TGF p 1 by chronic IL-lp 
stimulation.
(A) HK-2 cells were treated with IL-lp, dose range 1-1000 pg/ml, for 24 
hour before ELISA of cell culture supernatant total TGF- p 1. N=  3, mean± 
SEM is plotted. No significant differences were found. (B) Blockade of IL- 
1 p sensitization by an anti-TGF betal receptor antibody. HK-2 cells were 
transfected with Smad3 responsive (CAGA) and pRL-CMV renilla plasmids 
before treatment with lng/ml TGF p 1 ±  lng/ml IL-1 p, in combination 
with a blocking antibody to the TGF-p type II receptor (dose range 0-10 ug/ 
ml) for 24 h. Data are expressed as firefly/renilla luciferase activity, 
normalized to control cells. N=  3, mean ±  SEM is plotted. TGF p 1 versus 
TGF-P 1+IL-1 p #P < 0.01, TGF-p 1+IL-lp versus TGF-p +IL-1P +blocking 
antibody *P < 0.01 .One representative experiment of three separate 
experiments is shown.
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5.2.5 Smad3 dephosphorylation/degradation were not altered by IL-
i p
To evaluate possible changes in Smad dephosphorylation in response to IL-ip, the 
half-life of phospho-Smad3 was examined using the Alk5 kinase inhibitor SB431542. 
Similar decay rates for phospho-Smad3 were observed in control cells and cells 
treated with IL-ip (Figure 5.9 A and B), suggesting that phospho-Smad3 
dephosphorylation was not altered in response to IL-lp.
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Fig 5.9: Time course of phospho-Smad3 degradation/ 
dephosphory 1 ation.
(A) HK-2 cells were treated with IL-lp or the control medium for 24 hours, 
before TGF-P 1 lng/ml treatment for 30 minutes. Subsequently, the cells were 
again incubated in the medium containing the Alk5 inhibitor SB431542 
1 OuM for time points to 5 hours. Residual phospho-Smad3 was detected by 
immunoblot. (B )  Plot of densitometry results for immunoblots were shown. 
Phospho-Smad3 signal is plotted as a percentage of initial signals (time zero) 
for control and IL-1 p pre-treated cells. One representative experiment of 
three experiments is shown.
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5.2.6 The sensitization of PTC to TGF-p by chronic IL-lp is via 
increased IL-6 generation
The above data show that sensitization to TGF-P by IL-1 p is dependent on TGF-p 
receptors, but not involving alterations in TGF-p generation and Smad 
dephosphorylation, and suggested that IL-lp altered TGF-pl signalling at the 
receptor level. The previous work in our lab has shown that IL-6 sensitizes PTC to 
TGF-p signalling via a shift of receptors from the lipid raft to the non-raft 
component of the plasma membrane [309]. IL-6 may also be an important 
downstream mediator for IL-ip in chronic inflammation. Therefore, IL-6 generation 
in PTC in response to IL-lp was examined.
24 hours of IL-ip stimulation with doses as low as 10 pg/ml led to significant IL-6 
generation (Figure 5.10 A). The time course of IL-6 generation was examined, using 
stimulation with 1 ng/ml IL-lp based on the previous experiments. Increased IL-6 
generation was seen after 3 h or more IL-1 p stimulation, but not at earlier time points 
(Figure 5.10 B).
Subsequently, the effect of a blocking antibody to the IL-6 receptor on TGF-p 
responsiveness in the cells stimulated with IL-1 p for 24 h was determined. Phospho- 
Smad3 immunoblotting showed that IL-6 receptor blockade abrogated sensitization 
of Smad signalling by IL-ip, without inhibiting baseline TGF-pl response (Figure 
5.11).
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Fig 5.10: IL-6 generation by chronic IL-lp stimulation.
(A) Dose-dependent IL-6 generation following IL-lp stimulation. HK-2 cells 
were cultured in the medium containing IL-1 P (dose range 0-1000 pg/ml) for 
24 hours before the assay of IL-6 in the supernatant by ELISA. N=  3, mean 
+  SEM is plotted. P < 0.01 for IL-lp 10,100 and 1000 pg/ml compared to 
control. (B) Time course of IL-6 generation following IL-lp. HK-2 cells were 
cultured in the medium containing IL-1 p lng/ml for time points to 24 hours 
before assay of IL-6 in the supernatant by ELISA. N=  3,mean ±  SEM is 
plotted. P < 0.01 for time points of 3, 6, 12,24 h compared to control, P = NS 
for earlier time points. One representative experiment of three experiments is 
shown.
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Fig 5.11: Effect of IL-6 blockade on sensitization of TGF-pl 
signalling by IL-lp.
(A) HK-2 cells were cultured in the medium containing lng/ml IL-1 p and 
lng/ml TGF-p 1 ±  IL-6 receptor-blocking antibody for 24 hours. Control cells 
were cultured in the medium containing TGF-pl alone. Whole cell lysates 
were immunoblotted for phospho-Smad3 and reprobed for total Smad3. One 
representative blot of three experiments giving similar results is shown . (B) 
Combined densitometry results of the blots from three experiments is 
described . Mean phospho-Smad3/total Smad3 is blotted.
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5.2.7 Early inhibition and late enhancement of Smad signalling are 
independent effects
To test whether the early inhibitory and late stimulatory effects of IL-lp on TGF-pl 
signalling were independent, I examined whether IL-ip-mediated IL-6 generation 
required NF-kB signalling. Blockade of NF-kB with SN50 had no effect on IL-lp- 
stimulated IL-6 generation (Figure 5.12A).
Subsequently, the effect of NF-kB blockade on sensitization to TGF-pi by IL-lp 
was examined. Addition of SN50 had no effect on sensitization to TGF-pl by IL-lp 
(Figure 5.12 B).
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Fig. 5.12: Sensitization to TGF-pl by chronic IL-lp 
stimulation is independent of NF-kB.
(A) HK-2 cells were treated with IL-1 P, or IL-1 p and SN50, for 24 
hours. Control cells were treated with the IL-lp -free medium, or 
SN50 alone. Supernatant IL-6 was measured by ELISA, n = 4, mean 
±  SEM isplotted. IL -ip vs Both, P = NS. (B) HK-2 cells were 
treated with lng/ml TGF-pi ±  lng/ml IL-ip ±  SN50 for 24 hours; 
then total cell lysates were immunoblotted for phospho-Smad3 and 
total Smad3. One representative experiment of three experiments is 
shown.
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5.5 Discussion
In chapter three, I have described the biphasic effects of IL-1 (3 on TGF-pl signalling 
in PTC. Subsequently, I identified the independent mechanisms in this chapter. Since 
we know that canonical TGF-pi signalling involves binding of TGF-pi to its type II 
receptor and subsequent a heteromeric complex formation of type I and II receptors, 
leading to type I receptor autophosphorylation, followed up by R-Smads 
phosphorylation, I followed this route to explain the mechanism.
Firstly, I transfected HK-2 cells with p65, p50, or both over-expression vectors 
together with CAGA (4) Smad3 reporter constructs, followed up by TGF-pl 
stimulation for 6 hours. With the presence of p65 over-expression, there is a 
significant reduction on TGF-p 1 signalling whether in p65 alone or in both groups. 
Nevertheless, p50 over-expressed alone does not affect TGF-P 1 signalling. On the 
other hand, together with SN50, a peptide inhibiting translocation of the NF-kB 
active complex into the nucleus, blocking NF-kB activation prevents the early 
inhibition of IL-ip on TGF-pl signalling at Smad3 phosphorylation and the 
following DNA-binding activity. Moreover, the data show clear inhibition of Smad 
signalling at early time points by reporter gene assay, but the effect of IL-lp on 
Smad phosphorylation by TGF-P 1 at early time points is relatively modest, 
suggesting that NF-kB acts on Smad signalling predominantly beyond the level of 
Smad phosphorylation by the activated receptor complex.
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In order to further confirm the NF-kB subunits activation by IL-lp in PTC, I 
assessed NF-kB activation by EMSA and it shows the activation persisted from 15 
minutes to 24 hours. However, there was a change in appearance of the retarded 
band on EMSA that appears to coincide with the time of switch from inhibition to 
stimulation of TGF-P 1 signalling. Subsequent supershift results show a switch from 
p65/p50 complex to p50/p50 complex. The interesting thing is the complex switched 
from p65/p50 at early 1 hour IL-ip treatment to p50/p50 at late 24 hour IL-lp 
treatment, accompanying with the loss of NF-kB inhibitory effect on Smad 
signalling. It suggests that p65 plays a crucial role on IL-lp-induced early inhibition 
on TGF-P 1 signalling.
Then, I investigated the mechanism of how p65 inhibits TGF-pl signalling pathway. 
Previous work has suggested that NFkB may limit Smad signalling through up- 
regulation of Smad7 and down-regulation of type I TGF-p receptors [223, 224,298]. 
However, I found that in HK-2 cells, neither TGF-pl nor IL-ip stimulation up to 24 
hours altered Smad7 or TGF-pl R I expression. In addition, in the previous work 
quoted above, increased Smad7 protein was detected after 12 or more hours of IL-lp 
stimulation, whereas in my experiments, IL-1 had a detectable inhibitory effect on 
TGF-pl signalling within 1 hour. Some work has shown NF-kB inhibits TGF-P 1 
response via sequestration of the transcriptional coactivator p300 by p65 NF-kB 
[333], and it would be interesting to investigate the potential role of p300 
sequestration in the inhibitory effect of IL-1 that I have demonstrated.
Because of the important regulation axis of IKK- IkB on NF-kB signalling, I
detected them by Western Blot and have shown that at early time point of IL-lp up
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to 1 hour, IKK is phosphorylated leading to the final obvious degradation of IkBcl 
Following the degradation of IicBa, the NF-kB subunits are released and translocate 
from cytoplasm to nucleus, initiating NF-kB signalling pathway. The similar but 
weaker regulation is detected for IxBp, another member of IkB family. These data 
support transient NF-kB activation by IL-lp in PTC [334].
Having investigated the mechanism of early effect of IL-1 p on TGF-pl signalling, I 
have observed how the late enhancement effect of IL-lp on TGF-P 1 signalling 
processes.
In chapter three, I have shown that in PTC, the longer term presence of IL-lp leads 
to different augmentation of Smad2 and Smad3 response to TGF-pl compared to 
early inhibition effect of IL-lp and to detectable Smad3 phosphorylation in the 
absence of exogenous TGF-pl. Previous work has shown that HA leads to the 
activation of TGF-pl type I receptors via CD44 v3 and to R-Smads phosphorylation 
without TGF-P 1 ligand-receptor interaction or formation of the conventional 
activated receptor complex [289]. However, the augmentation of TGF-pl signalling 
by IL-lp is prevented by a type II receptor blocking antibody, suggesting that IL-lp 
is dependent on TGF-P receptor/ligand interaction. Also, IL-lp does not alter TGF- 
pl synthesis. After formation of the activated receptor complex, the next step is R- 
Smads phosphorylation. It was demonstrated that the TGF-P 1-regulated R-Smads, 
Smad2 and Smad3, constantly shuttle between the nucleus and the cytoplasm both in 
uninduced cells [175] and during TGF-p 1 signalling, Smad nucleocytoplasmic 
shuttling monitored receptor activity [102]. Most importantly, nucleocytoplasmic
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Smad shuttling in the presence of TGF-P 1 appears to require the cycles of Smad 
phosphorylation and dephosphorylation. With SB 431542, an inhibiter of ALK-5 
(TGF-pl type I receptor) [338], my results show IL-lp does not affect the R-Smads 
dephosphorylation in response to TGF-p 1. Thus, these outcomes together suggest 
that IL-lp enhances response to endogenous/exogenous TGF-pl via alteration in the 
signalling initiation of TGF- p receptor expression or distribution.
TGF-p receptors internalize into both caveolin- and EEA1-positive vesicles. 
Clathrin-dependent internalization into the EEA1 -positive endosome promotes TGF- 
P signalling. In contrast, the lipid raft-caveolar internalization pathway contains the 
Smad7-Smurf2-bound receptor and is essential for a rapid receptor turnover [153]. 
My results show Smad7 and type I receptor expression is not changed by long time 
treatment of IL-1 p response to TGF-pl. The previous work in our lab has shown that 
in PTC, TGF-p receptor distribution in the plasma membrane is regulated by stimuli 
including hyaluronic acid (via CD44), which leads to the attenuation of TGF-P 1 
signalling and IL-6, which contributes to enhance TGF-pl signalling via a shift of 
receptors from lipid rafts to non-raft associated plasma membrane [156, 309].
IL-6 is a multifunctional cytokine produced by a variety of cells in response to IL-lp 
during infection, trauma and immunological challenge [339]. In my work, IL-lp 
leads to increased PTC IL-6 generation after 3 hours treatment, and IL-ip doses and 
times required to stimulate IL-6 generation mirrored those required to sensitize PTC 
signalling response to TGF-P 1, which matches the time point switch from signalling 
inhibition to signalling enhancement. Additionally, a blockade of IL-6 signalling
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abrogated sensitization of TGF-pl signalling by IL-ip, confirming that in PTC, IL- 
lp  augments Smad signalling response to TGF- p via an autocrine IL-6 loop.
As the results described above, IL-ip functions through NF-kB signalling up to 24 
hours. In order to confirm if NF-kB activation is a precondition for later IL-6 
generation and TGF-P 1 sensitization by IL-ip, I blocked NF-kB action with SN-50 
to evaluate the Smad3 phosphorylation and IL-6 generation. The data show that 
blocking NF-kB activation has no influence either on IL-6 generation or Smad3 
phosphorylation, suggesting that the early and late effects of IL-1 P on TGF-p 1 
signalling are independent.
In conclusion, these results suggest that early inhibition effect of IL-1 p on TGF-pl 
signalling is via NF-kB, but that after 3 hours there is a switch from p65/p50 to 
p50/p50 complexes, Furthermore, the later prolonged enhancement effect of IL-lp 
on TGF-pl signalling is via an autocrine IL-6 loop. This data scores how the relative 
simplicity of TGF- p signalling pathways contrasts with the complexity and diversity 
of epithelial cell responses to IL-1 p. Changes in epithelial cell response to TGF-P 
secondary to important environmental cues such as inflammation provide an 
explanation for the apparently contradictory roles of TGF-p in the kidney, suggesting 
how this cytokine can be involved in controlled healing following acute injury on the 
one hand, yet be the principal promoter of scarring in chronic disease on the other.
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Chapter Six:
The mechanisms of BMP-7 effect on 
TGF-pi signalling
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6.1 Introduction
In chapter three, I showed BMP-7 inhibits TGF-pl Smad3 but not Smad2 signalling 
without apparent reduction Smad3 phosphorylation.
BMP-7 and TGF-P 1 belong to TGF-p super family. BMP-7 signalling has its own 
two type receptors on the cytoplasm membrane and R-Smads.
BMP-7 signalling pathway and its regulation
Like TGF-p signalling pathway, BMP7 receptors are type I/II heterodimeric 
serine/threonine kinase receptors. Several different type I receptors, namely the 
activin receptor-like kinases (Aik) Alk2 (activin receptor I), Alk3 (BMP receptor 
IA), and Alk6 (BMP receptor IB), associate with the BMP type II receptor (BMPRII). 
Receptor activation induces intracellular recruitment and serine/threonine 
phosphorylation of Smad substrates. Smadl, -5, and -8 are BMP-restricted Smads, 
and Smadl and/or -5 are signalling substrates for BMP-7 in different cell types [252, 
314]. However, in some other cell types including endothelial cells, TGF-p ligand 
can phosphorylate Smadl, Smad5 and Smad8 through a receptor complex that 
contains the tissue-specific ALK1 type I receptor [93, 340-342].Similar to TGF-p, 
BMP-7 can also regulate cell type and context, dependently other signals including 
the tyrosine kinases ERK, JNK, and p38 [240]. In mPTC, murine mesangial cells, 
and murine podocytes, studies indicate that the preferred Smad signalling candidate 
for BMP-7 is Smad5 [240, 252]. Moreover, phosphorylation of Smad5 by BMP-7 is
i
not inhibited by coincubation with TGF-p [252]. TGF-P- restricted Smad2 and 3 are 
not activated by BMP-7[252].
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The bioactivity of BMP-7, is further regulated by a series of secreted, extracellular 
proteins that bind and neutralize peptide activity, including BMP-7 antagonists such 
as, noggin, follistatin, and gremlin, USAG-1 [252, 253, 343, 344]. The activity of 
BMP-7 also can be enhanced by endoglin and KCP [343, 344]. CTGF, another 
profibrotic player is not only induced by TGF-pl, but also a major enhancer of the 
biological activity of TGF-pl. Recent work has shown that CTGF inhibits BMP-7 
signal transduction in the diabetic mice kidney, thus reducing MMP activity, and 
albuminuria [345]. In the human patients, pSmadl/5/8 was decreased along with 
increased CTGF expression. Whereas in CTGF(+/-) mice, pSmadl/5/8 were 
preserved compared to diabetic CTGF(+/+) mice [346]. In myoblastic L6E9 cells, 
endoglin inhibits TGF-pl-induced ALK-5/Smad3 signalling but enhanced the BMP- 
7/Smadl/Smad5 pathway [347]. Another TGF-P type III receptor, betaglycan, can 
specifically bind to multiple numbers of BMP family including BMP-7 in vitroy 
enhancing ligand binding to the BMP type I receptors to attenuate BMP-mediated 
Smadl phosphorylation [348].
MAPKs (especially ERK1/2, GSK3-p (Glycogen synthase kinase-3)) also 
phosphorylate the linker of Smad 1/5, creating a docking site for the E3 ubiquitin 
ligase, Smurfl. Smurfl not only causes ubiquitin-proteasome degradation of the 
Smads but also prevents Smad complex translocation from the cytoplasm to the 
nucleus to block their interaction with the nuclear pore complex [222]. In some 
conditions BMP7 may activate JNK [349] in human mesangial cells and ERK in 
proximal tubular epithelial cells [252]. The canonical Wnt signalling pathway, which 
functions through the inhibition of Glycogen Synthase Kinase 3 activity (GSK3-P), 
reduces Smadl ubiquitination and stabilizes the BMP-Smad signalling [350].
Possible mechanisms of BMP-7 effects on chronic renal injury in response to 
TGF-P
BMP-7 is a well known cytokine to protect TGF-P-dependent renal fibrogenesis due 
to various causes. We know EMT is a pivotal process contributing to fibrosis. 
Interestingly, some work has shown that cardiac fibrosis is associated with the 
participation of fibroblasts deriving from endothelial cells, suggesting an endothelial- 
mesenchymal transition (EndMT), which can be induced by TGF-P 1. The systemic 
administration of recombinant human BMP-7 (rhBMP-7) significantly inhibited 
EndMT and the progression of cardiac fibrosis in mouse model [351]. Recent results 
found out that EndMT is also a novel mechanism for accumulation of fibroblasts and 
myofibroblasts in kidney fibrosis [22, 352].
Since massive work has shown BMP-7 can antagonize TGF-P-induced cellular and 
histological changes contributing to renal fibrosis, some work has been done to 
explore the mechanisms on TGF-p signalling pathway regulation. In BMP-7 
transgenic mice, BMP-7 transgene leads to elevated phosphorylated Smadl/5 and 
moderately reduces p-Smad2/3 levels without affecting TGF-p levels in kidney [254]. 
In mesangial cells in vitro, BMP-7 opposes the TGF-p-dependent fibrogenesis via 
activation of downstream of Smad5, the inhibitory Smad6 and subsequently reduces 
the availability of Smad3 in the nucleus [314]. The aim in this chapter was to 
characterize the mechanism of inhibition effect of BMP-7 on TGF-pl signalling in 
HK-2 cells.
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6.2 Results
6.2.1 BMP-7 does not alter Smad3 nuclear accumulation, or 
dephosphorylation
The inhibition of Smad3 but not Smad2 signalling suggests that BMP-7 acts beyond 
the point of TGF-P ligand-receptor interaction. In our lab, the preliminary 
experiments showed Smad2 and Smad3 phosphorylation detectable for 24h 
following TGF-p treatment, with a maximal response by 30 minutes to lh. Although 
Smadl phosphorylation was readily detected following BMP-7 treatment, 
confirming signalling response to BMP-7, BMP-7 had no effect on Smad2 or Smad3 
phosphorylation in cells pre-incubated with BMP-7 then exposed to TGF-p (Figure 
6.1). Transient Smadl phosphorylation was also evident following TGF-p treatment, 
in keeping with recent reports of transient Smad 1/5 phosphorylation in epithelial 
cells in response to TGF-pl [353].
Nuclear import and export of Smad3, together with its dephosphorylation, 
ubiquitinylation, and degradation, are highly regulated [354, 355]. To study possible 
Smad3 dephosphorylation or degradation in response to BMP-7,1 examined the half- 
life of phospho-Smad3. HK-2 cells were incubated with BMP-7 or control medium, 
then Smad3 phosphorylation was stimulated with TGF-pl. After 30 minutes, further 
Smad3 phsophorylation was inhibited using the Alk5 Kinase inhibitor SB431542, 
and the rate of decline of phospho-Smad3 was evaluated with Immunoblotting. 
Similar rate of decline in phospho-Smad3 was observed in control cells and cells 
treated with BMP-7 (Figure 6.2), suggesting that phospho-Smad3 dephosphorylation
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and degradation are not altered in response to BMP-7. Next, nuclear accumulation of 
phospho-Smad3 was assessed by immunoblotting and by fluorescence microscopy. 
Immunoblots of nuclear protein fractions suggested that BMP-7 did not alter nuclear 
accumulation of Smad3 (Figure 6.3A). Similarly, immunocytochemistry did not 
detect differences in TGF-p-dependent nuclear accumulation of Smad3 following 
BMP-7 treatment (Figure 6.3B), confirming the outcome that BMP-7 has no effect 
on Smad3 nuclear accumulation.
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Fig 6.1: Time course of Smad phosphorylation in response to BMP-7 
±  TGF-P 1
(A) HK-2 cells were incubated with BMP-7 50ng/ml for time points up to 24 
hours. The whole cell lysates were immunoblotted with phospho-Smad3/l. The 
TGF-pl treated lane takes as a control to show the pSmad3 band. Blots were 
stripped and reprobed for total Smad3.
(B) HK-2 cells were incubated with BMP-7 50ng/ml for time points up to 24 
hours before incubation with TGF-pl lng/ml for 1 hour. Whole cell lysates were 
immunoblotted with antibodies against phospho-Smadsl,2,3, and total Smads 1 
and 3. Stripping and reprobing for Gapdh was used to confirm approximately 
equal loading.
One representative experiment of three separate experiments is shown.
155
ApSmad3/l 
Total-Smad3
TGF-pl 30’
The following 
SB431542
pSmad3/l
Total-Smad3
BMP-7 24h,then TGF-P 1 30’ 
The following SB431542
B
m
+
' V::- :
get* . j n r
+ +
30’ 60’
pSmadl
pSmad3
+ +
5h
m m
- pSmadl 
* <4-  pSmad3
+ + +
30’ 60’
+
90’
+
5h
■o
E
© s
-S  4» U
o £
6£ B C 0£
;= & X
E
120
100
80
60
40
20
0
2 3 41 5
Control
BMP-7 Pre 
Treatm ent
Time Following SB431542,Hours
Fig 6.2: Time course of Smad dephosphorylation/degradation in 
response to TGF-pl and BMP-7
HK-2 cells were incubated with control medium or BMP-7 50ng/ml for 24 hours 
before incubation with TGF-P 1 lng/ml for 30 minutes. (A and B) Cells were 
washed and incubated in control medium or medium containing the ALK5 Kinase 
Inhibitoe SB431542 for time points up to 5 hours. Residual phospho-Smad3 
activity was detected by immunoblot before stripping and reprobing for total 
Smad3. One representative experiment of three experiments is shown. (C) Plot of 
densitometry results for immunoblots were shown in.phospho-Smad3 signal is 
plotted as a percentage of initial signals (time zero) for without and with BMP-7 
pre-treated cells .
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Fig 6.3: Nuclear accumulation of Smad3.
HK-2 cells were incubated with control medium or BMP-7 50ng/ml 
for 24 hours before incubation with TGF-P 1 lng/ml for 1 hour. (A) 
Immunoblotting of nuclear extracts for phospho-Smad3/l, and 
subsequently reprobing for C-Jun to confirm approximately equal 
nuclear protein loading. (B) Immunoflurorescent localization of 
Smad3.
One representative experiment of three separate experiments is 
shown.
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6.2.2 BMP-7 inhibits Smad3 DNA Binding
The above data suggest that BMP-7 specific limits Smad3 signalling responses to 
TGF-P 1, without altering TGF-p-dependent Smad phosphorylation and nuclear 
accumulation, or subsequent Phospho-Smad3 decay rate. Therefore, potential 
alterations in Smad3 DNA binding were investigated by Electrophoretic Mobility 
Shift Assay. Probe retardation was detected in nuclear protein extracts from TGF-p- 
treated cells, but this was attenuated in cells by BMP-7 (Figure 6.4). In order to 
confirm the presence of Smad3 and Smad4 in the complexes formed, supershift 
experiments were performed with relevant antibodies (Figure 6.5). Smad5 is reported 
to bind to consensus Smad3 elements, such that the potential for competitive 
inhibition of Smad3 binding by Smad5 exists [356]. However, no binding of Smad 5 
was seen following addition of anti-Smad5 antibody (Figure 6.6). This data suggests 
that BMP-7 specifically limits Smad3 DNA-binding, without altering Smad3 
phosphorylation or nuclear import.
Subsequently, endogenous Smad3 DNA binding was further evaluated by Chromatin 
Immunoprecipitation (ChIP), measuring Smad3 DNA-binding to the endogenous 
PAI-1 promoter. PAI-1 is a major contributor to progressive renal fibrosis in chronic 
kidney diseases, its promoter element contains several Smad Binding Elements, of 
which two cooperatively regulate the transcriptional response of PAI-1 to TGF-p 
[38]. ChIP showed increased Smad3 binding to these two PAI-1 promoter Smad- 
responsive elements, with maximal Smad3 binding detected 6 hours post-TGF-pl 
stimulation (Figure 6.7). BMP-7 alone did not significantly alter Smad3 binding to 
PAI-1 promoter sites, but inhibition of binding was seen when cells were co­
incubated with TGF-pl and BMP-7 (Figure 6.8).
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Fig 6.4: EMSA of consensus Smad3/4 Binding 
Element Probe with nuclear protein extract.
HK-2 cells were incubated with control medium or BMP- 
7 50ng/ml for 24 hours before incubation with TGF-pl 
lng/ml for 1 hour. Retarded probe and free probe are 
indicated. One representative experiment of three 
separate experiments is shown.
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Fig 6.5: Supershift assay with antibodies of Smad2,3,4 with 
nuclear protein.
HK-2 cells were incubated with control medium or TGF-P 1 lng/ml for 
1 hour . (Lane 1) Probe only. (Lane 2) Control cells without antibody. 
(Lane 3) TGF-pl treated cells without antibody. (Lane 4-6) TGF-P 1 
treated cells with Smad2,3,4 antibodies. (Lane 7-8) TGF-pl treated 
cells with relevant IgGs. Supershift probe, retarded probe and free 
probe are indicated. One representative experiment of three separate 
experiments is shown.
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Fig 6.6: Supershift assay with antibodies of Smad3,4,5 
with nuclear protein extract.
HK-2 cells were incubated with control medium or BMP-7 50ng/ml 
for 24 hours before incubation with TGF-P 1 lng/ml for 1 hour . 
(Lane 1) Probe only. (Lane 2-4) Supershift without antibody. (Lane 
5-6) Supershift with Smad3 antibody. (Lane 7-8) Supershift with 
Smad5 antibody. (Lane 9-10) Supershift with Smad4 antibody. 
Supershift probe, retarded probe and free probe are indicated. One 
representative experiment of three separate experiments is shown.
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3 r d  P r o m o te r  SBE
Fig 6 .7: Chromatin Immunoprecipitation (ChIP): Smad3 
binding to the PAI-1 promoter.
Following chromation immunoprecipitation with Smad3 antibody or 
pre-immune globulin, two of PAI-1 promoter Smad3 binding 
elements were detected by QPCR.
HK-2 cells were incubated with TGF-pl lng/ml for up to 24 hours 
before CHIP. Data is presented as Smad3-precipitated signal/pre- 
immune globulin-precipitated signal, normalized to control. One 
representative experiment of three separate experiments for each PAI- 
1 Smad3 binding site is shown.
162
2nd promoter
o 120
cQ 100
c_> 80
"O 60o
40
-*->c 20*< 0taoa Con TGF 6h BMP 6h Both 6h
g  50 
3 40 
>> 30 
2 20
c<
10
0
3rd promoter
Con TGF 6h BMP 6h Both 6h
Fig 6.8 : Chromatin Immunoprecipitation (ChIP): 
Smad3 binding to the PAI-1 promoter.
Following chromation immunoprecipitation with Smad3 antibody 
orpre-immune globulin,PAI-1 promoter Smad3 binding 
elements were detected by QPCR.
HK-2 cells were incubated with BMP-7 50ng/ml with or without 
TGF-pl lng/ml for 6 hour. Data is presented as Smad3- 
precipitated signal/pre-immune globulin-precipitated signal, 
normalized to control. One representative experiment of three 
separate experiments for each PAI-1 Smad3 binding site is 
shown.
6.2.3 Inhibition TGF-pi-induced Smad3 signalling by BMP-7 is not 
via Ids
Overall, the above results show the core inhibition effect by BMP-7 is on Smad3 
DNA-binding. Next, I assessed several transcriptional factors that might be involved 
in this process. The Id family is the helix-loop-helix (HLH) family of transcriptional 
factors, as an inhibitor of DNA-binding/differentiation. Idl, 2 and 3 all are BMPs 
target genes performing various functions depending on the cell types. Firstly, I 
assessed the expression of Ids in PTC by QPCR after the HK-2 cells were incubated 
with lng/ml TGF-pl ± 50ng/ml BMP-7 for 24 hours. The data shows that BMP-7 
alone dominantly increases all Ids expression, whereas a faint induction by TGF-pl 
alone treatment is detected in PTC. When the cells were co-treated with TGF-pl and 
BMP-7 together, all the Ids expression were reduced but still higher than the control 
cells (Figure 6.9). To examine the possible involvement of Ids in BMP-7 inhibition 
on Smad3 DNA-binding, I used Ids siRNA to knock down their expression alone or 
in combination. The results are not consistent with a role for Id proteins in the BMP- 
7 in response to TGF-pl (Figure 6.10).
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Fig 6.9: QPCR o f Idl-3 expression by BMP-7 response to 
TGF-pl
HK-2 cells were growth arrest and exposed to BMP-7 50ng/ml with 
or without TGF-pl lng/ml for 24 hours. The relative quantification 
is calculated as described in the method with endogenous control 
Gapdh, normalized to control. N=  3,Mean +  SEM is plotted. *P < 
0.01 for both and BMP-7 alone compared to control and TGF-pl 
alone. One representative experiment of four separate experiments is 
shown.
165
ADC«
•a
E
C/3
60
50
= 40
30 -
Z 20
10
Con TGF 6h BMP 24h
I
BMP
24h+TGF
6h
□ Scrambled  
■ Id2 s i  RNA
Con TGF 6h BMP 24h+TGF 6h
S  Scrambled 
EJIdl si RNA 
□  Id 2+3 si RNA
Fig 6.10: Effect o f Ids on Smad3 signalling
HK-2 cells were transfected with Idl (B) ,Id2 (A) , or Id2 and 3 siRNA 
together (B) for 24h, parallel with scrambled si RNA, then transfected 
Smad3 reporter construct CAGA(4)) together with pRL-CMV renilla. 
After incubation with control medium or BMP-7 50ng/ml for 24h,then 
incubated with control medium or lng/ml TGF-pl for 6 hours. Ratio of 
firefly to renilla luciferase is displayed and normalized to control. *P < 
0.01 for BMP-7 ±  TGF-pi compared to TGF-pl alone. Results 
represent Mean ±  SEM of 3 individual experiments.
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6.2.4 BMP-7 Inhibits Smad3 DNA Binding by preventing SnoN 
degradation but not Ski
Three key Smad transcriptional co-repressors, namely Ski, SnoN, and TGIF, have 
been identified. They are unique regulatory components within the nuclei during the 
final stage of TGF-p 1 signalling binding to Smad proteins and to Smad binding 
elements in DNA, repressing Smad-dependent transcriptional activation.
Recent work demonstrates that SnoN degradation is required for Smad3-, but not for 
Smad2-dependent transcription [357]. Accordingly, Ski and SnoN expression were 
examined in PTCs following TGF-p stimulation. Immunoblot showed reduced SnoN 
expression from 15 minutes to 6 hours post-TGF-p stimulation, but from 12 or more 
hours post-TGF-p stimulation, SnoN was reaccumulatd (Figure 6.12A). No changes 
in Ski expression were seen in response to TGF-P over the time course examined 
(Figure 6.11 A). Subsequently, cells were incubated for 24h with 50ng/ml BMP-7 or 
control medium, followed by addition of TGF-P lng/ml for 30 minutes. Pre­
incubation with BMP-7 prevented loss of SnoN expression seen with TGF-p alone 
(Figure 6.12 B).
The above data is consistent with reduction in Smad3 DNA binding due to a failure
to degrade SnoN in BMP-7 treated cells. Accordingly, the effect of SnoN and Ski
knockdown on TGF-P signalling by BMP-7 was examined. In subsequent
experiments, PTCs were co-transfected with siRNA and with the Smad3 reporter
vector CAGA (4). Basal Smad3 reporter activity was not altered by SnoN
knockdown. BMP-7 inhibited reporter response in control transfected cells, but not
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in those transfected with SnoN siRNA (Figure 6.13). In contrast, Ski knockdown did 
not prevent inhibition of reporter activation by BMP-7 (Figure 6.11 B).
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Gapdh
TGF-P 1 - 15’ 30’ lh  3h 6h 12h 24h
B
80
BMP-7 24h + +
TGF-P 1 6h - + - +
□  Scrambled 
■ sk i s i  RNA
Fig 6.11: Effect of ski on Smad3 signalling
(A) TGF-p 1 1 ng/ml was added to growth arrest HK-2 cells 
under serum free conditions for time points to 24 hours, before 
protein extraction and immunoblotting for ski. Blots were 
stripped and reprobed for Gapdh. (B) HK-2 cells were 
transfected with ski siRNA for 24h, parallel with scrammbled si 
RNA, then transfected Smad3 reporter construct CAGA(4) 
together with renilla as above. *P < 0.01 for BM P-7± TGF-p 1 
compared to TGF-p 1 alone. Results represent Mean ±  SEM of 
3 individual experiments.
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Gapdh
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B
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TGF-pi 30’ +
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+
Fig 6.12: SnoN expression levels in response to TGF-p 1 and 
BMP-7
(A) TGF-p 1 1 ng/ml was added to growth arrested HK-2 cells under 
serum free conditions for time points to 24 hours, before protein 
extraction and immunoblotting for SnoN. Blots were stripped and 
reprobed for Gapdh. (B) HK-2 cells were treated with BMP-7 50ng/ml 
for 24 hours before incubation with TGF-p 1 1 ng/ml alone for 30 
minutes. After immunoblotting for SnoN, blots were stripped and 
reprobed for Gapdh. One representative experiment of three separate 
experiments is shown.
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Fig 6.13: Effect o f SnoN on Smad3 signalling
HK-2 cells were transfected with SnoN siRNA for 24h, parallel 
with scrammbled si RNA, then transfected Smad3 reporter 
construct CAGA(4) together with renilla as above. *P < 0.01 
for BMP-7 ±  TGF-p 1 compared to TGF-p 1 alone within 
scrammbled group. P=NS for for BMP-7 ±  TGF-p 1 compared 
to TGF-p 1 alone within SnoN si RNA group. One 
representative experiment of three separate experiments is 
shown.
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6.2.5 BMP-7 inhibition effect is reproduced by MG132
Degradation of SnoN may be prevented by the proteasome inhibitor MG 132 [358]. 
The effect of MG132 on SnoN expression and Smad3 signalling in PTC was studied 
instead of BMP-7. Immunoblotting showed that MG 132 did not alter basal SnoN 
expression, but that TGF-P-induced SnoN degradation was prevented by prior 
treatment with MG132 (Figure 6.14 A). MG132 treatment of cells transfected with 
CAGA (4) reporter did not alter reporter activity. However, reporter activity in 
response to TGF-p was diminished in cells pre-treated with MG132 (Figure 6.14 B). 
Subsequently, induction of PAI-1 by TGF-P was studied in MG132-treated PTC by 
qRT-PCR. PAI-1 induction by TGF-p was diminished by MG132 (Figure 6.15). 
Taken together, this data shows that prevention of SnoN degradation reproduces the 
effect of BMP-7 on Smad3 signalling.
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ASnoN 
Gapdh
TGF-p 1 30’ - + - +
MG132 30’ + +
B
*
TGF-p 1 6h - + - +
MG 132 6h - - + +
Fig 6.14: Effect of proteasome inhibitor MG 132 on SnoN 
expression, Smad3 signalling
(A) HK-2 cells were incubated with control medium or TGF-p 1 1 
ng/ml +M G132 lOum for 30 minutes, and immunoblots of whole 
cell extracts for SnoN. Then blots were reprobed for Gapdh. (B) HK- 
2 cells were transfected with Smad3 and renilla reporter constructs, 
before incubation with control medium or TGF-p 1 1 ng/ml ±MG132 
lOum for 30 minutes. *P < 0.01 for TGF-p 1 vs Control, #P < 0.01 
for MG 132 +  TGF-p 1 vs TGF-P 1 alone. Data is presented as 
firfly/renilla luciferase activity, normalized to control. Result 
represented is from one of three individual experiments .
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Fig 6.15: Effect o f proteasome inhibitor MG 132 on 
TGF-pl -induced PAI-1 expression.
HK-2 cells were incubated with control medium or TGF-pl 1 
ng/ml ±M G  132 lOum for 30 minutes, before detection of 
PAI-1 mRNA by QPCR, *P < 0.01 for TGF-pl vs Control, *P 
< 0.01 for MG132+ TGF-P 1 vs TGF-P 1 alone. Results 
represent Mean ±  SEM of 3 individual experiments.
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6.2.6 Initial results about Arkadia effect on BMP-7 inhibition effect 
in response to TGF-pi
Recently, several groups have showed Arkadia, an E3 ubiquitin ligase, targets SnoN 
for degradation[357, 359]. Thus, I checked the Arkadia expression with TGF-pl 
treatment from 15 minutes to 24 hours, and pre-treat BMP-7 for up to 24 hours prior 
30 minutes TGF-P 1 in PTC. No change was observed by immunoblotting (Figure 
6.16 A-B). With QPCR, there is no difference at transcriptional change by TGF-pl 
with or without BMP-7 treated for 24 hours (Figure 6.17).
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TGF-pl - 15’ 30’ lh  3h 6h 12h 24h
BMP-7 - - 15’ 30’ lh  3h 6h 12h 24h
TGF-pl - + +  + + + + + +
Fig 6.16: Time course of Arkadia expression in 
response to TGF-pl ±  BMP-7 
(A) TGF-pl 1 ng/ml was added to growth arrest HK-2 cells 
under serum free conditions for time points to 24 hours, before 
protein extraction and immunoblotting for Arkadia. Blots were 
stripped and reprobed for Gapdh. (B ) Growth arrest HK-2 cells 
were treated with BMP-7 at 50ng/ml up to 24 hours , before 
incubation with 1 ng/ml TGF-pl for 30 minutes. The whole 
lysate was probed with Arkadia. Blots were stripped and 
reprobed for Gapdh. One representative experiment of three 
separate experiments is shown.
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Fig 6.17: Arkadia expression in response to TGF-pl and 
BMP-7
Growth arrest HK-2 cells were incubated with BMP-7 50ng/ml 
with or without TGF-p 1 1 ng/ml for 24 hour under serum free 
conditions. qRT-PCR analysis shows expression of Arkadia. 
Results represent Mean +  SEM from one of three individual 
experiments.
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6.3 Discussion
In chapter three, I have observed that BMP-7 exclusively lessens Smad3 signalling 
without alteration Smad2 in PTC via DNA-binding with EMSA but not Smad3 
phosphorylation. In this chapter, I examined the mechanism further for this.
After Smad3 phosphorylation, the nuclear import and export of Smad3, together with 
dephosphorylation, ubiquitination, and degradation will be regulated.
Firstly, my initial results have shown BMP-7 decreases TGF-pl Smad3 signalling 
with CAGA (4) reporter gene assay. Then I attempted to find out the upstream 
mechanisms leading to attenuation of this DNA-binding. On the basis of the TGF-P 1 
signalling pathway, shuttling of phospho-Smad3 between the cytoplasm and nucleus 
monitors TGF-P 1 receptors activity. I examined the phospho-Smad3 half-life or 
degradation by BMP-7 in response to TGF-P 1 with ALK5 kinase inhibitor 
SB431542. The rate of decline of phospho-Smad3 in response to TGF-pl is not 
altered by BMP-7.
Together with the unchanged immunoblotting of phospho-Smad3 by BMP-7 in 
response to TGF-pl, these data suggest that the regulation of Smad3-DNA-binding 
occurs beyond the R-Smads phosphorylation, mainly in the nucleus.
Following the route of TGF-pl signalling, after Smad3 phosphorylation, the R- 
Smad-Smad4 complex moves into the nucleus. In mesangial cells, previous work has 
shown BMP-7 leads to the loss of TGF-P 1 signalling via BMP-7-induced Smad5
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downstream inhibitory Smad6 induction following the failure of Smad3 nuclear 
accumulation [314]. Compared to this, whereas my results demonstrated no 
difference in TGF-pl-induced phospho-Smad3 nuclear accumulation and BMP-7 
treated cells.
My EMSA and ChIP results show that BMP-7 inhibits Smad3 DNA binding. 
Previous work suggests Smad5 may compete with Smad3 at consensus Smad 
binding elements [356]. However, my SuperShift experiments showed no evidence 
for this.
As outlined in chapter one, Smads have DNA-binding capability, but do not act as 
transcriptional inhibitors in isolation. Instead, co-activators and repressors take part 
in transcriptional regulation progress. Therefore, I studied the role of known 
transcriptional co-repressors of TGF-pl signalling in the reduction of Smad3 DNA- 
binding by BMP-7.
Activated R-Smads-Smad4 complex achieves target genes promoter to initiate 
transcription by association with diverse DNA-binding factors. There are some 
transcriptional repressors such as Ski, SnoN, TGIF, and inhibitors of differentiation 
(Ids) to inhibit Smads DNA-binding.
There are four known members of the Id family in vertebrate (called Idl, Id2, Id3 
and Id4) that constitutes the helix-loop-helix (HLH) family of transcription factors, 
which lack a DNA-binding domain, and then fail to bind DNA specifically or form 
an active heterodimers [360]. And its activity as an inhibitor of DNA-binding is cell
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type dependent. Idl is a well known BMPs target gene and regulates differentiation 
switches in osteoblasts, fibroblasts, epithelial cells, and endothelial cells[361], also 
associated with cell dedifferentiation including tubular epithelial cells by suppressing 
E-cadherin and ZO-1 [362]. Id2 and Id3 expression is also induced by BMPs, but 
their physiological roles remain unknown [361]. TGF-pl can repress or induce Idl 
expression, in a cell type specific manner [361, 362]. My results show that both 
BMP-7 and TGF-pl induce Id l-3 mRNA expression in PTC, with substantially 
greater induction of Ids by BMP-7 than by TGF-pl. However, siRNA-mediated 
repression of Id expression did not affect the inhibitiory action of BMP-7 on TGF-P 1 
signalling.
Ski and SnoN are important transcriptional repressors of TGF-pl-induced Smads 
signalling. Both are markedly reduced in the fibrotic kidney induced by UUO mice 
[363]. In addition to disruption of Smad complexes activity, Ski or SnoN also 
prevents R-Smads from binding to transcriptional co-activators and recruits 
transcriptional co-repressors to integrate with R-Smads to the targeted promoters 
DNA-binding elements [364]. Thus, my finding shows that Ski is not involved in the 
inhibitory role of BMP-7 on TGF-P 1 signalling. As for SnoN, my data show that 
BMP-7 repressed specific TGF-pl Smad3 signalling via preventing SnoN 
degradation.
The previous work has shown that Ski, SnoN are involved in the downregulation of 
Smads signalling [363, 365]. In the current study, I have found that BMP-7 
specifically limits Smad3 dependent transcriptional activation in PTC, via preventing
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SnoN degradation, which is required for Smad3 but not Smad2 dependent 
transcriptional events.
SnoN is a member of the ski family of oncoproteins that binds to the consensus 
Smad3 binding element (GTCTAGAC) and represses transcription [366]. 
Interestingly, SnoN specifically inhibits Smad3 DNA binding activity , and SnoN 
degradation is required for transduction of the Smad3, but not Smad2 signal 
cascade[357]. SnoN expression is progressively reduced in the kidney following 
unilateral ureteric obstruction in mice, and loss of SnoN expression sensitizes renal 
tubular epithelial cells to EMT [363]. SnoN may be degraded by recruitment to the 
proteasome by Smad3 [358], and loss of SnoN expression in animal models of 
progressive renal fibrosis occurs via enhanced ubiquitin-mediated degradation [367, 
368]. Interestingly, Hepatocyte Growth Factor exerts an anti-fibrotic effect in the 
kidney by enhancing SnoN expression in PTCs [43, 369].
Arkadia, an E3 ubiquitin ligase, is involved in the ubiquitin-dependent proteasomal 
degradation of Smad7 [173, 174], amplifying TGF-P signalling. In addition, Arkadia 
interacts with SnoN in their free forms as well as in the forms bound to Smad 
proteins complex, and constitutively down-regulates levels of their expression [359]. 
Moreover, Arkadia promotes specifically transcription via Smad3/Smad4 binding 
sites by degrading the transcriptional repressor, SnoN, in response to TGF-pl 
signalling [357]. Smad7 is an important negative regulator in TGF-pl signalling in 
the cytoplasm especially at TGF-p receptor level [370], and recently it has been 
shown that Smad7 disrupts the formation of the TGF-P-induced functional Smad- 
DNA complex in the nucleus independent of TGF-p type I receptor [161]. I have
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shown that the regulation level of BMP-7 on TGF-pl signalling is in the nucleus, 
and then the possible mechanisms are the involvement on Arkadia-Smad7 DNA- 
binding interaction or Arkadia-SnoN interaction on Smad3-DNA-binding. Firstly, I 
examined the expression of Arkadia in PTC by TGF-P 1 and/ or BMP-7, and the data 
show there is no change on mRNA and protein level expression by Immunoblotting 
and QPCR. The next possibility is the association change between Arkadia and 
SnoN or Smad7. This is a possible future direction for this work.
In summary, my current data demonstrate that preservation of SnoN expression 
underlies antifibrotic actions of BMP-7, loss of SnoN expression may be a key 
element of progressive renal fibrosis.
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Chapter Seven: 
General Discussion
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TGF-pl is a vital cytokine for organ development, maintaining the balanced tissue 
homeostasis. TGF-P 1 has critical functions in embryogenesis, tissue repair, 
inflammation and immunity, as well as the generation of cancer and fibrosis. It is 
also a well known key pro-fibrotic factor in fibrotic progress including renal fibrosis. 
In the kidney, the degree of tubulointerstitial fibrosis is correlated well with the rate 
of renal function loss, leading to ESRD. And TGF-pl plays important roles in the 
development of tubulointerstitial fibrosis. TGF-pl acts through its Smads-related 
signalling pathway. Thus the regulation of TGF-pl signalling pathway is a main 
point to determine the final response of TGF-p 1 in renal fibrosis without affecting its 
other key functions.
Since renal inflammation is thought to be an important determinant of progressive 
interstitial fibrosis injury involving infiltration of the tublo-interstitum by 
macrophages, and consequent release of cytokines including interleukin-1, the first 
stimulus on TGF-pl signalling regulation I selected was IL-lp. I have focused on the 
effect of IL-lp on TGF-pl signalling in the proximal tubular cells. HK-2 cells were 
incubated with TGF-p l±IL-lp from a short-time point 15 minutes to a long-time 
point up to 24h. I have demonstrated a switch from an inhibitory to a sensitising 
effect of IL-lp on Smad signalling after approximately 3 hours with immunoblot of 
phospho-Smad3. I obtained the similar results for phospho-Smad2. In order to 
confirm these findings, the transient transfection of reporter gene constructs 
confirmed these two contrary effects of IL-lp for both Smad2 and Smad3 signalling. 
The second stimulus I selected is BMP-7 because it is highly expressed in the kidney, 
and can block fibrogenic actions of TGF-P 1 including epithelial to mesenchymal 
transition (EMT). In my work of this part, I have shown that BMP-7 significantly
decreased Smad3 signalling specifically but not Smad2 in PTC with the transient 
transfection of reporter gene constructs, whereas phospho-Smad3 is not lessened by 
BMP-7 in response to TGF-pl by immunoblot.
In our lab, we have previously shown that in PTC, TGF-p receptor distribution in the 
plasma membrane is regulated by stimuli including HA (via CD44). CD44 is co­
localized with TGF-P 1 type I receptor in the cytoplasmic membrane of PTC, leading 
to altered TGF-P receptor distribution and association in response to HA-CD44 
interaction. This relationship led to a hypothesis that HA-CD44 was a potential 
mediator by which both IL-lp and BMP-7 might affect TGF-pl signalling. I have 
found that IL-lp induced CD44 expression at 24h but found no change in the 
isoform of CD44 previously shown to alter TGF-pl signalling, CD44v3. 
Furthermore, following siRNA-mediated repression of CD44, increased Smad 
signalling response was still seen following chronic incubation with IL-lp. Similarly, 
I did not detect any change in PTC CD44 expression following incubation with 
BMP-7, and repression of CD44 expression with siRNA did not alter the effect of 
BMP-7 on TGF-pl signalling. Moreover, adding in or removing HA in the medium 
did not change the effects of IL-1 or BMP-7 on TGF-pl signalling. The above 
results showed HA/CD44 is not involved in both TGF-pl Smad signalling regulation 
by these stimuli.
NF-kB is an important downstream effector stimulated by IL-1 p and has been linked 
to inhibition of TGF-P signalling. One subunit of NF-kB, p65, is showed to inhibit 
TGF-pl-induced Smads phosphorylation, nuclear translocation, and DNA binding 
by TNF-a. The previous work in PTC has indicated IL-6 leading to enhancement of
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TGF-pl signalling via a shift of type I receptors from lipid rafts to non-raft 
associated plasma membrane. To explore the possible roles of P65 and IL-6 in the 
early inhibitory effect and later stimulatory effect of IL-1 p respectively on TGF-pi 
signalling, I sought to determine the P65 activation and IL-6 generation during the 
whole time points of IL-lp. The data demonstrate that early inhibition effect of IL- 
lp  on TGF-pl signalling is via NF-kB activation, a switch from p65/p50 to p50/p50 
complexes, consistent with the time curve of upstream regulators, IKK and IKB. 
Furthermore, the later prolonged enhancement effect of IL-lp on TGF-pl signalling 
is via an autocrine IL-6 loop.
In terms of the further mechanism of how P65 regulates IL-lp inhibition TGF-pl 
signalling, some work has previously been shown to inhibit TGF-pl-induced gene 
expression via sequestration of the transcriptional coactivator p300. This will be a 
possibility to do for the future work. As for IL-6, it will be interesting to examine if 
it is a mediator for other proinflammational stimuli and if it is the same story in vivo.
A lot of work in vivo and in vitro has shown BMP-7 has a protective effect on renal 
fibrosis, but the mechanism is not clear. My data has indicated that BMP-7 inhibits 
TGF-P 1 Smad3 but not Smad2 signalling via DNA-binding without apparent 
reduction in Smad3 phosphorylation and translocation into the nucleus. This led to a 
hypothesis that the regulation site is in the nucleus around DNA-binding. Thus, I 
examined the role of transcriptional co-repressors such as Ski, SnoN and Id proteins 
in this process.
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SnoN binds to the consensus Smad3 binding element and represses transcription. 
Interestingly, SnoN has a specific inhibitory action on Smad3 DNA binding, and 
SnoN degradation is required for transduction of the Smad3, but not Smad2 signal to 
recruit to the proteasome. My data showed that BMP-7 prevented the SnoN 
degradation in response to TGF-pl, thus disturbed the Smad3 DNA-binding. With 
SnoN siRNA, the effect of BMP-7 on TGF-pl Smad3 signalling reduction is at least 
partly lost, suggesting SnoN degradation is involved in BMP-7 role on Smad3 
signalling.
Arkadia, an E3 ubiquitin ligase, degrades ubiquitin-dependent Smad7, thus 
amplifying TGF-p signalling. In addition, Arkadia interacts with SnoN and 
constitutively down-regulates SnoN expression. Moreover, Arkadia promotes 
specifically transcription via Smad3/Smad4 binding sites by degrading SnoN, in 
response to TGF-pl signalling [357]. In order to investigate if Arkadia is involved in 
SnoN degradation by BMP-7,1 examined the expression of Arkadia preliminary in 
PTC and it showed no change on its expression. The next possibility is the 
interaction between Arkadia and SnoN or Smad7, this will be a possible further 
direction to do.
In addition to BMP-7, there is another well known anti-fibrotic cytokine, HGF. 
Some work have shown HGF blocks EMT by antagonizing TGF-Pl's action via 
upregulating Smad transcriptional co-repressor SnoN expression in HKC cells [371]. 
The investigation has shown that HGF induces SnoN expression in a cell type 
specific manner coordinating with CREB activation and Spl [369]. This will lead to
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another area of how SnoN and Arkadia take part in HGF performance in renal 
fibrosis in vivo and in vitro.
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